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Abstract 
 
Ageing is associated with a decline in vitamin B12 status. Overt vitamin B12 deficiency 
can lead to neurologic disturbances but the public health impact for neurological disease 
of moderately low vitamin B12 status in older people is unclear. This study aimed to 
assess the relationship between vitamin B12 status and neurologic function in older 
people by systematically reviewing existing evidence and conducting secondary analyses 
on an existing high quality dataset. 
 
A systematic review of observational studies showed limited evidence of an association 
of vitamin B12 status with neurological function in older people. The possibility of an 
association between vitamin B12 status and neurologic function was further explored in 
cross-sectional analyses of baseline data from the Older People and Enhanced 
Neurological Function (OPEN) study, which investigated the effectiveness of vitamin B12 
supplementation on electrophysiological indices of neurological function in 
asymptomatic older people with moderately low vitamin B12 status. This secondary 
analysis did not show any association between any measure of vitamin B12 status with 
electrophysiological indices or clinical markers of neurologic function. 
 
A systematic review of intervention studies suggested no benefits of vitamin B12 
supplementation on neurologic function in asymptomatic older people; but it remained 
possible that improvement is only apparent in people with the lowest vitamin B12 
status. This hypothesis was explored in further secondary analyses of OPEN data: there 
were no differences in the neurologic response to vitamin B12 supplementation 
according to baseline or change in vitamin B12 status.  
 
The available evidence indicates that concerns over the neurologic impact of moderately 
low vitamin B12 status in otherwise healthy older people may be unwarranted. Evidence 
is insufficient to support population screening for moderate vitamin B12 deficiency or 
population-wide recommendations for vitamin B12 supplementation in healthy 
asymptomatic older people, even among those with the lowest vitamin B12 status. 
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DrPH Integration statement  
 
I decided to pursue a Doctorate in Public Health (DrPH) because I wanted to gain 
experience that would help me deal with the application of research to achieve public 
health gains, and develop skills to prepare me for management and leadership positions. 
Having already worked in the field of public health nutrition for several years, I decided 
to progress the DrPH on a part-time basis alongside working in several roles across the 
governmental and non-governmental health sector. 
 
In 2009-2010 I completed the compulsory taught component of the DrPH, namely 
modules in ‘Leadership, Management and Personal Development (LMPD)’ and 
‘Evidence-based Public Health Policy (EBPHP)’. LMPD introduced organisational 
management and leadership concepts and facilitated personal development of 
individual leadership and management skills. EBPHP explored the relationship between 
research and policy making and focused on key skills required for shaping policy and 
practice, involving accessing, understanding, developing, disseminating and facilitating 
the use of the evidence base for better public health outcomes. Whilst completing the 
taught component of the course, I was also working as a Senior Nutrition Scientist at the 
British Nutrition Foundation (BNF) and then subsequently as a nutritionist at the 
Department of Health, focusing on maternal and infant nutrition policy. I was able to 
draw on many aspects of the taught course in my daily work, particularly around 
leadership and management at BNF as I was responsible for managing and training 
junior colleagues, and around use of evidence in policy making at the Department of 
Health, where a large part of my role was working as a member of the Secretariat for 
the UK’s Scientific Advisory Committee on Nutrition. This committee advises 
government agencies and departments on nutrition and related health issues. 
 
My knowledge of the process of policy making as well as what makes good management 
and leadership certainly expanded through the taught component of the DrPH, and I 
was able to put these new skills to use in the second component of the DrPH, the 
Organisational Policy Analysis (OPA). I conducted my OPA at small charity called Coeliac 
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UK, dedicated to the support of people with coeliac disease. I was employed full-time at 
the charity as the Deputy Head of Diet and Health on a fixed term contract, and 
conducted my OPA alongside this role. Careful observation of the organisation allowed 
me to prepare an OPA project protocol and ethics application (from September to 
December 2011), which was in line with my interests but also of value to Coeliac UK as 
my host organisation.   
 
My OPA was an analysis of the use of research by Coeliac UK, with a particular focus on 
the research it funds. In conducting the OPA, I was able to draw on skills learned from 
both compulsory modules and build on these further. The OPA critically assessed: 1) 
how the organisation uses research, which was relevant to the relationship between 
research and policy making covered in EBPHP; this was extended further to an analysis 
of research funding priorities; and 2) how the structure of the organisation affects the 
charity’s abilities to meet its strategic aims on research, which drew on organisation and 
management theories from LMPD. In doing this I was able to gain experience in applying 
policy science and organisational management theories to the critical analysis of a real 
world organisational case study. 
 
I collected data for my OPA from January to July 2012, namely through observation, 
documentation review and conducting semi-structured interviews. I therefore gained 
valuable skills in qualitative data collection and synthesis.  Through these activities I was 
able to develop recommendations to increase the effectiveness of the organisation in 
terms of funding of and using scientific evidence in order to deliver its strategic aims. In 
particular, the findings of my OPA were subsequently used to inform Coeliac UK’s new 
research strategy (see Appendices). 
 
I left Coeliac UK at the end of 2012 to pursue the research component of my DrPH 
alongside working part-time for Cancer Research UK. For the final part of the DrPH I 
returned to my background of public health nutrition and was able to take up the 
opportunity of working on an existing dataset at LSHTM from the Older People and 
Enhanced Neurological Function (OPEN) study to develop my research questions. The 
OPEN study is an individually randomised double-blind placebo-controlled trial which 
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aimed to assess whether dietary supplementation with vitamin B12 will improve 
electrophysiological indices of neurological function in older people. 
 
Frank vitamin B12 deficiency can typically present with neurological disturbances, but 
the functional significance of ‘subclinical’ low B12 status in older people is not clear, 
particularly in terms of neurological manifestations. This is of public health concern 
because low vitamin B12 status is relatively common in old age. I was keen to use the 
opportunity to conduct original research in an area of public health nutrition that I had 
no specific previous experience of, so I could gain new knowledge. Vitamin B12 status 
and its relationship with neurological function in older people is an interesting area of 
public health nutrition that I had never studied before and is explored in my research 
thesis presented here. 
 
Firstly, it was important to review existing evidence on vitamin B12 status and 
neurological function. During 2013, I conducted two systematic reviews: 1) of 
observational studies and 2) of vitamin B12 intervention studies, to assess evidence of 
an association between vitamin B12 status and neurological function, and effectiveness 
of vitamin B12 interventions on neurological function respectively. The first of these is 
published in the British Journal of Nutrition (Chapter 2) and the second report is 
presented in Chapter 4. My skills in systematic review have therefore been further built 
upon, and this again draws on methods taught in the EBPHP module of the course. I also 
presented the results of the systematic review of observational studies at the 2014 
LSHTM student poster day. 
 
I presented my literature review findings and research protocol for further analyses 
using OPEN data, at my DrPH review in early 2014. As a high quality existing dataset, the 
OPEN study provides evidence that addresses many inadequacies of the existing studies 
on vitamin B12 and neurological function. The primary trial results for the OPEN study 
have been published by others, and I was able to develop two research questions to 
further explore the relationship between vitamin B12 status and neurological function 
in older people in secondary analyses: 1) to assess whether any cross-sectional 
associations exist between vitamin B12 and neurological function in the baseline dataset 
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and 2) to conduct a longitudinal analysis of the trial data to investigate whether the 
effectiveness of the intervention alters according to baseline or change in B12 status.  
 
In preparation for the work on statistical analysis, I attended three MSc modules on 
statistics at the School: Statistics for epidemiology and population health (2013); 
Statistical methods for epidemiology (2014); and Advanced statistical methods for 
epidemiology (2015). Each of these helped to refresh and develop my understanding of 
statistical concepts and methods. I started work in earnest on statistical analyses of the 
OPEN dataset in late Spring 2015, following a year of maternity leave. 
 
By progressing secondary analyses on an existing dataset, I have been able to hone my 
skills in data management and detailed statistical analysis. I overcame many challenges 
associated with working on existing data generated from several sources and in multiple 
files and climbed a learning curve in terms of statistical analysis. I am now competent in 
using STATA statistical software and have performed several exploratory and regression 
analyses. Furthermore, I have further developed my understanding of epidemiological 
concepts and now have experience of writing up results from an original research study 
for publication. Further manuscripts prepared for publication are presented in Chapters 
3 and 5.  
 
Finally, the research component of the DrPH has enabled me to integrate and synthesise 
scientific evidence from the existing evidence-base alongside new study findings, in 
order to present a cohesive discussion of the state of knowledge in my chosen area of 
public health nutrition. The act of ‘pulling everything together’ is a valuable exercise 
which I have found satisfying, and will no doubt be a useful experience when consulting 
scientific evidence to inform policy making in the future. 
 
The DrPH programme at LSHTM is an excellent format of study designed to train future 
leaders in public health. It is a challenging programme with many different components, 
but certainly rewarding. I feel I have further developed many skills to complement my 
experience gained in the work place and gained a wealth of knowledge that I hope to 
put into practice in my future career. 
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Chapter 1: Background 
 
1.1  Introduction 
The number and proportion of older people in populations around the world is 
increasing, and the pace of increase is remarkable. If trends continue, most babies born 
since 2000 in several Western countries, including the UK, will celebrate their 100th 
birthdays1. Figure 1 shows the rapid increase in life expectancy at birth seen in England 
and Wales. These changes are driven largely by increasing survival in older age2. Over 
the last 30 years there has been an upward trend in life expectancy at older ages in 
England3. By 2025 about one-third of Europe’s population will be aged 60 years and 
over, and there will be a particularly rapid increase in the number of people aged 80 
years and older4.  
 
Figure 1: Life expectancy at birth in England and Wales from 1991-93 to 2012-145. 
 
 
Ageing populations offer substantial opportunities: older people contribute to society in 
many ways, for example through informal care of family members and as an experienced 
workforce that can benefit local communities or society more generally. Yet, making the 
 17 
 
most of older people in society is enhanced if their extra years are spent in good health, 
and this presents a public health challenge. Healthy ageing is defined by the World 
Health Organization (WHO) as the process of developing and maintaining the functional 
ability that enables well-being in older age.  Functional ability comprises the health-
related attributes that enable people to be and to do what they have reason to value. 
Maintaining functional ability in older age reduces the need for dependence on carers 
and health services, and the costs associated with them. Maintaining independence in 
older age can also improve quality of life as well as economic and social productivity, 
and importantly reduce frequency of hospital admissions2, 4, 6. 
 
23% of the global burden of disease arises in older people. Age-related disorders 
increase in prevalence in parallel with the numbers of people aged over 60 years. 
Chronic non-communicable disease accounts for most of this burden including 
cardiovascular disease, cancer, chronic respiratory diseases, musculoskeletal diseases 
and mental and neurological disorders in rank order globally; although mental and 
neurological disorders make a greater contribution in high-income countries7. Together, 
these disorders contribute greatly to loss of functional ability in older age. Specifically, 
it has been estimated that neurologic and psychiatric disorders account for 28% of all 
years of life lived with a disability8, 9. 
 
Health in later life reflects the interaction of a wide range of factors: some intrinsic to 
the individual such as biological and genetic factors; and other factors related to 
interaction with the environment such as behavioural and social factors. Nutrition is one 
of several lifestyle factors that can affect healthy ageing and this has been subject to 
considerable research2, 6. Although energy needs decrease with age, the demand for 
essential nutrients remains, highlighting the importance of a nutrient dense diet. 
However, the ageing process is associated with physiological changes that affect 
nutrition status (Box 1). 
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Box 1: Age-related physiologic changes that can affect nutrition2, 4, 10 
 
National survey data shows that older people living in the UK, particularly in institutions, 
have low intakes of a range of vitamins and minerals. Adult aged 65 years and over living 
in institutions are amongst specific population groups identified as most at risk of poor 
dietary variety, low nutrient intake and biochemical status11. Men and women aged 65 
years and over have biochemical evidence of low vitamin D and iron status for 
example11, 12. 
 
Vitamin B12 is a nutrient whose status is affected by physiologic changes seen with 
ageing. A decline in vitamin B12 status is associated with ageing and this is largely due 
to impaired absorption rather than reduced intakes (see Sections 1.4 and 1.8). There are 
several age-related contributory factors including a decrease in gastric acidity, presence 
of atrophic gastritis, compromised functional and structural integrity of the  vitamin B12 
binding proteins and lack of liver vitamin B12 stores13.  
 
Vitamin B12 deficiency is one of many known causes of peripheral neuropathy (others 
include diabetes, alcohol misuse, renal or liver disease, HIV and some malignancies14) 
but up to a third of patients are without a known cause (cryptogenic sensory peripheral 
neuropathy)15. Estimates indicate that 8% of people aged over 55 years have peripheral 
neuropathy and this figure rises with increasing age16, 17. Clinical recognition of 
neurological impairment in older people is challenging. It is easy to miss neurological 
impairments because they are often assumed to be part of the natural ageing process 
or a result of ‘wear and tear’. However, these assumptions cause potential opportunities 
 
- Changes to senses of taste and smell 
- Poor oral/dental health and reduced saliva production 
- Side effects of medication eg constipation, reduced appetite 
- Gastric atrophy and reduced gastric secretions 
- Impaired vision, hearing and/or mobility affecting ability to shop and prepare food 
- Chronic disease including dementia and depression 
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for prevention or treatment to be missed. Aging is not an invariable and sufficient cause 
of peripheral neuropathy but could be the result of preventable disease18, 19. 
 
This thesis focuses on the relationship between vitamin B12 and the nervous system in 
older people. Though vitamin B12 also has a key role in blood cell formation, adequate 
vitamin B12 is also important for neurologic function (Section 1.5.2). This thesis has a 
specific focus on central and peripheral nerve function as existing research on these 
outcomes is limited. Cognitive function has been researched and reviewed extensively 
elsewhere20-23.  
 
1.1.1  Aims and research questions 
This study aims to assess the relationship between vitamin B12 status and neurologic 
function in older people. This is done firstly by systematically reviewing existing 
evidence, and secondly, by conducting secondary analyses using data from the OPEN 
Study. The present study aims to address the following two research questions in 
systematic reviews of the literature: 
 
1a) Is there any evidence in the available literature that vitamin B12 status is 
associated with neurological function in older people? 
1b) Is there any evidence in the available literature that vitamin B12 
supplementation improves neurological function in older people? 
 
The findings of the systematic reviews are then used to identify gaps in the evidence-
base. Secondary analyses (using data from the OPEN study) are then conducted to 
address these evidence gaps. Based on the findings of the systematic reviews, the 
following research questions for the secondary analyses were developed: 
 
2a) Is vitamin B12 status associated with electrophysiological indices of peripheral 
or central neurologic function in asymptomatic older people with moderately 
low vitamin B12 status? 
2b) Does baseline vitamin B12 status or change in vitamin B12 status alter the 
effectiveness of dietary supplementation with vitamin B12 on 
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electrophysiological indices of neurologic function in asymptomatic older people 
with moderately low vitamin B12 status? 
 
In order to provide further context to the study, the remainder of Chapter 1 provides 
background information relevant to the study of vitamin B12 and neurologic function, 
including data on vitamin B12 status, measurement of vitamin B12 status and neurologic 
function and the potential mechanisms by which vitamin B12 status affects neurologic 
function. 
 
1.2 Vitamin B12 function  
Vitamin B12, or cobalamin, is a water-soluble vitamin with a key role in blood cell 
formation and normal functioning of the brain and nervous system. Vitamin B12 
functions as a cofactor for two coenzymes that are active in human metabolism: 
methionine synthase and L-methlymalonyl CoA mutase. Together with folate, vitamin 
B12 is required for methyl group transfer during protein metabolism, DNA synthesis and 
the methylation of DNA and other substrates. Specifically, methionine synthase requires 
methyl-cobalamin as for a cofactor for the methyl transfer from methyltetrahydrofolate 
to homocysteine (hcy) to form methionine and tetrahydrofolate. L-methylmalonyl CoA 
mutase requires adenosylcobalamin to convert L-methylmalonyl CoA to succinyl-CoA in 
an isomerisation reaction13, 24. 
 
1.3 Dietary vitamin B12 
The original source of vitamin B12 in the diet is from microorganisms (bacteria and 
algae) that synthesise it.  Vitamin B12 then enters the human food chain through 
incorporation into foods of animal origin. Therefore,  vitamin B12 is found in the diet in  
all foods of animal origin and certain seaweed (Table 1)25.  
 
Diet-related vitamin B12 deficiency is usually restricted to vegans or strict vegetarians. 
Hydroxocobalamin and, in particular, cyanocobalamin are synthetic forms used in 
vitamin supplements and in the fortification of food26. The UK reference nutrient intake 
(RNI) for vitamin B12 for adult men and women (including those aged 50+ years) is 1.5 
µg/day, and the lower reference nutrient intake (LRNI) is 1.0 µg/day27. The US 
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Recommended Daily Allowance (RDA) for vitamin B12 is 2.4 µg/day for adults, though 
adults aged >50 years are advised to meet their RDA mainly by consuming food fortified 
with vitamin B12 or a vitamin B12-containing supplement13. The European Food Safety 
Authority has recently proposed an Adequate Intake for cobalamin at 4 μg/day for adults 
based on data on different biomarkers of vitamin B12 status and in consideration of 
observed mean intakes across Europe, which range between 4.2 and 8.6 μg/day in 
adults28. Vitamin B12 has low toxicity and no safe upper limit has been identified26. 
 
Table 1: Food sources of vitamin B1229 
 
Food Amount of vitamin B12 per 100g 
edible portion (µg) 
Semi-skimmed milk 0.4 
Whole milk yoghurt (plain) 0.2 
Egg (boiled) 1.1 
Cheddar cheese 2.4 
Beef topside (cooked) 3 
Lamb leg (cooked) 2 
Cod (cooked) 2 
 
 
1.4 Absorption of vitamin B12  
There are two pathways by which vitamin B12 is absorbed: a) via intrinsic factor and b) 
by passive diffusion. The intrinsic factor–mediated pathway requires vitamin B12 to be 
released from dietary protein in the stomach by the action of acid and pepsin. The 
vitamin B12 then binds to R proteins secreted by the salivary glands and gastric mucosa. 
R proteins are then degraded in the alkaline environment of the small intestine, 
releasing vitamin B12 to bind with intrinsic factor. The resulting complex of intrinsic 
factor-vitamin B12 is then taken up by receptors in the ileum and absorbed by 
phagocytosis. Absorption via intrinsic factor has a limited capacity of 3µg at one meal. If 
larger doses of vitamin B12 are consumed, absorption by passive diffusion can occur; 
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the rate of absorption is 1% of the ingested amount of vitamin B1213, 24. Although the 
total amount of vitamin B12 absorption increases with increasing dose, the percentage 
absorption decreases24. All circulating vitamin B12 is bound to plasma binding proteins, 
transcobalamin I, II or III. Vitamin B12 enters cells mainly in the form bound to TCII, 
known as holotranscobalamin (holoTC). The liver is the main storage site for vitamin B12 
in the body. Body storage is relatively high at about 1-5mg so deficiency from diminished 
intake or absorption may not manifest for several years after the depletion of stores30. 
 
A decline in vitamin B12 status is associated with ageing24, 31 (Section 1.8) and this is 
largely attributed to absorption issues. There are several contributory factors associated 
with ageing including a decrease in gastric acidity, presence of atrophic gastritis, 
compromised functional and structural integrity of the vitamin B12 binding proteins and 
lack of liver vitamin B12 stores13. Lack of stomach acid (a physiological state called 
hypochlorhydria) is a major issue: there is an age-related reduction in the ability of 
parietal cells to secrete hydrochloric acid. It is thought that up to 25% of older people 
can have some degree of hypochlorhydria as a result of atrophic gastritis. It is proposed 
that the absence of acid in the stomach prevents the release of protein-bound vitamin 
B12 in food but does not have such an effect on free vitamin B12 found in supplements 
or fortified foods 25. Bacterial overgrowth associated with atrophic gastritis can also 
reduce absorption of vitamin B12. 
 
1.5 Vitamin B12 deficiency 
Dietary vitamin B12 deficiency is rare in healthy populations32, 33. However, food-
cobalamin malabsorption can account for up to 60-70% confirmed cases of vitamin B12 
deficiency in older patients33. Food-cobalamin malabsorption is most commonly caused 
by gastric atrophy, which is present in 40% of patients aged over 80 years, and is 
characterised by the inability to release cobalamin from food or intestinal transport 
proteins (Section 1.4).  
 
A known cause of severe clinical vitamin B12 deficiency is pernicious anaemia, which is 
an autoimmune gastritis where autoantibodies cause loss of parietal cells in the 
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stomach. This progressive destruction leads to loss of intrinsic factor and so limits 
intrinsic factor–mediated vitamin B12 absorption. 
 
The clinical manifestations of vitamin B12 deficiency can be haematologic, neurologic or 
both32. Neurological symptoms can occur in the absence of anaemia in 20-30% of 
cases34; it has been suggested that the occurrence of neurological manifestations is 
inversely related to the degree of anaemia13, 24, 35. Cognitive and gastrointestinal 
disturbances can also occur24, 32, 33. Standard treatment of vitamin B12 deficiency in the 
UK is to begin parenteral treatment with intramuscular hydroxocobalamin. Initial 
treatment for patients without neurological involvement is 1000 μg intramuscularly 
three times a week for two weeks (or alternate days for up to three weeks in patients 
with neurological involvement). 
 
1.5.1 Impact on haematology 
Megaloblastic anaemia is the classical manifestation of vitamin B12 deficiency. 
Haematological investigations may show an increased mean cell volume (reflecting 
macrocytosis), low haemoglobin, hypersegmentation of neutrophils and presence of 
oval macrocytes30, 33, 36. A patient affected by vitamin B12 deficiency may complain of 
fatigue and/or weakness as a result of the anaemia. The haematological effects of 
vitamin B12 deficiency are often indistinguishable from folate deficiency; the underlying 
mechanism for both deficiencies is interference with DNA synthesis. The haematological 
complications of vitamin B12 deficiency are reversible by treatment13. 
 
1.5.2 Impact on the nervous system 
The nervous system is organised into the central nervous system (CNS) and the 
peripheral nervous system (PNS) (Figure 2). At the cellular level, neurons allow electric 
signals to travel between the central and peripheral systems in both directions (Figure 
3). The afferent neurons carry sensory signals from the periphery to the spinal cord then 
brain. The efferent neurons carry motor signals from the brain to the periphery. 
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Figure 2: Organisation of the central and peripheral nervous system (reproduced from 
Tortora, 1995, p439)37 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3: Diagrammatic representation of a neuron and the neuronal connections in the 
central nervous system and peripheral nervous system (adapted from Vander, 1994, 
p181 and 183)38. 
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The axons of neurons constitute nerve fibres and these vary in length from a few mm (in 
the brain) to a metre (in nerves reaching from the spinal cord to the feet). Axons can be 
myelinated, that is surrounded by a fatty myelin sheath which is deposited around the 
axons by Schwann cells (Figure 4). Myelin acts as an insulator to decrease ion flow 
through the membranes. However, ions flow quickly through the junctions between two 
Schwann cells (nodes of Ranvier). This structure causes depolarisation to jump across 
intervals, thereby increasing the velocity of signals along the nerve. Nerve conduction in 
myelinated nerve fibres is at a much greater velocity than in unmyelinated nerve fibres39 
 
Figure 4: Myelination of axons (reproduced from Vander, 1994, p182)38 
 
 
Vitamin B12 is required for the initial myelination of the nervous system, and its 
maintenance27, 32. In vitamin B12 deficiency pathological investigations reveal 
demyelination in the spinal cord, peripheral nerves and/or the white matter of the 
brain32 and an abnormal increase in astrocytes in the brain due to damage to nearby 
neurons (astrogliosis)40. 
 
The full neurological syndrome associated with vitamin B12 deficiency is called subacute 
combined degeneration of the cord (SCD) due to demyelination of the posterior columns 
and PNS, giving rise to ataxia (a lack of voluntary coordination of muscle movements) 
and impaired cutaneous sensation respectively. Other neurologic symptoms associated 
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with vitamin B12 deficiency include symmetric paresthesias, numbness, gait problems, 
impaired vibration or position sensation and weakness24, 32. The reversibility of 
neurological complications associated with vitamin B12 deficiency is not clear and may 
depend on their duration13. 
 
1.6 Mechanisms by which vitamin B12 affects neurologic function 
 
1.6.1 Role of vitamin B12 metabolites  
Early theories of the mechanisms to explain the neurological manifestations of vitamin 
B12 deficiency focussed on impaired activity of the two vitamin B12-dependent 
enzymes: methionine synthase (MeS) and L-methylmalonyl CoA mutase (MCM). MeS 
requires methyl-cobalamin as a cofactor for the methyl transfer from 
methyltetrahydrofolate to hcy to form methionine and tetrahydrofolate. Impairment of 
this function in the case of vitamin B12 deficiency leads to an elevation in hcy. MCM 
requires adenosylcobalamin to convert L-methylmalonyl CoA to succinyl-CoA in an 
isomerisation reaction. Impairment of this function with vitamin B12 deficiency leads to 
an elevation in MMA. 
 
There have been various reports that the metabolites MMA and hcy, which are elevated 
as a result of impaired enzyme activity, act as neurotoxins, whose accumulation may be 
responsible for the onset of SCD41. However, hypotheses (discussed further below) rely 
heavily on animal and cell culture work; there is a paucity of mechanistic studies 
conducted in humans. 
 
1.6.1.1 Impaired function of MeS and elevated hcy 
It has been proposed that vitamin B12-dependent neurological effects may be due to a 
defect in MeS. The hypothesis was developed because monkeys treated with nitrous 
oxide (which blocks MeS) develop neurological disease similar to that observed in 
vitamin B12 deficient humans42.  
 
Vitamin B12 regulates, together with 5-methyl-tetrahydrofolate, the remethylation of 
hcy to L-methionine and the subsequent formation of S-adenosylmethionine (SAM). 
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SAM is a methyl donor essential to most biological methylation reactions, which can be 
genomic or non-genomic43. In the brain, SAM-dependent methylations are extensive44. 
As a result, inadequacy in vitamin B12 can lead to impaired DNA synthesis and 
transcription, impaired genomic methylation and epigenetic mechanisms and hcy-
mediated DNA damage45 as well as  impaired methylation of myelin, neurotransmitters 
and phospholipids in the CNS, which may contribute to demyelination41, 44, 45. It has also 
been proposed that hcy may also have direct neurotoxic effects in the CNS via NMDA 
(N-methyl-D-aspartate) receptor activation46 or oxidative damage44. However, there is 
a lack of supportive evidence to suggest the concentrations of hcy in human brain or 
cerebrospinal fluid reach neurotoxic levels44. 
 
1.6.1.2 Impaired function of MCM and elevated methyl malonic acid 
Impairment of the function of MCM in vitamin B12 deficiency causes accumulation of 
methylmalonyl CoA in the mitochondria, an elevation in methyl malonic acid (MMA), 
acidosis and elevated MMA excretion. The accumulation of mitochondial methylmalonyl 
CoA depletes the CoA pool available for other mitochondrial enzymes and metabolites, 
and the increased propionyl CoA can be incorporated into long chain fatty acids in place 
of acetyl CoA. It has been proposed that there is a resultant accumulation of unusual 
fatty acids in myelin affecting the integrity of the myelin structure, which causes 
demyelination41, 42, but the evidence for this is not resolved42, 45. 
 
1.6.2 Other proposed mechanisms  
Some clinical and experimental findings defy the biochemical/enzyme impairment 
theories described in Section 1.6.1. In particular, inherited deficits in MCM in children 
and MeS knockout rats do not show typical SCD lesions, and patients with 
homocysteinemia for any reason other than vitamin B12 deficiency do not show SCD-
like neurological manifestations41. This has led to further research on other proposed 
mechanisms. 
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Scalabrino and Peracchi47 have demonstrated that the severity of neuropathological 
features in the white matter of the spinal cord of TGX rats1 (an experimental rat model 
of vitamin B12 deficiency) does not correlate with progressive accumulation of hcy and 
MMA in the spinal cord or serum, thereby suggesting that these metabolites are unlikely 
to cause SCD-like lesions. Scalabrino’s research group has conducted extensive research 
using experimental rat models to propose new mechanisms responsible for the 
pathogenesis of SCD41. It has been known for a long time that various cytokines and 
neurotrophic growth factors are synthesised and released by CNS cells, mainly glial cells.  
Mechanisms have been proposed that focus on an imbalance in growth factors and 
cytokines in the CNS seen with vitamin B12 deficiency.  
 
In vivo evidence from the CNS and cerebrospinal fluid (CSF) of rats has demonstrated an 
overproduction of myelinolytic tumour necrosis factor (TNF) α and reduced synthesis of 
two neurotrophic agents, epidermal growth factor (EGF) and interleukin-6 (IL-6).  TNFα 
is implicated in the pathogenesis of some neurological diseases and EGF positively 
regulates the proliferation and/or differentiation of neurons and/or glia. IL-6 is a multi-
functional cytokine. The imbalance between TNFα and EGF induced by vitamin B12 
deficiency has been verified in the sera of patients with pernicious anaemia and the CSF 
of SCD patients.  
 
The cytokine and growth factor abnormalities, as well as the morphological lesions and 
biochemical abnormalities, in TGX rats are substantially corrected by chronic vitamin 
B12 treatment; this suggests that they are all specifically linked to vitamin B12 
deficiency47. 
 
Demonstration of these new mechanisms does not exclude the possibility that the 
classical biochemical enzyme mechanisms coexist. Further research is needed to 
reconcile these new and classic theories. Further, research is ongoing to determine 
whether cytokine/growth factor mediated pathology extends to the PNS. Much of this 
                                                          
1 This experimental rat model mimics the pathogenesis of pernicious anaemia using gastrectomised rats and reproduces typical 
SCD lesions and reduced nerve conduction velocity. Hallmarks are also intramyelinic and interstitial oedema of the white matter of 
the CNS. 
 29 
 
research focuses on the role of normal cellular prion protein (PrPc), which is involved in 
maintenance of myelinated fibres in both the CNS and PNS, and its regulation by the 
cytokines and growth factors shown to be linked to vitamin B12 deficiency48, 49. At the 
moment it is not possible to determine whether the imbalance in cytokine/growth 
factors is a cause or consequence of vitamin B12 deficiency in humans, but it does 
appear to be necessary for the development of SCD in the experimental rat model41, 50. 
 
1.7 Measuring vitamin B12 status 
 
1.7.1 Serum/plasma vitamin B12 
There is currently no ‘gold standard’ test for the diagnosis of vitamin B12 deficiency, 
though a serum vitamin B12 assay is usually the standard initial diagnostic test in routine 
clinical practice36. It is low cost and widely available. The concentration of vitamin B12 
in the serum or plasma reflects both vitamin B12 intake and the status of body stores 
and quantitates inactive (holohaptocorrin) and active (holotranscobalamin) forms of 
vitamin B1230, 36. However, as deficiency develops, serum vitamin B12 may be 
maintained at the expense of body stores, so an adequate vitamin B12 plasma/serum 
does not necessarily indicate adequate vitamin B12 status13. It is relatively common for 
false negatives and false positives to be reported with use of serum vitamin B12, which 
may be a result of both inactive and active forms being measured32. 
 
Various assays for vitamin B12 are available. Historically, the microbiological assay for 
vitamin B12 was standard51 and it has been suggested that this assay can be reliably 
established in most laboratories52. Now, the most common assays in clinical laboratories 
are based on intrinsic factor binding of vitamin B12 and immune-chemiluminescence 
based assays36, 53. Comparability has therefore become an issue because the 
microbiological assay is a functional measurement and the intrinsic factor and immune-
chemiluminescence based assays are substance quantity measurements51. 
 
Furthermore, particular issues have been reported when intrinsic factor is used as the 
assay binding protein in competitive binding methods. Anti-intrinsic factor antibodies 
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need to be removed from samples; otherwise there is a risk of false normal results to be 
reported, especially in patients with pernicious anaemia32, 54, 55. 
 
A review of the published biomarkers and cut-offs for the diagnosis of vitamin B12 
deficiency has highlighted that a wide range of laboratory assays have been used to 
measure vitamin B1253. Standardisation of assays and development of an international 
reference standard across laboratories would be ideal. Otherwise, each laboratory 
should have its own reference range identified locally. However, serum vitamin B12 
levels can be affected by diet, use of supplements/medication, pregnancy and age; 
therefore establishment of local reference ranges can be difficult36. Robust studies that 
have accounted for these variables are possible but rare56. 
 
Inconsistency in how vitamin B12 deficiency is defined is not only hindered by the 
various assays used, but also a lack of consensus on cut-off points. Several thresholds to 
indicate low vitamin B12 status and/or deficiency have been used, ranging from 
100pmol/L to 350 pmol/L53 and there has been much debate about how stringent a 
threshold to use24, 30. The WHO has recognised the lack of a universally accepted cut-off 
to define vitamin B12 deficiency and developed a consensus statement to define a cut-
off that should be used for assessing the nutritional status of populations: plasma 
vitamin B12 <150 pmol/l (note no specific guidance on use of assay was given) 57. This 
cut-off is based on vitamin B12 concentrations below which plasma MMA becomes 
elevated. Similarly, the British Society of Haematology advise that a serum vitamin B12 
cut-off level of either 148 pmol/L or one derived from a local reference range be 
evidence of vitamin B12 deficiency, when present alongside clinical symptoms36. Again, 
the British Society of Haematology cut-off is not provided alongside guidance on the use 
of a specific assay so issues of comparability across assays has not been taken into 
account. 
 
1.7.2 Holotranscobalamin  
New immunoassays for holotranscobalamin (holoTC) are now available; measuring 
holoTC has the advantage of measuring the active fraction of vitamin B12 by measuring 
the vitamin B12 saturation of the binding protein transcobalamin. Studies have shown 
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the holoTC assay to provide some improvement in specificity for detecting elevated 
MMA over assays of total serum cobalamin32, 58. Using MMA as the reference standard, 
it has been suggested that holoTC has a modestly superior diagnostic accuracy for the 
detection of vitamin B12 deficiency, when compared to conventional serum vitamin 
B1259. Using red cell cobalamin (as an index of vitamin B12 stores) as the reference 
standard, it has also been shown that holoTC performs significantly better than all other 
indicators in older people56. However, these findings have limitations as it is not clear 
whether MMA or red cell cobalamin are suitable gold standard tests in themselves; 
elevated MMA in particular is associated with renal failure in older people. Nevertheless, 
it has been suggested that holoTC is a suitable, and even preferred, assay for assessment 
of vitamin B12 status36, 56. It has been reported that the uncertainty range for holoTC is 
smaller than for assays of vitamin B1236, 56. Consequently, some authors view holoTC 
abnormality as the earliest possible marker of vitamin B12 deficiency because it occurs 
in patients with normal concentrations of all other biomarkers, and so may be 
appropriate for the subclinical situation52, 60.  
 
Like serum vitamin B12, use of holoTC also suffers from lack of consensus in cut-offs. In 
a recent review, cut-offs for holoTC ranged between 20 and 50 pmol/L53. HoloTC assays 
are also less widely available and consequently factors that influence holoTC have not 
been widely studied60: holoTC was used in less than a third of studies assessing vitamin 
B12 status published between 1992-2014 53. 
 
1.7.3 MMA and hcy 
Blood levels of these metabolites are also valuable indicators of vitamin B12 status, as 
they are components of the vitamin B12 metabolic pathway. The levels of hcy and/or 
MMA are elevated in the majority of patients with clinical vitamin B12 deficiency. These 
metabolites can be used in combination with measures of vitamin B12 to confirm 
deficiency or marginal status. 
 
The concentration of MMA rises when the supply of vitamin B12 is low because of 
impaired function of the enzyme L-methlymalonyl coA mutase. However, elevated MMA 
is not entirely specific to low vitamin B12 status because it can also be elevated as a 
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result of renal failure32. Yet, because elevated MMA represents a metabolic change as a 
result of vitamin B12 deficiency it is often used an indicator of vitamin B12 status13. 
Vitamin B12 is also a cofactor for the enzyme methionine synthase; impaired function 
of this enzyme when vitamin B12 supply is low leads to elevated hcy. However, a lack of 
vitamin B6 or folate also results in elevated hcy concentration and so hcy has poor 
specificity as an indicator of vitamin B12 status. Renal insufficiency can also be a cause 
of elevated hcy61, often with aging, so is an important consideration when using these 
metabolites to assess vitamin B12 status.  
 
1.7.4 Composite markers to assess vitamin B12 status 
Several studies have used a combination of measures of vitamin B12 to confirm 
deficiency or marginal status, further expanding the number of ways in which vitamin 
B12 status can be assessed. Issues around the use of a composite marker for vitamin 
B12 have been explored in detail at a roundtable held in 2010 to assess measurement 
procedure issues for the monitoring of folate and vitamin B12 status by the US National 
Health and Nutrition Examination Survey (NHANES)62. The roundtable discussed the 
relative merits of two biomarkers of circulating vitamin B12: serum vitamin B12 and 
holoTC and two functional biomarkers of vitamin B12: the metabolites hcy and MMA. 
Overall, the roundtable regarded information from both types of biomarker 
concurrently as preferable to either alone, because of problems with each biomarker’s 
sensitivity and specificity. The roundtable agreed the need for including at least one 
biomarker of circulating vitamin B12 (serum vitamin B12 or holoTC) and one functional 
biomarker (MMA or hcy) in NHANES 60, 62. 
 
The roundtable also noted that, despite slightly better sensitivity and specificity over 
vitamin  B12, the full range of alternative influences on holoTC concentrations has not 
been adequately explored60. Therefore, if a choice must be made between serum 
vitamin B12 and holoTC, the roundtable felt that because holoTC measurement is new 
and would benefit from performance studies, it was agreed that serum vitamin B12 was 
preferable as the measure of circulating vitamin B1262. 
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Plasma hcy has a comparable sensitivity to MMA for vitamin B12 deficiency and both 
are excellent for monitoring response to vitamin B12 supplementation63. However, use 
of hcy is limited because it is particularly susceptible to changes in folate status. Indeed, 
a greater proportion of hcy variation is attributed to folate than vitamin B12 status in 
countries without folate fortification60. The roundtable therefore agreed that if a choice 
must be made between use of hcy and MMA, MMA is preferable because it increases 
with vitamin B12 inadequacy but hcy increases with both folate and vitamin B12 
inadequacies62. 
 
1.7.4.1 Novel composite marker, cB12 
A novel approach has been developed to use a composite marker of vitamin B12, called 
cB12, that combines measures of vitamin B12, holoTC, hcy and MMA into one indicator 
using the following equation64: 
 
cB12 =  [ log10 (
ℎ𝑜𝑙𝑜𝑇𝐶∙𝐵12
𝑀𝑀𝐴∙𝐻𝑐𝑦
) Test − log10 (
ℎ𝑜𝑙𝑜𝑇𝐶∙𝐵12
𝑀𝑀𝐴∙𝐻𝑐𝑦
) Ref]  − 
3.79
1 + (𝑎𝑔𝑒
230
)2.6
 
 
The model mathematically connects all the markers and presents four independent 
measurements as a single point on a ‘diagnostic surface’. The first element of the above 
equation represents the logarithmic ratio of test measurements, and the second 
element is a reference combination at the stipulated age. The final component is an 
adjustment for aging.  
 
cB12 is more reliable when based on all four markers because of the larger amount of 
information encoded, but can be derived using equations that allow incomplete 
indicators, i.e. based on two or three markers. When using three markers, having hcy 
missing is more reliable than having any of the other three markers missing64. 
Adjustment of cB12 is required if serum folate is <10 nmol/L and hcy is measured.  cB12 
values are classified as follows: >1.5=elevated vitamin B12; -0.5-1.5=adequate vitamin 
B12; -1.5 – -0.5=low vitamin B12; -2.5 - -1.5=possible vitamin B12 deficient; and <-
2.5=probable vitamin B12 deficient. These cut-points are based on statistical criteria and 
physiological indicators based on haemoglobin and cognitive score, and are relevant for 
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adults only. A key advantage of using cB12 to measure vitamin B12 status is its use of 
both circulating and functional markers of vitamin B12.  
 
However, cB12 has been used in only four65-68 studies to date. One of these is a small 
pre-treatment and post-treatment study65 of older subjects excluded from taking part 
in a larger cluster RCT69 looking at nerve conduction and cognitive function (because 
their vitamin B12 level was <120 pmol/l). In relation to cB12, this study reported that, in 
response to intramuscular treatment of 10 mg cyanocobalamin, 100mg pyridoxine and 
100 mg thiamin for 4 months, subjects with baseline serum folate above the median had 
statistically significantly less improvement in cB12 than those with baseline folate below 
the median. Risch et al.66 measured several indicators of vitamin B12 status, including 
cB122, and its association with age, gender and kidney function in a healthy Swiss 
population aged ≥60 years. cB12 was independently associated with renal function but 
not age. As discussed in Section 1.7.3, elevated MMA and hcy are also associated with 
impaired renal function. The remaining two studies were conducted in cancer patients 
and subjects with mild cognitive impairment. Vashi et al.68 used ROC (receiver operating 
characteristic) curves to evaluate the diagnostic accuracy of vitamin B12, MMA and hcy 
using cB12 as the ‘gold standard’ in cancer patients. Kobe et al.67 conducted secondary 
cross-sectional analyses using cB12 and memory performance and hippocampal 
structure in a subjects with mild cognitive impairment. Associations between lower 
serum vitamin B12 and poorer memory performance, recognition scores and lower 
delayed-recall scores were largely unchanged when cB12 was used as a measure of 
vitamin B12 status instead. Overall, use of cB12 as a measure of vitamin B12 status is in 
its early stages and to date has not been specifically validated against neurologic 
outcomes.  
1.8 Vitamin B12 status in the UK  
This section presents data on vitamin B12 intakes and status in the UK, based on the 
National Diet and Nutrition Survey (NDNS). This is a survey of the nutritional status of 
the UK population; it is now a rolling programme updated annually.  
                                                          
2 In this study cB12 was calculated using an earlier version of the cB12 equation without the age adjustment factor. 70. Fedosov, 
S.N., Metabolic signs of vitamin B(12) deficiency in humans: computational model and its implications for diagnostics. Metabolism, 
2010. 59(8): p. 1124-38. 
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1.8.1 Intakes 
The most recent NDNS reports vitamin B12 intakes across all age groups for years 1-4 of 
the rolling programme (data collected from 2008/2009 – 2011/12)12. Vitamin B12 
intakes (measured by 4 day food diaries) were adequate across adults and older adults 
(mean daily intake was 6.4µg for adults aged ≥65 years). Only 1% of adults aged ≥65 
years had vitamin B12 intakes below the LRNI3. 
 
1.8.2 Biological measures of status 
Results from years 1-4 of the NDNS rolling programme12 report mean serum vitamin B12 
and % below 150 pmol/l as shown in Table 2. The assay used was a competitive 
immunoassay using direct chemiluminescence (ADVIA Centaur vitamin B12 assay). This 
survey shows some evidence of low vitamin B12 status in women and older men and 
women. 
 
Table 2: Vitamin B12 status in National Diet and Nutrition Survey, by age and sex 
 Men Women Total 
 19-64y ≥65y 19-64y ≥65y 19-64y ≥65y 
Mean (SD) serum   
vitamin B12 (pmol/l) 
265 (96.1) 254 (95.3) 265 (97.6) 283 (109.8) 265 (96.8) 270 (104.6) 
% below 150 pmol/l 2.5 5.9 7.1 5.9 4.9 5.9 
 
An earlier NDNS published in 1998 focussed on adults ≥65 years71. Serum vitamin B12 
(measured using a radioimmunoassay using human intrinsic factor as a binder) data 
showed that 8% and 7% of men and 5% and 10% of women (free-living and living in 
institutions respectively) had serum vitamin B12 <118 pmol/l. This older survey clearly 
shows some evidence of low vitamin B12 status in older adults. 
 
Clarke et al.31 studied the prevalence of vitamin B12 deficiency in an elderly population 
in the UK. In this study conventional vitamin B12 deficiency was defined as vitamin 
B12<150pmol/l and metabolically significant vitamin B12 deficiency as vitamin B12<200 
                                                          
3 LRNI is the amount of a nutrient that is enough for only the small number of people who have low requirements (2.5%). 
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pmol/l and hcy>20µmol/l. The results of three population based studies of older people 
[The Oxford Healthy Aging Project (OHAP)72, the NDNS of people aged 65 years and 
older71 and the Medical Research Council (MRC) nutrition study73] were used, from 
which 1549 subjects with complete data were included in analyses. Each study used a 
different vitamin B12 assay: the OHAP used a competitive protein-binding 
radioimmunoassay on an ACS Centaur using an automated chemiluminescence system; 
the NDNS used a radioimmunoassay using human intrinsic factor as a binder; and the 
MRC nutrition study used a Becton Dickinson simultrac kit. The variability between 
assays limits the application of a universal cut-off value to define vitamin B12 status. 
However, the use of the ‘metabolically significant vitamin B12 deficiency definition’ 
attempts to compensate for this by including hcy status in the definition; hcy correlates 
more closely between individuals. Overall, 5% of people aged 65-74 years and 10% 
people aged ≥75 years had low vitamin B12 levels or metabolically significant vitamin 
B12 deficiency. In all three studies, the prevalence of vitamin B12 deficiency increased 
with age. 
 
Further afield, there is evidence of a high prevalence (up to 15%) of elevated MMA and 
associated low/low-normal vitamin B12 in older population groups across the US and 
Europe74. Less is known about vitamin B12 status in developing countries. 
 
1.9 Measuring neurological function 
 
1.9.1  Clinical assessment 
The neurological effects of vitamin B12 status can be measured in many ways. Some 
methods rely simply on symptoms reported by a subject/patient. A subject might be 
asked questions about pain, feelings of altered sensation (eg tingling/burning known as 
paresthesia) or numbness (reduced sense of touch known as hypoesthesia), unsteady 
gait or weakness. 
 
Clinicians can conduct a number of examinations to detect neurological impairment. 
Common tests and signs are described in Box 2. These can be used in studies as clinical 
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markers of neurological function, but these methods are not free from subjectivity of 
the clinician conducting the examinations and can also be influenced by the patient. 
 
Box 2: Common clinical signs used to assess neurological function 
 
 
1.9.2 Nerve conduction studies 
 
1.9.2.1 Nerve conduction in the peripheral nervous system 
Nerve conduction studies provide objective information about different types of 
neuropathy in the PNS: axonal degeneration and demyelination. They can also tell us 
about the anatomical distribution of neuropathies and whether they are sensory or 
motor75, 76. 
 
In nerve conduction studies, the nerve is stimulated by placing a negative cathode and 
adjacent anode over the nerve and then generating an electrical pulse between them (a 
supramaximal stimulus is used to ensure that all nerve fibres within the nerve are 
activated). Signals are then recorded from an electrode placed over another distant part 
of the nerve (for sensory nerves) or over the innervated muscle (for motor nerves). The 
Proprioception/position sense is the sense of the relative position of neighbouring parts of 
the body and strength of effort being employed by movement.  In the Romberg’s test, the 
patient is stood up and asked to close his eyes. A loss of balance is interpreted as a positive 
Romberg's sign. 
Vibration sensation is the sense of vibration sometimes tested by placing a vibrating tuning 
fork on the skin and asking the patient whether they can detect any vibration. 
Ataxia is the lack of voluntary coordination of muscles. Finger-nose and heel-knee-shin 
tests can be used to assess a patient’s ability to judge the position of a target. 
Monofilament testing is used to detect peripheral neuropathy in the feet. The 
monofilament is placed on the foot to assess the loss of protective sensation.  
The plantar response/reflex is elicited when the sole of the foot is stimulated with a blunt 
instrument. When normal this causes a downward response of the great toe. When an 
upward response of the great toe is seen this is called the Babinski sign.  
Ankle/knee jerk reflexes are sought in response to taps on the Achilles tendon or patellar 
ligament with a reflex hammer. Absence of a reflex response (hyporeflexia) is a sign of 
nerve pathology.  
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recording electrode registers a signal with a distinctive shape; there is an initial upward 
(negative) deflection followed by a downward deflection. The recorded signals are called 
the compound muscle action potentials (CMAPs) for motor nerves (Figure 5)  or sensory 
(nerve) action potentials (SNAPs or SAPs) for sensory nerves (Figure 6)77. Sensory nerve 
responses are three times smaller than motor responses so several signals need to be 
averaged when recording to be able to produce reliable results. 
 
Figure 5: Motor nerve conduction study and sample of compound muscle action potential 
recording (adapted from Misulis, 2003, p13578) 
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Figure 6: Sensory nerve conduction study and sample of sensory nerve action potential 
recording (adapted from Misulis, 2003, p13978) 
 
 
The signal amplitude (max height of the negative deflection), the area (under the 
negative deflection) and the signal latency time (time from stimulus onset to onset of 
negative deflection) are all used to interpret function of the nerve. The latency can be 
used to calculate nerve conduction velocity (NCV). To ensure that the conduction 
velocity only reflects the conduction in the nerve alone (i.e. not including conduction in 
the muscle or at the neuromuscular junction) the stimulus is applied at two points along 
the nerve; the difference in latencies reflects the NCV between the two points of 
stimulation on the nerve77. 
 
Axonal degeneration is characterised by reduced signal amplitude as there are fewer 
functional nerve fibres to carry the action potential that is picked up by the recording 
electrode. Demyelination is characterised by reduced conduction velocities77. Vitamin 
B12 has a role in myelination of nerves so NCV is of particular interest when investigating 
the relationship between vitamin B12 status and neurological function.  
 
1.9.2.2 Nerve conduction in the central nervous system 
Methods have also been developed to investigate neurological function in the CNS. 
Motor evoked potentials (MEP) are signals recorded from muscles following direct 
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stimulation of the motor cortex of the brain. Stimulation can be induced by transcranial 
magnetic stimulation (TMS) or using an electrical stimulator. TMS involves inducing a 
rapidly changing magnetic field in the brain by passing a massive current through a coil 
of wire held over the scalp79, and is painless for the subject. This initiates motor nerve 
signals and a muscle twitch. 
 
Central conduction can be assessed from the delay, or latency, between the stimulus 
and the evoked response. Signals running from the brain to muscles not only involve the 
CNS but also involve the PNS. This causes variations in the delay between stimulus and 
response, largely because conduction velocity in peripheral nerves is sensitive to 
temperature of the limbs79. It is possible to isolate measurement of nerve conduction in 
the central nervous system alone by calculating the central motor conduction time 
(CMCT), which is a measure of nerve conduction from the motor cortex of the brain to 
the spinal cord. 
 
There are two approaches to measuring CMCT. The first is an F-wave study which 
involves stimulating a peripheral motor nerve at the muscle to elicit a signal (F-wave) 
that travels to the spinal cord (opposite to usual direction) and back to the muscle80. The 
F wave latency is then divided by two and subtracted from the latency of the signals 
(MEPs) running from the cortex to the muscle. Alternatively MEPs are recorded 
following stimulus at the cervical/lumbar region of the spinal cord. CMCT can be 
calculated as the difference between the latency to the muscle after cortical stimulation 
and latency to the muscle after cervical/lumbar stimulation81. 
 
There are other measures used to assess function of the CNS. The cortical silent period 
is an electrical silence lasting 40-300ms in a contracting muscle following a TMS-induced 
MEP. The cortical silent period is useful for investigating some neurological disorders 
and is thought to reflect function of the inhibitory neurotransmitter GABA (gamma 
aminobutyric acid)82. The corticomotor threshold is defined as the lowest stimulation 
intensity able to evoke a MEP of minimal size and is usually assessed in the small hand 
muscle82. A raised threshold could represent inexcitability of spinal motoneurons or 
motor cortex neurons and is implicated in various neurological disorders80. 
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1.10 Uncertainties in the neurological effects of low vitamin B12 status. 
It is known that low vitamin B12 status affects many older people but the functional 
significance of ‘subclinical’ low vitamin B12 status (absence of symptoms) in older 
people is not clear. In particular, the public health significance of low vitamin B12 status 
on neurological manifestations remains unknown. Neurological signs and symptoms 
caused by low vitamin B12 status may be non-specific and often attributed to 'old age'. 
Such symptoms can nevertheless have an important impact on functional ability in terms 
of physical function, social independence, mobility and ability to conduct activities of 
daily life. For example, researchers have shown a link between peripheral neuropathy 
and impaired balance and falls. Older people prone to falls may then limit their physical 
activity further adding to loss of functional ability. Peripheral neuropathy has also been 
associated with lower health-related quality of life, foot deformity and pain and skin 
ulceration18, 19, 83.  
 
Accordingly, the neurologic impact of low vitamin B12 status in older people could 
contribute significantly to the burden of loss of functional ability in older age, with public 
health consequences at a population level. Currently, very little is known about the 
neurologic implications of low vitamin B12 status outside the clinical setting where the 
focus is on direct examination or treatment of patients. Impaired neurological function 
is a recognised consequence of frank vitamin B12 deficiency but it is not known what 
needs to be done to identify and treat those at risk. It has been suggested that routine 
vitamin B12 supplementation is needed in older people in light of the high prevalence 
of mild, preclinical deficiency61 but it is important to gather evidence on whether those 
at risk will benefit.  In order to optimise assessment and monitoring of interventions the 
WHO has identified a research need to establish objective criteria to assess early 
neurological impairment caused by vitamin B12 deficiency, ideally using 
neurophysiologic measurements57. Early detection of ‘subclinical’ vitamin B12 status 
could lead to a reduction in vitamin B12-neurological impairment and consequent 
impaired functional ability by preventing progression to a more serious clinical 
deficiency state.  
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Maintenance of functional ability in later life has become a major public health concern, 
a key area of ageing research and a target for the development of effective policies and 
programmes2, 4. To help answer the uncertainties outlined above, this thesis aims to 
improve our understanding of the contribution of vitamin B12-neurological impairment 
to the public health challenge of ageing. Determining whether subclinical low vitamin 
B12 status is a problem and should be treated requires evidence on the number of 
people likely to develop neurological impairment and the efficacy of treatment31. The 
research questions outlined in Section 1.1.1 focus on the neurological effects of low 
vitamin B12 status in older people and will be addressed in the subsequent chapters of 
this thesis. 
 
1.10.1   Structure of the thesis 
The thesis has been presented in research paper style and includes three manuscripts 
prepared for publication in peer-reviewed journals, alongside additional material in 
linking chapters. Each manuscript prepared for publication and included as a thesis 
chapter is preceded by a cover sheet on publication details and a preface describing how 
the manuscript fits into the thesis as a whole.  
 
Chapter 2 (addressing research question 1a) is a systematic review of observational 
studies that has been published in the British Journal of Nutrition. Chapter 3 (addressing 
research question 2a) is a secondary analysis of baseline data from the OPEN study 
prepared and submitted for publication. Chapter 4 reports the findings of a systematic 
review of intervention studies (addressing research question 1b). Chapter 5 is a 
manuscript prepared for submission to a peer-reviewed journal, reporting further 
secondary analyses using data from the OPEN study (addressing research question 2b). 
Finally, Chapter 6 discusses and integrates the findings from each of the research 
questions to derive overall conclusions and draw policy implications for the study 
findings. Chapter 6 also outlines the strengths and limitations of all the work conducted 
and suggests directions for further research. 
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Chapter 2: Is there an association of vitamin B12 status with neurological 
function in older people? A systematic review 
 
Preface 
 
As described in Chapter 1, this study aims to improve our understanding of the 
contribution of vitamin B12-neurological impairment to the public health challenge of 
ageing. By assessing the relationship between low vitamin B12 status and neurologic 
function in older people, it is hoped that findings will help determine whether subclinical 
low vitamin B12 status in older people is a public health problem.  To date, the 
epidemiological evidence of the association of vitamin B12 status with neurological 
function has not been systematically reviewed. Chapter 2 presents a systematic review 
which aims to evaluate the association of low vitamin B12 status with neurological 
outcomes relevant to central and peripheral nerve function in older people. The 
research question addressed here is: 
 
1a) Is there any evidence in the available literature that vitamin B12 status is 
associated with neurological function in older people? 
 
My role in this research was to develop the protocol for the review, conduct the 
systematic search of the literature, select articles for inclusion, complete data extraction 
and quality assessment of included studies, interpret results of the review and write the 
manuscript. 
 
This systematic review has already been published in the British Journal of Nutrition so 
the manuscript is presented here alongside supplemental materials available on the 
journal website, namely A) Medline search strategy B) Study characteristics used to 
assess risk of bias and Supplemental tables S1 (Study characteristics and main findings 
of studies based on subjects from the general population) and S2 (Study characteristics 
and main findings of studies based on subjects with low vitamin B12 status). 
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Abstract
Low vitamin B12 status is common in older people; however, its public health significance in terms of neurological manifestations remains
unclear. The present systematic review evaluated the association of vitamin B12 status with neurological function and clinically relevant
neurological outcomes in adults aged 50þ years. A systematic search of nine bibliographic databases (up to March 2013) identified
twelve published articles describing two longitudinal and ten cross-sectional analyses. The included study populations ranged in size
(n 28–2287) and mean/median age (range 65–81 years). Studies reported various neurological outcomes: nerve function; clinically
measured signs and symptoms of nerve function; self-reported neurological symptoms. Studies were assessed for risk of bias, and results
were synthesised qualitatively. Among the general population groups of older people, one longitudinal study reported no association, and
four of seven cross-sectional studies reported limited evidence of an association of vitamin B12 status with some, but not all, neurological
outcomes. Among groups with clinical and/or biochemical evidence of low vitamin B12 status, one longitudinal study reported an associ-
ation of vitamin B12 status with some, but not all, neurological outcomes and three cross-sectional analyses reported no association. Over-
all, there is limited evidence from observational studies to suggest an association of vitamin B12 status with neurological function in older
people. The heterogeneity and quality of the evidence base preclude more definitive conclusions, and further high-quality research is
needed to better inform understanding of public health significance in terms of neurological function of vitamin B12 status in older people.
Key words: Vitamin B12: Neurological function: Nerve conduction: Older people
Ageing is associated with a decline in vitamin B12 status
(1,2),
and there is widespread evidence of low vitamin B12 status
in older people(1,3). In the UK, 5% of adults aged 65–74
years and 10% adults aged $75 years have low vitamin B12
levels (defined as vitamin B12 ,150 pmol/l) or metabolically
significant vitamin B12 deficiency (defined as vitamin B12
,200 pmol/l and homocysteine level .20mmol/l)(1). How-
ever, intakes of vitamin B12 in adults are mostly adequate
and in the most recent National Diet and Nutrition Survey of
the UK, only 1% of adults aged 65–74 years and $75 years
had vitamin B12 intakes below the lower reference nutrient
intakes(4). Several factors relating to vitamin B12 absorption
may contribute to poor status in older people, including a
decrease in gastric acidity, the presence of atrophic gastritis,
compromised functional and structural integrity of vitamin
B12-binding proteins, and lack of liver vitamin B12 stores
(5).
Indeed, food-cobalamin malabsorption can account for up
to 60–70% of confirmed cases of vitamin B12 deficiency in
older people(6).
The clinical manifestations of vitamin B12 deficiency can be
haematological, neurological or both(7); neurological symp-
toms can occur in the absence of anaemia in 20–30% of
cases(8). Pathological investigations in vitamin B12 deficiency
reveal demyelination in the spinal cord, peripheral nerves
and/or the white matter of the brain(7) and an abnormal
increase in astrocytes in the brain due to damage to nearby
neurons(9). It has been proposed that the mechanism by
which vitamin B12 deficiency affects neurological function
involves impairment of vitamin B12-dependent enzyme
functions. Impaired function of methionine synthase leads to
elevated homocysteine levels, and impaired function of
L-methylmalonyl-CoA mutase leads to elevated methyl
*Corresponding author: Lisa M. Miles, email lisa.miles@lshtm.ac.uk
Abbreviation: SIGN, Scottish Intercollegiate Guidelines Network.
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malonic acid concentrations, each resulting in impaired
methylation reactions and changes to fatty acid incorporation
in myelin(10,11). However, there is recent evidence to suggest
that mechanisms involving an imbalance in cytokines and
growth factors in the central nervous system may be import-
ant; it is not yet clear whether these findings can be extended
to the peripheral nervous system(12,13). Symptoms of periph-
eral neuropathy associated with vitamin B12 deficiency
commonly include symmetric paresthesias, numbness or gait
problems. Other neurological defects include impaired
vibration sense, impaired position and cutaneous sensation,
ataxia, and weakness(2,7). The relationship between vitamin
B12 status and cognitive function has been reviewed exten-
sively elsewhere(14–17).
The functional and public health significance of low vitamin
B12 status in older people is currently unclear. In the clinical
setting, impaired neurological function is a known marker of
frank vitamin B12 deficiency. However, whether neurological
impairment is associated with low vitamin B12 status at a
population level is unknown. To date, the epidemiological
evidence of the association of vitamin B12 status with neuro-
logical function has not been systematically reviewed. The
present systematic review aims to evaluate the association of
low vitamin B12 status with neurological outcomes relevant
to central and peripheral nerve function in older people. It
is hoped that findings will inform public health and nutrition
guidance to be provided on the functional relevance of
vitamin B12 status in later life.
Experimental methods
Methods of analysis and inclusion criteria were specified in
advance and documented (protocol available on request
from the authors). The present systematic review is reported
according to the Preferred Reporting Items for Systematic
Reviews and Meta-Analyses guidelines.
Search strategy
A systematic search of bibliographic databases was conducted
on 28 March 2013. All observational study designs assessing
the association of vitamin B12 status with neurological out-
comes in older people were included except case reports/
series, narrative reviews, editorials and conference reports.
Included subject groups were older people with a median
or mean age $50 years and could be resident in institutions
or the community. Studies of subject groups with known
existing medical conditions affecting neurological function
(including alcoholism, HIV, diabetes-associated neuropathy
or motor neurone disease), vitamin B12 status (including
bariatric surgery) or metabolites of vitamin B12 (including
renal insufficiency) were excluded. Included exposures were
serum/plasma vitamin B12, transcobalamin (a binding protein
for vitamin B12), holotranscobalamin (the form of vitamin B12
able to cross into the cells), methyl malonic acid (a metabolite
of vitamin B12) and dietary vitamin B12 (but not multiple
vitamin and mineral supplements). Included outcomes were
peripheral sensory or motor nerve function/conduction,
central motor conduction; peripheral neuropathy; clinical
signs and symptoms of neurological (but not cognitive) func-
tion (somatosensory disorders, knee and ankle jerk/reflexes,
joint, position and vibration sense, ataxia, and propriocep-
tion); and self-reported neurological (but not cognitive)
symptoms (pain, altered sensation, unsteadiness, prickly
feelings, weakness, numbness, and difficulty walking).
Search terms were developed for nine medical and public
health databases using both MeSH terms and text terms
where possible: MEDLINE (1946 to March week 3, 2013; see
online Supplementary data); Global Health (1910 to February
2013); EMBASE (1974 to 27 March 2013); PsycInfo (1806 to
March week 3, 2013); CINAHL Plus (1937 to March 2013);
Cochrane Library (inception to March 2013); ClinicalTrials.gov
(inception to March 2013); Scopus (1823 to 28 March 2013);
TRIP database (inception to March 2013). Papers not trans-
lated into English and grey literature were excluded. The
reference lists of included studies were hand-searched for
any further articles relevant to the review.
Assessment of eligibility of studies and data extraction
Articles were assessed for inclusion first using titles and
abstracts, and then full copies of articles considered poten-
tially relevant were reviewed. Eligibility assessment was
carried out by two independent reviewers (L. M. M. and
A. D. D.). Disagreements were resolved by discussion
between the two reviewers; if no agreement could be reached,
a third party was available to arbitrate.
Once the included list of papers was finalised, one reviewer
(L. M. M.) extracted data and assessed risk of bias in each
paper; another author (A. D. D.) checked the extracted data.
Disagreements about extracted data were resolved by discus-
sion between the two reviewers. Forms for data extraction and
assessment of risk of bias were developed based on checklists
developed by the Scottish Intercollegiate Guidelines Network
(SIGN)(18). These checklists relate to study characteristics that
are likely to have a significant influence on the validity of the
reported results. Data were extracted into forms, defined accord-
ing to the SIGN guidance, and risk of bias was assessed for
each study based on the research question, selection of
subjects (including age and population type), exposure and
outcome assessment, comparisons made and effect sizes/
summary measures, follow-up time (where appropriate),
adjustment for confounders, and statistical analysis. Each
of these study characteristics was judged as ‘well
covered’, ‘adequately addressed’, ‘poorly addressed’, ‘not
addressed’, ‘not reported’ or ‘not applicable’. Neurological
outcomes were categorised as measures of nerve function
(nerve conduction studies), clinically assessed signs and
symptoms of peripheral neuropathy or self-reported symp-
toms. The latter outcomes were judged to be ‘poorly
addressed’ because self-reported symptoms are subjective
and open to bias from the subject. Studies mostly achieving
‘well covered’ or ‘adequately addressed’ were judged to
have a low risk of bias; others were judged to have a risk of
bias. The assessment of risk of bias was completed at the
study level (see online Supplementary data) and was used in
the qualitative synthesis of results to place greater emphasis
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on studies of higher quality. No study was excluded based on
the assessment of risk of bias.
All study characteristics, effect sizes and summary measures
were extracted from studies and tabulated to allow compari-
son. Care was taken to identify cases where multiple articles
were published from the same study. When a report referred
to data on relevant exposures and outcomes that could be
included in the review, or when potentially relevant
exposures or outcomes were not reported, efforts were
made to contact the author for further information. The
authors of eight articles were contacted by email and four
authors responded. Of these, two authors provided further
information that has been included in the results and two
authors did not provide any additional information.
Resultswere synthesised in a qualitativemanner. Studieswere
reviewed to assess whether findings varied according to the
study population (general population or subjects with evidence
of vitamin B12 deficiency), category of neurological outcome,
definition of low vitamin B12 status, adjustment for confounders
or age. Combining data by meta-analysis was not possible as a
result of the heterogeneity of the available evidence. To identify
risk of bias from selective reporting, for each included article,
the reviewers checked whether all exposures and outcomes
measured were also reported in the results section. No formal
testing of publication bias was possible.
Results
Study selection
The search identified 982 records. Of these, 835 were
excluded as not relevant following title and abstract review.
Full-text articles for the remaining 147 records were sought,
though one was not retrievable(19). Furthermore, two
additional articles identified through hand-searching did not
meet the inclusion criteria. A total of 148 full-text articles
were examined in detail; 136 did not meet the pre-defined
inclusion criteria. Full-text articles were most commonly
excluded because they were not original reports from
observational studies, neurological outcomes focused only
on cognition, and/or the mean/median age of the study
subjects was #50 years. Finally, twelve articles were included
in the review (Fig. 1).
Study characteristics
Twelve reports from ten studies (two longitudinal and ten
cross-sectional analyses) met the inclusion criteria. Of these,
six were conducted in Europe(20–27), with the remaining
studies conducted in the USA(28), Asia(29,30) and Australia(31).
Of the European articles, three were from Denmark with over-
lapping samples of participants from the same study(20–22).
There was heterogeneity in the types of population from
which subjects were drawn; eight articles(23,24,26–31) were
based on general population groups of older people, though
two of these recruited from hospitals (see online Supplemen-
tary Table S1), and four articles(20–22,25) (from two studies)
were based on subjects with clinical and/or biochemical evi-
dence of low vitamin B12 status (see online Supplementary
Table S2). The studies included in the review involved partici-
pants aged 65–81 years. There was heterogeneity between
studies in the definition of vitamin B12 status and in the neuro-
logical outcomes reported. Most studies reported on more
than one category of neurological outcome. Five studies
measured electrophysiological measures of nerve function,
1648 records were identified through database search
982 records were screened for inclusion based on the title/abstract
147 full-text articles were identified  to assess for eligibility
Two articles were identified
through hand-searching
One article was not
retrievable
148 full-text articles were assessed for eligibility
Twelve articles were included in the qualitative analysis
982 unique records were identified after removing duplicates
835 records were excluded
136 full-text articles were
excluded
Fig. 1. Study selection process for the systematic review of the association of vitamin B12 status with neurological function in older people.
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ten studies reported clinically measured signs and symptoms
of neuropathy, and eight studies collected self-reported neuro-
logical symptoms.
Studies based on subjects from the general population
One longitudinal(23) and seven cross-sectional(24,26–31) ana-
lyses were based on general population groups of older
people (see online Supplementary Table S1). One longitudinal
study(23) with a follow-up of 3 and 6 years and low risk of bias
provided no evidence of an association of vitamin B12 status
or change in vitamin B12 status with electrophysiological
measures of nerve function or peripheral neuropathy. One
cross-sectional analysis(28) with a low risk of bias suggested
an association of low vitamin B12 status with some, but not
all, electrophysiological measures of nerve function. One
small cross-sectional analysis(29) with an identified risk of
bias found no association of vitamin B12 status and electro-
physiological measures of nerve function. Five further
cross-sectional studies with low(24,26) or identified(27,30,31)
risk of bias reported clinically measured signs and symptoms
of neuropathy and self-reported neurological symptoms, and
provided mixed results. Three analyses(24,27,30) identified a
statistically significant association of vitamin B12 status with
some, but not all, clinical signs of neuropathy or self-reported
symptoms, the remaining two cross-sectional studies(26,31)
reported no associations with any outcome. Four studies
based on subjects from the general population adjusted for
at least age and sex in the analyses; there was no clear pattern
in findings according to adjustment for confounders.
Studies based on subjects with low vitamin B12 status
One longitudinal analysis(22) (mean follow-up1·0–3·9 years) and
three cross-sectional analyses(20,21,25) were based on subjects
with clinical and/or biochemical evidence of low vitamin B12
status (see online Supplementary Table S2). One small cross-
sectional study(25) with an identified risk of bias found no
association of vitamin B12 status with electrophysiological
measures of nerve function (no adjustment for confounders).
The remaining three articles from one Danish study had
identified risk of bias, reported neurological signs and symptoms
as outcomes, and adjusted for age and sex. The cross-sectional
analyses(20,21) from the Danish study did not identify any
association of vitamin B12 status with neurological symptoms;
the results from the longitudinal analysis were mixed.
The next two paragraphs refer to all the results, not just
studies based on subjects with low vitamin B12 status.
Overall, there was no clear pattern in findings according to
ageof subjects or adjustment for confounders.Of thefive studies
that reported positive associations between vitamin B12 status
and neurological function, three used composite definitions of
low vitamin B12 status involving plasma/serum vitamin B12
plus elevated methyl malonic acid or homocysteine levels.
The exercise to identify selective reporting bias showed
that two cross-sectional studies(27,30) did not report results for
all neurological outcomes measured. In addition, one longitudi-
nal analysis of participants with low vitamin B12 status
(22)
measured dietary vitamin B12 intake, but did not report any
results for associations with neurological outcomes. Overall,
this suggests that selective reporting of outcomes within some
studiesmayhave affected risk of bias in the cumulative evidence.
Discussion
Overall, there is limited evidence from observational studies of
older people living in the general population to suggest an
association of vitamin B12 status with neurological function.
Few studies are available, and the majority are cross-sectional
in design, limiting any causality inference. The single longi-
tudinal analysis using a general population group found no
association between vitamin B12 status and nerve conduc-
tion(23). The limited evidence for an association comes from
four of seven cross-sectional analyses(24,27,28,30) that identified
positive associations of vitamin B12 and neurological function
for some, but not all, outcomes. There is a similar lack of
evidence of an association from studies of subjects with low
vitamin B12 status. None of the three cross-sectional analyses
(from two studies)(20,21,25) reported any association of vitamin
B12 status with neurological function, and in the single longi-
tudinal analysis(22), results were mixed.
This is the first systematic review investigating the associ-
ation of vitamin B12 status with neurological function in
older people. Systematic reviews specifically aim to minimise
bias resulting from partial identification, evaluation and
reporting of the available evidence base. The search strategy
used in the present systematic review was comprehensive,
study eligibility assessment was carried out by two indepen-
dent reviewers, and each included study was assessed for
risk of bias. The literature search was limited to English
language and published literature, and may have missed
relevant studies published in other languages and in the
grey literature such as conference proceedings. The hetero-
geneity of the available evidence precluded the conduct of
meta-analysis.
Studies assessed a heterogeneous range of neurological
outcomes. The most sensitive and objective measures of
neurological function relevant to vitamin B12 status are electro-
physiological measures of nerve conduction. However, many
of the included studies were reliant only on self-reported
symptoms and/or signs and symptoms of neuropathy, which
are open to bias from the subject or clinician. It is possible
that outcome ascertainment is a limitation of the review.
There was also clinical heterogeneity in study populations
(general population or vitamin B12 deficient) and in how
low vitamin B12 status was defined. Debate continues about
the most appropriate method for assessing vitamin B12 status
in terms of the thresholds used to define low status or deficiency
and the use of various biomarkers. Recent developments
suggest the need to measure vitamin B12 status using both a
biomarker of circulating vitamin B12 and a functional biomarker
such asmethyl malonic acid or homocysteine(32). This approach
of using a composite measure was used in three of the included
studies, all of which reported some positive associations. Close
attention to the most appropriate definition of low vitamin B12
status is warranted in future research.
Lisa M. Miles et al.4
B
ri
ti
sh
Jo
ur
na
l
o
f
N
ut
ri
ti
o
n
Several studies identified in the review were subject to risk
of bias. Some studies did not provide adequate information
about response rates when recruiting to the study or infor-
mation about non-respondents, and five studies did not
adjust for confounders (age and sex) in the analyses. In
addition, selective reporting of outcomes within some studies
may have affected risk of bias in the cumulative evidence.
Overall, the lack of longitudinal studies, heterogeneity of the
evidence, and risk of bias made it difficult to reach any firm
conclusions.
Overall, there is limited evidence from observational studies
to suggest an association of vitamin B12 status with neurologi-
cal function in older people. Further high-quality research is
needed to better inform understanding of the clinical signifi-
cance (in terms of neurological function) of vitamin B12
status in older people. Well-designed observational studies
that comply with the latest recommendations on measuring
vitamin B12 status
(32) and measure neurological function by
nerve conduction would be most valuable. It is also important
that any studies measuring associations also identify and
adjust appropriately for confounders. Such evidence is
required in order to provide robust conclusions on whether
measures of vitamin B12 status are clinically relevant markers
of central and peripheral nerve function in older people.
Supplementary material
To view supplementary material for this article, please visit
http://dx.doi.org/10.1017/S0007114515002226
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A. Medline Search Strategy 
 
Database: Ovid MEDLINE(R) <1946 to March Week 3 2013> 
-------------------------------------------------------------------------------- 
1     Vitamin B 12/ (16932) 
2     Transcobalamins/ (929) 
3     Vitamin B 12 Deficiency/ (4745) 
4     vitamin b12.ab,ti. (11012) 
5     cobalamin.ab,ti. (2945) 
6     cyanocobalamin.ab,ti. (1016) 
7     hydroxocobalamin.ab,ti. (512) 
8     holotranscobalamin.ab,ti. (124) 
9     (vitamin b12 adj4 (supplement or supplementation)).ab,ti. (242) 
10     (dietary adj4 (cobalamin or vitamin b12)).ab,ti. (169) 
11     (vitamin b12 adj4 (deficient or deficiency or status)).ab,ti. (2328) 
12     (cobalamin adj4 (deficient or deficiency or status)).ab,ti. (809) 
13     1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 (23474) 
14     Geriatrics/ (25951) 
15     Middle Aged/ (3098034) 
16     Aged/ (2159247) 
17     Aging/ (177196) 
18     "Aged, 80 and over"/ (554589) 
19     Frail Elderly/ (6054) 
20     elderly.ab,ti. (150170) 
21     geriatric.ab,ti. (24101) 
22     veteran.ab,ti. (2218) 
23     "senil*".ab,ti. (13776) 
24     Neurologic Examination/ (23007) 
25     Nervous System/ (18420) 
26     Peripheral Nervous System/ (2786) 
27     Paresthesia/ (4930) 
28     Hypesthesia/ (2112) 
29     Hyperesthesia/ (794) 
30     Hyperalgesia/ (6580) 
31     Somatosensory Disorders/ (888) 
32     Reflex/ (29643) 
33     Sensation/ (12176) 
34     Proprioception/ (5817) 
35     Touch/ (12279) 
36     Ataxia/ (6102) 
37     Peripheral Nerves/ (19809) 
38     Neural Conduction/ (24964) 
39     Motor Neurons/ (33288) 
40     Motor Activity/ (70355) 
41     (neur* adj4 function*).ab,ti. (62314) 
42     (nerv* adj4 function*).ab,ti. (18456) 
43     paresthesia.ab,ti. (2748) 
44     numbness.ab,ti. (4575) 
45     hyp#sthesia.ab,ti. (705) 
46     hyperalgesia.ab,ti. (7821) 
47     (sensory adj4 (impair* or coordinat* or perform* or funct*)).ab,ti. (9706) 
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48     (neur* adj4 (examin* or test*)).ab,ti. (59739) 
49     ataxia.ab,ti. (22229) 
50     proprioception.ab,ti. (2255) 
51     (motor adj4 (funct* or skill* or neur* or activit* or nerv* or conduct* or impair* or coordinat* 
or 
perform*)).ab,ti. (83854) 
52     (nerv* adj4 (conduct* or funct* or perform*)).ab,ti. (32451) 
53     (neur* adj conduct*).ab,ti. (501) 
54     somatosensory disorders.ab,ti. (14) 
55     touch.ab,ti. (12006) 
56     Neurophysiology/ (5808) 
57     (old adj4 (people or person or m#n or wom#n or femal* or mal* or adult)).ab,ti. (281586) 
58     (frail adj4 (people or person or m#n or wom#n or femal* or mal* or adult)).ab,ti. (935) 
59     (senior adj4 (people or person or m#n or wom#n or femal* or mal* or adult)).ab,ti. (623) 
60     (elderly adj4 (people or person or m#n or wom#n or femal* or mal* or adult)).ab,ti. (31643) 
61     (aged adj4 (people or person or m#n or wom#n or femal* or mal* or adult)).ab,ti. (94672) 
62     (mature adj4 (people or person or m#n or wom#n or femal* or mal* or adult)).ab,ti. (6430) 
63     (advanced age adj4 (people or person or m#n or wom#n or femal* or mal* or adult)).ab,ti. (884) 
64     14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 57 or 58 or 59 or 60 or 61 or 62 or 63 
(3912034) 
65     Action Potentials/ (71309) 
66     Electromyography/ (63955) 
67     Sensory Thresholds/ (14561) 
68     Evoked Potentials, Motor/ (5579) 
69     Kinesthesis/ (2853) 
70     (nerv* adj4 (examin* or test*)).ab,ti. (9593) 
71     compound muscle action potential.ab,ti. (1015) 
72     F-wave.ab,ti. (970) 
73     corticomotor threshold.ab,ti. (13) 
74     evoked potential.ab,ti. (9488) 
75     (monofilament adj4 (test* or examin*)).ab,ti. (255) 
76     (CMAP or SNAP or MEP or NCS or NCV or TMS or CMCT).ab,ti. (19770) 
77     transcranial magnetic stimulation.ab,ti. (6891) 
78     "central motor conduction stud*".ab,ti. (15) 
79     ((jerk or reflex) adj4 (knee or ankle)).ab,ti. (496) 
80     24 or 25 or 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33 or 34 or 35 or 36 or 37 or 38 or 39 or 40 
or 41 or 42 or 
43 or 44 or 45 or 46 or 47 or 48 or 49 or 50 or 51 or 52 or 53 or 54 or 55 or 56 or 65 or 66 or 67 or 68 
or 69 or 70 or 
71 or 72 or 73 or 74 or 75 or 76 or 77 or 78 or 79 (596558) 
81     13 and 64 and 80 (381) 
82     limit 81 to english language (284) 
83     Transcranial Magnetic Stimulation/ (5498) 
84     80 or 83 (596991) 
85     13 and 64 and 84 (381) 
86     limit 85 to english language (284) 
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B. Study characteristics used to assess risk of bias (based on adapted Scottish 
Intercollegiate Guidelines Network checklist) 
 
i. Longitudinal studies 
Study characteristics Hvas et al (2001)22  Leishear et al (2012) 23  
Focussed research question Adequately addressed Well covered 
Groups being studied are selected from source 
populations that are comparable 
Poorly addressed Well covered 
Study indicates how many people were asked to take 
part in study 
Adequately addressed Well covered 
Percentage drop-out before study completed 7% 18% at 3 y 
38% at 6y 
Comparison is made between full participants and 
those lost to follow-up, by exposure status 
Not reported Not reported 
Outcomes are clearly defined Adequately addressed 
(neurological markers based 
on clinical examination) 
Poorly addressed (self-
reported neurological 
symptom score) 
 
Well covered 
Measurement of exposure is reliable/validated Adequately addressed Adequately addressed 
Measurement of outcome is reliable/validated Poorly addressed  Well covered 
Exposure level is assessed more than once Well covered Well covered 
Confounding taken into account Adequately addressed Well covered 
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ii. Cross-sectional studies 
Author (year) Focussed research 
question 
Subjects 
representative of 
larger population 
Study indicates 
how many 
people were 
asked to take 
part in study 
Information 
provided on non-
respondents 
Outcomes clearly defined Measurement 
of exposure 
reliable/ 
validated 
Measurement of outcome 
reliable/validated 
Confounding 
taken into 
account 
Bjorkegren and 
Svardsudd 
(2003)26 
Well covered Well covered Well covered Adequately 
addressed 
Adequately addressed 
(neurological markers based on 
clinical examination) 
Poorly addressed (self-reported 
neurological symptoms) 
 
 
Adequately 
addressed 
Adequately addressed 
(neurological markers based on 
clinical examination) 
Poorly addressed (self-reported 
neurological symptoms) 
Adequately 
addressed 
Gadoth et al 
(2005)27 
Adequately 
addressed 
Adequately 
addressed 
Poorly addressed Not reported Adequately addressed 
(neurological markers based on 
clinical examination) 
Poorly addressed (self-reported 
neurological symptoms) 
Well covered Adequately addressed 
(neurological markers based on 
clinical examination) 
Poorly addressed (self-reported 
neurological symptoms) 
Not addressed 
Hin et al (2006)24 Well covered Well covered Well covered Poorly addressed Adequately addressed 
(neurological markers based on 
clinical examination) 
Poorly addressed (self-reported 
neurological symptoms) 
Adequately 
addressed 
Adequately addressed 
(neurological markers based on 
clinical examination) 
Poorly addressed (self-reported 
neurological symptoms) 
Adequately 
addressed 
Hvas et al  
(2001)21  
Well covered Poorly addressed Adequately 
addressed 
Poorly addressed Adequately addressed 
(neurological markers based on 
clinical examination) 
Poorly addressed (self-reported 
neurological symptoms) 
Adequately 
addressed 
Adequately addressed 
(neurological markers based on 
clinical examination) 
Poorly addressed (self-reported 
neurological symptoms) 
Adequately 
addressed 
Hvas and Nexo 
(2005)20 
Poorly addressed Poorly addressed Not addressed Not addressed Adequately addressed 
(neurological markers based on 
clinical examination) 
Poorly addressed (self-reported 
neurological symptoms) 
Adequately 
addressed 
Adequately addressed 
(neurological markers based on 
clinical examination) 
Poorly addressed (self-reported 
neurological symptoms) 
Adequately 
addressed 
Leishear et al 
(2012)28 
Well covered Adequately 
addressed 
Not addressed Not addressed Well addressed (NCS) 
Adequately addressed 
(neurological markers based on 
clinical examination) 
Poorly addressed (self-reported 
neurological symptoms) 
Well covered Well addressed (NCS) 
Adequately addressed 
(neurological markers based on 
clinical examination) 
Poorly addressed (self-reported 
neurological symptoms) 
 
Well covered 
Metz et al 
(1996)31 
Adequately 
addressed  
 
Not addressed Not reported Not reported Adequately addressed  
 
Adequately 
addressed  
 
Poorly addressed  
 
Not addressed 
Sucharita et al 
(2012)29 
Adequately 
addressed 
Poorly addressed Adequately 
addressed 
Not addressed Well covered Adequately 
addressed 
Well covered Not addressed 
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Turgut et al 
(2006)25 
Poorly addressed Not addressed Not addressed Not reported Well covered Poorly 
addressed 
Well covered Not addressed 
Wang et al 
(2009)30 
Poorly addressed Not addressed Not reported Not reported Poorly addressed (NCS only in 
B12 deficient subjects) 
Adequately 
addressed 
Well addressed (NCS) 
Adequately addressed 
(neurological markers based on 
clinical examination) 
Poorly addressed (self-reported 
neurological symptoms) 
Not addressed 
 
NCS, Nerve Conduction Studies 
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Supplementary Table S1: Study characteristics and main findings of studies based on subjects from the general population  
 
Author (year) Subject characteristics Exposures Outcomes Effect sizes 
     
Leishear et al 
(2012)23 
General population in Italy 
(n=678). Mean age = 72.2 
±6.2y  
 
Serum B12  
Change in 
serum B12 at 
3y 
 
NF: CMAP and NCV measured between fibular head 
and ankle 
NP: Abnormal touch/vibration sensitivity, impaired 
sense of ankle position, abnormal deep tendon 
reflexes, positive Babinski sign and  positive 
Romberg sign 
NS: Pain and sensation  in feet 
 
NFa: 
- No stat sig differences in CMAP at baseline, 3y or 6 y (p=0.43, p=0.99, 
p=0.64) or NCV at baseline, 3y or 6 y (p=0.90, p=0.46, p=0.12) by change in 
B12 at 3y 
- In multivariate mixed models*, no stat sig association between change in 
B12 at 3y and change in CMAPs (low to normal B12, p=0.84, normal to low 
B12 p=0.55) or NCV(low to normal B12, p=0.88, normal to low B12 p=0.20) 
NSa: 
- No association between baseline B12 and symptoms, cross-sectionally or 
longitudinally (6y)**:  Low B12 (<260pmol/l ) and feeling numbness 
OR=1.30 (95% CI 0.81-2.07); Low B12 and feeling coldness OR=1.18 
(95%CI 0.81-1.72). 
 
Bjorkegren and 
Svardsudd (2003)26 
General population in 
Sweden (n=161), mean 
age=77y. 
 
Serum B12  
Serum MMA 
NP: Vibration perception threshold (carpal, tibial, 
tarsal), Romberg’s sign, reflex response (biceps, 
brachoradial, triceps, patellar, Achilles) 
NS: Numbness, paresthesia, walking difficulties, 
fumblingness and impaired touch perception 
 
NP: 
- No stat sig associations between serum B12 and vibration sense, Romberg 
sign or reflex response*** 
- No stat sig associations between serum MMA and vibration sense, Romberg 
sign or reflex response*** 
NS: 
- No stat sig association between serum B12 or serum MMA and neurological 
symptoms*** 
 
Gadoth et al (2005)27 Older people living in 
institutions/visiting day 
care centres, based in 
Israel. Mean age=79.5y. 
Subjects with B12 
deficiency (n=113) and 
controls (n=212) 
 
P-B12  
MMA 
NP: Sensory neuropathy based on symmetrical glove 
and stocking hypoesthesia, decreased vibration 
sensation and hyporeflexia 
Neurological impairment score based on sensory 
neuropathy and MMSE, myelopathy and history of 
confusional state 
 
NP:  
- Subjects with B12 deficiency (P-MMA ≥0.24 µmol/l and B12≤147 pmol/l) 
were 3.0 (95%CI 1.6-5.4, p<0.001) times more likely to have sensory 
neuropathy and 2.1 (95% CI1.3-3.3, p=0.002) times more likely to have 
decreased vibration sensation than controls; subjects with DM excluded. 
- Subjects with B12 deficiency had a stat sig higher neurological impairment 
score than controls (46.7%  versus 19.5%, p<0.0001) 
 
Hin et al (2006)24 General population in the 
UK, mean age=81.4y. 
Patients with low serum 
B12 (n=125) and normal 
serum B12 (n=875) 
 
Serum B12 
Serum 
HoloTC  
Serum MMA 
NP: Knee/ankle tendon jerks, joint position sense  
(great toe) and plantar response 
NS: unsteadiness, altered sensation, falls and pins and 
needles 
PN present if clinical sign score and symptom score 
both >2 
 
NP: 
- Stat sig association between  low holoTC (OR=1.49, 95% CI 1.00-2.21 
lowest v highest quartile) and elevated  MMA (OR=1.76, 95% CI 1.18-2.62, 
highest v lowest quartile) with risk of missing ankle tendon jerks**** 
NS: 
- No stat sig difference in neurological symptoms between patients with low 
(serum B12<133pmol/l, Beckman assay) versus normal 
(serumB12≥133pmol/l, Beckman assay) B12 status. 
- No stat sig associations between HoloTC, Serum B12 or MMA (as 
continuous variables) and PN**** 
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Leishear et al 
(2012)28 
General population in the 
USA; n=2287; mean age 
76.5y 
 
Serum B12  
Serum MMA 
2MCA 
Hcy 
Crystathione   
NF: CMAP and NCV (between popliteal fossa and 
ankle) 
NP: Monofilament testing and average vibration 
threshold (great toe) 
NS: Numbness, prickly feelings and aching/burning 
pain 
 
NF: 
- Compared to reference group , deficient B12 subjects (B12 <260pmol/l and 
MMA>0.27 µmol/l and MMA>2MCA) were stat sig more likely to have a 
lower mean NCV (p=0.006)***** 
- No significant differences found between deficient B12 status and reference 
group in CMAP***** 
- In multivariate analyses, compared to reference group, B12 deficient subjects 
had lower NCV (β=-1.16, p=0.01)******* 
- In multivariate analyses, no significant differences were found between 
deficient B12 status and reference group in CMAP********* 
NP:  
- Compared to reference group , deficient B12 subjects were stat sig more 
likely to be unable to detect 1.4g monofilament (p=0.01) and have a greater 
(worse) mean vibration threshold (p=0.003)***** 
- No significant differences found between deficient B12 status and reference 
group in ability to detect standard 10g monofilament and  % unable to detect 
vibration***** 
- In multivariate analyses, compared to reference group, B12 deficient subjects 
were (OR=1.5, 95% CI 1.06-2.13) more likely to be unable to detect 1.4g 
monofilament****** 
- In multivariate analyses, no significant differences were found between 
deficient B12 status and reference group in mean vibration threshold******** 
NS: 
- No significant differences found between deficient B12 status and reference 
group in PN symptoms***** 
- No significant differences found between deficient B12 status and reference 
group in % of subjects reporting numbness or aching/burning pain. 
- Using the alternative defn of low serum B12 (B12 <260pmol/l only), 
univariate and multivariate associations were similar  
 
Metz et al (1996)31 Hospital patients based in 
Australia. Mean age in 
patients with normal B12 = 
80.7y (n=51) subnormal 
B12= 79.8y (n=43).  70 
completed neurological 
examinations 
 
Serum B12  
HoloTCII 
NP: Neurological score based on vibration sense, 
joint position sense, cutaneous sensation, knee jerk 
reflex, plantar response and Romberg sign 
 
NP:  
- No stat sig difference in mean neurological score between subnormal B12 
(<150 pmol/l )  group (7.2 ±0.7) or normal B12 (≥150 pmol/l) group  
(6.6±0.4), p=0.457 
- No stat sig correlation  between HoloTCII and  neurological score  (no effect 
sizes given) 
 
Sucharita et al 
(2012)29 
General population in 
India, mean age =67±7y 
(B12 deplete, n=29), 
62±4y (B12 replete, n=18) 
 
Serum B12 NF: Nerve conduction assessment on median nerve 
(sensory and motor) 
NF:  
- No stat sig difference in median motor NCV in B12 deplete (serum B12 
<148pmol/l) (55.4±2.7 m/s) versus B12 replete (serum B12 ≥148pmol/l) 
(55.7±4.2 m/s) patients.  
- No stat sig difference in median sensory NCV in B12 deplete (58.4±4.8 m/s) 
versus B12 replete (57.7±4.8 m/s) patients.  
- Distal latencies for median motor nerve and amplitudes for median sensory 
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nerve were also comparable between the two vitamin B12 status groups (no 
effect sizes given) 
 
Wang et al (2009)30 Neurology dept patients, 
based in China. Mean age 
= 77.1±7.5y. B12 deficient 
patients n=163, normal 
B12 patients n=664. 
 
Serum B12 NFb: NCV, Sensory, brainstem auditory and visual 
evoked potentials and EEG 
NPc: Ankle/knee tendon jerks 
Joint position sense of great toe 
Plantar responses 
NSc: Unsteady walking in the dark, paresthesia, 
altered sensation in feet on walking 
NF: 
- Amongst B12 deficient patients, there is no stat sig association of  B12 status 
with any NF measure (no effect sizes given).  
NP: 
- B12 deficient (serum B12 <189 pmol/l and Hcy >15µmol/l ) patients 
(34.36%) stat sig more likely to have hypopallesthesia compared to normal 
B12 patients (22.29%), p<0.01. 
- No stat sig differences in absent knee/ankle tendon jerks in B12 deficient 
versus normal B12 patients 
NS: 
- B12 deficient patients (26.99%) stat sig more likely to experience unsteadily 
walking in the night compared to normal B12 group (19.43%), p<0.05. 
- No stat sig differences in altered sensation  in feet on walking or paresthesia 
in B12 deficient versus normal B12 patients 
 
 
2MCA,  2-methylcitrate; BMI, body mass index; CMAP, compound muscle action potential; defn; definition; DM, diabetes mellitus; EEG, electroencephalography; Hcy, homocysteine; HoloTC, holotranscobalamin; 
MMA, methyl malonic acid; MMSE, mini-mental state examination; n, sample size; NCV, nerve conduction velocity; NF, electrophysiological measure of nerve function; NP, clinically assessed signs of neuropathy; 
NS, self-reported neurological symptoms; P-B12, plasma vitamin B12; P-MMA, plasma methyl malonic acid; PN, peripheral neuropathy; stat sig, statistically significant; y, years. 
 
Footnotes: 
*Adjusted for age, sex, clinic site, DM. 
**Numbness adjusted for age, sex, site, diabetes, BMI and coldness adjusted for age, sex, site, diabetes, alcohol, physical activity 
*** Adjusted for age, sex and creatinine 
****Adjusted for age, sex, smoking 
*****Univariate analyses 
******Multivariate analyses, adjusted for age, sex, race, clinic site, DM, height, alcohol use and MMSE score 
*******Multivariate analyses, adjusted for age, sex, race, clinic site, DM, height, weight, alcohol use, ankle-brachial index and systolic blood pressure 
********Multivariate analyses, adjusted for age, sex, race, clinic site, DM, height, weight, ankle-brachial index, MMSE score, high cystatin-C, 3MS score and vibration variance 
*********Multivariate analyses, adjusted for age, sex, race, clinic site, DM, height, ankle-brachial index, cholesterol level and high cystatin-C 
 
a odds ratios and p values shown for Leishear et al (2012)23 obtained from additional information from the author 
b measured in B12 deficient subjects only 
c measured in all study subjects 
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Supplementary Table S2: Study characteristics and main findings of studies based on subjects with low vitamin B12 status 
 
Author (year) Subject characteristics Exposures Outcomes Effect sizes 
Hvas et al 
(2001)22 
Patients with elevated MMA 
>0.28µmol/l recruited 1995-98 
based in Denmark (n=432). Mean 
age=72y 
 
P-B12: 
follow-up 
(mean 1.0-
3.9y) 
P-MMA: 
baseline and 
follow-up 
NP: Neurological disability score based on 
vibration sense, joint position sense, 
cutaneous sensation, Romberg sign, gait, 
finger-nose test and heel-knee-shin test 
NS: Patient interview 
NP: 
- Significant but weak association between baseline P-MMA and  neurological disability score 
(R=0.10, p=0.05, log transformed)* 
- No associations between either P-MMA or P-B12 at follow-up and  neurological disability score (or 
component measures) (p=0.64,p=0.39) * 
- No association between change in P-MMA and neurological disability score * 
NS: 
- No associations between either P-MMA or P-B12 at follow-up and  neurological symptoms 
(p=0.73,p=0.57)* 
- No association between change in P-MMA and neurological symptoms * 
- No association between baseline P-MMA and neurological symptoms(p=0.56)*  
     
Hvas and Nexo 
(2005)20  
Patients with elevated MMA (P-
MMA >0.28µmol/l if recruited 
1995-98, ≥0.40µmol/l if recruited 
1998-2000), based in Denmark. 
Mean age=75y, n=534 
P-B12  
HoloTC  
TC  
TC saturation 
(holoTC/TC) 
MMA  
NP: Vibration sensation and neurological 
disability score based on muscle strength, 
reflexes and sensory loss 
NS: Neurological symptom score 
 
NP: 
- No stat sig association between HoloTC (<40pmol/l versus ≥40pmol/l), TC saturation (<4% versus 
≥4%), P-B12 (<200pmol/l versus ≥200pmol/l) or MMA (≥0.29 µmol/l versus <0.29 µmol/l) and 
neurological disability score [(ORs= 1.20 (0.80-1.82), 1.04 (0.69-1.57), 0.73 (0.45-1.18) and 0.92 
(0.61-1.38) respectively]* 
NS: 
- No stat sig association between HoloTC, TC saturation, P-B12  or MMA  and neurological 
symptoms [ORs= 1.21 (0.80-1.81), 1.40 (0.94-2.10), 1.35 (0.86-2.12) and 1.09 (0.72-1.64) 
respectively]* 
 
Hvas et al  
(2001)21 c 
Patients with elevated MMA 
(0.40-2.00 µmol/l), based in 
Denmark. Median age=74y 
(placebo, n=70), 75y (treatment, 
n=70) 
P-MMA  NP: Vibration sensation and neurological 
disability score based on clinical 
examination of finger-nose test, heel-knee-
shin test, dysdiadochokinesis, Romberg test 
and gait.  
NS: Score based on absence/presence of 
muscle weakness, sensory disturbances or 
autonomic symptoms 
NP: 
- No stat sig association between P-MMA and reduced vibration sensation [upper (p=0.36) or lower 
(p=0.31) extremities]*  
- No stat sig association between P-MMA and  neurological disability score (p=0.89), finger-nose test 
(p=0.07), knee-heel-shin test (p=0.97), dysdiadochokinesis (p=0.25), Romberg sign (p=0.38) and 
abnormal gait (p=0.38)* 
NS: 
- No stat sig association between P-MMA and neurologic symptoms (p=0.29)* 
Turgut et al 
(2006)25  
Patients with megaloblastic 
anaemia / B12 deficiency (serum 
B12 <147 pmol/l), based in 
Turkey (n=28), median age=66y. 
 
Serum B12  NF: CMAPs (median, ulnar, tibial and 
common peroneal nerves) and SNAPs 
(median , ulnar and dorsal sural nerves); 
sural antidromic sensory nerve conduction 
studies and tibial somatosensory evoked 
potentials 
NF: 
- No stat sig correlation between all NF measures and serum vitamin B12 (no effect sizes given) 
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CMAP, compound muscle action potential; HoloTC, holotranscobalamin; MMA, methyl malonic acid; n, sample size; NF, electrophysiological measure of nerve function; NP, clinically-assessed signs of neuropathy; 
NS, self-reported neurological symptoms; P-B12, plasma vitamin B12; P-MMA, plasma methyl malonic acid; SNAP,  sensory nerve action potential; stat sig, statistically significant; TC, transcobalamin; y, years. 
 
Footnotes: 
*Adjusted for age and sex 
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Chapter 3: Vitamin B12 status and neurologic function in older people: a 
cross-sectional analysis of baseline trial data from the OPEN study 
 
Preface 
 
As described in Chapter 2, the systematic review of observational studies identified 
several sources of heterogeneity and risks of bias in the available evidence, which have 
been useful to inform further research. There was considerable heterogeneity between 
studies in the definition of vitamin B12 status and in the neurological outcomes 
reported; few studies used a composite measure of vitamin B12 status and only five of 
the included studies used electrophysiological measures of nerve conduction to assess 
neurologic function; and many existing studies failed to identify and adjust appropriately 
for confounders. 
 
The OPEN study afforded an opportunity to test whether there was a cross-sectional 
association between vitamin B12 status and neurologic function in a high quality dataset 
with data on electrophysiological indices of peripheral and central neurologic function. 
By identifying limitations in the currently available evidence, this component of this 
study (presented here in Chapter 3) could be designed to address these evidence gaps.  
A composite indicator of vitamin B12 status (cB12) was included in the analyses and an 
extensive exercise was conducted to identify potential confounders.  
 
Chapter 3 presents a secondary analysis of baseline data from the OPEN study to address 
the following research question: 
 
2a) Is vitamin B12 status associated with electrophysiological indices of peripheral 
or central neurologic function in asymptomatic older people with moderately 
low vitamin B12 status? 
 
My role in this research was to design the study, conduct the statistical analyses, 
interpret findings and write the manuscript. 
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This report has been prepared for publication and has already been submitted to a peer-
reviewed journal. The manuscript is presented here alongside supplemental materials 
submitted to the journal for online supporting material, namely: 
 
x Supplemental table 1: Multivariate regression models to assess association  
between vitamin B12 status and nerve conduction outcomes (unadjusted 
analyses)  
x Supplemental table 2:   Logistic regression models to assess association between 
vitamin B12 status and clinical markers of nerve function  
x Supplemental table 3: Sensitivity analyses showing multivariate regression 
models to assess association between vitamin B12 status and nerve conduction 
outcomes in subjects with carpal tunnel syndrome excluded  
x Supplemental table 4: Subgroup analyses showing multivariate regression 
models to assess interaction between vitamin B12 status and age for nerve 
conduction outcomes. 
 


 
 
73 
 
Vitamin B-12 status and neurologic function in older people: a cross-sectional 
analysis of baseline trial data from the OPEN study 
Authors 
Lisa M Miles, Elizabeth Allen, Kerry Mills, Robert Clarke, Ricardo Uauy and Alan D 
Dangour 
Affiliations 
Faculty of Epidemiology and Population Health, London School of Hygiene & 
Tropical Medicine, London, UK (LMM, EA, RU and ADD) 
Clinical Trial Service Unit & Epidemiological Studies Unit, University of Oxford, 
Oxford, UK (RC) 
Department of Clinical Neurosciences, King’s College, London, UK (KM) 
Author last names 
Miles, Allen, Mills, Clarke, Uauy and Dangour 
Corresponding authors and person from whom reprints will be available 
Alan Dangour, Faculty of Epidemiology and Population Health, London School of 
Hygiene & Tropical Medicine, Keppel Street, London, WC1E 7HT, UK. Tel: 020 7958 
8133; email: alan.dangour@lshtm.ac.uk 
Lisa Miles, Faculty of Epidemiology and Population Health, London School of 
Hygiene & Tropical Medicine, Keppel Street, London, WC1E 7HT, UK. Tel: 
07962865272; email: lisa.miles@lshtm.ac.uk 
Sources of support 
Funding for the OPEN study was provided by the Food Standards Agency (N05072) 
and the Department of Health.  National Health Service Research and Development 
and King’s College Hospital Trust Research and Development provided service 
 
 
74 
 
support costs.  No further funding was received for the secondary analyses 
presented here. 
 
Running head Vitamin B-12 status and neurologic function  
 
Trial registration www.isrctn.com ISRCTN54195799 
 
Abbreviations 
ADM: Abductor digiti minimi 
AD: Abductor hallucis 
CMAP: Compound muscle action potential 
CMCT: Central motor conduction time 
HoloTC: Holotranscobalamin  
Hcy: Homocysteine 
MEP: Motor evoked potentials 
MMA: Methyl malonic acid 
OPEN: Older People and Enhanced Neurological Function study 
SAP: Sensory action potentials 
 
 
75 
 
Abstract 1 
Background 2 
Ageing is associated with a progressive decline in vitamin B-12 status. Overt vitamin 3 
B-12 deficiency causes neurologic disturbances in peripheral and central motor and 4 
sensory systems, but the public health impact for neurological disease of moderately 5 
low vitamin B-12 status in older people is unclear. Evidence from observational 6 
studies is limited by heterogeneity in definition of vitamin B-12 status and imprecise 7 
measures of nerve function.   8 
Objective 9 
This study aims to determine whether vitamin B-12 status is associated with 10 
electrophysiological indices of peripheral or central neurologic function in 11 
asymptomatic older people with moderately low vitamin B-12 status.  12 
Design 13 
We report cross-sectional analysis of baseline data from the Older People and 14 
Enhanced Neurological Function study conducted in the South East of England.  This 15 
trial investigated the effectiveness of vitamin B-12 supplementation on 16 
electrophysiological indices of neurological function in asymptomatic older people 17 
(mean age 80y) with moderately low vitamin B-12 status (n=201). Vitamin B-12 18 
status was assessed using total vitamin B-12, holotranscobalamin and a composite 19 
marker, cB-12. Electrophysiological measures of sensory and motor components of 20 
peripheral and central nerve function were assessed in all participants by a single 21 
observer.   22 
Results 23 
In multivariate models, there was no evidence of an association between any 24 
measure of vitamin B-12, holotranscobalamin or cB-12 and any of the nerve 25 
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conduction outcomes. There was no evidence of an association between vitamin B-26 
12 status and clinical markers of neurologic function.  27 
Conclusion 28 
This secondary analysis of high quality trial data did not show any association 29 
between any measure of vitamin B-12 status with either peripheral or central 30 
neurological function or any clinical markers of neurologic function in older people 31 
with moderately low vitamin B-12 status. Nevertheless, vitamin B-12-dependent 32 
impairment of neurological function in less healthy and more vitamin B-12 deplete 33 
populations cannot be excluded. 34 
Keywords 35 
Neurologic, older people, vitamin B-12, peripheral and central nerve conduction. 36 
 37 
 38 
 39 
 40 
  41 
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Introduction 42 
Ageing is associated with a decline in vitamin B-12 status, and vitamin B-12 43 
deficiency is relatively common in older people (1-3). In the UK, 5% of adults aged 44 
65–74 years and 10% adults aged ≥75 years have low vitamin B-12 levels (defined 45 
as vitamin B-12 <150 pmol/L) or metabolically significant vitamin B-12 deficiency 46 
(defined as vitamin B-12 <200 pmol/L and homocysteine level >20 mmol/L) (1). As 47 
intakes of vitamin B-12 are mostly adequate (4), poor status in older people is largely 48 
attributable to age-related malabsorption of vitamin B-12 (5). 49 
 50 
Vitamin B-12 is required for the initiation and maintenance of myelination of the 51 
nervous system (6). The classical manifestation of overt vitamin B-12 deficiency, 52 
subacute combined degeneration of the spinal cord, involves demyelination of the 53 
posterior and lateral tracts of the spinal cord (6, 7). Neurologic disturbances 54 
associated with B-12 deficiency can affect peripheral motor and sensory systems and 55 
include ataxia, gait disturbance, symmetric paresthesias, numbness, impaired 56 
vibration or position sensation, abnormal balance, reflexes and weakness (3, 6, 7). 57 
 58 
Although impaired neurologic function is a characteristic feature of overt vitamin B-12 59 
deficiency, the neurologic and public health impact of moderately low vitamin B-12 60 
status in older people is currently unclear. Neurological signs and symptoms 61 
associated with moderately low vitamin B-12 status can be non-specific and often go 62 
undetected because they are attributed to 'old age’, yet can have an important impact 63 
on physical function.  A recent systematic review (8) evaluated the association of 64 
vitamin B-12 status with neurological function and clinically relevant neurological 65 
outcomes in older people. Evidence from observational studies was limited and the 66 
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heterogeneity and quality of the available studies precluded definitive conclusions. 67 
Few studies used electrophysiological measures of nerve conduction, which are the 68 
most sensitive and objective measure of neurological function relevant to vitamin B-69 
12 status. Many studies were constrained by bias; and few used composite 70 
measures of vitamin B-12 status involving both a biomarker of circulating vitamin B-71 
12 and a functional biomarker (methyl malonic acid or homocysteine), as now 72 
recommended (9). 73 
 74 
The Older People and Enhanced Neurological Function (OPEN) study afforded an 75 
opportunity to test whether there was an association between vitamin B-12 status 76 
and neurologic function in a high quality dataset derived from asymptomatic older 77 
people with moderately low vitamin B-12 status. The aim of the present study was to 78 
determine whether vitamin B-12 status is associated with electrophysiological indices 79 
of peripheral or central neurologic function or clinical markers of neurologic function 80 
in older people with moderate vitamin B-12 deficiency. 81 
 82 
Participants and Methods 83 
Recruitment and procedures 84 
This study is a secondary analysis of cross-sectional baseline data from the OPEN 85 
study, the protocol of which has been published (10) (www.isrctn.com; 86 
ISRCTN54195799). The OPEN study was a randomised double-blind placebo-87 
controlled trial that investigated the effectiveness of dietary supplementation with oral 88 
vitamin B-12 on electrophysiological indices of neurological function in older people 89 
with moderate B-12 deficiency (11). 90 
 91 
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Participants aged ≥75 years were recruited from 7 general practices in South East 92 
England. Individuals with diabetes, dementia, epilepsy, alcohol addiction, 93 
pacemakers or other implanted metallic devices, residents of nursing homes, or a 94 
previous diagnosis of pernicious anaemia were excluded. Those who reported 95 
current consumption of vitamin B-12 supplements or who had received a vitamin B-96 
12 injection in the previous 6 months were also excluded, as were potential 97 
participants with significant cognitive impairment. Individuals with moderate vitamin 98 
B-12 deficiency who did not have anaemia (serum vitamin B-12 concentrations ≥107 99 
and <210 pmol/L [Beckman Coulter assay] and haemoglobin concentrations ≥110 g/L 100 
for women and ≥120 g/L for men) were eligible to join the OPEN study. Screening 101 
took place between November 2008 and February 2010. 102 
 103 
Baseline data from 201 participants enrolled in the OPEN study were used in this 104 
secondary analysis. The sample size for the trial was determined by a sample size 105 
calculation designed to achieve 90% power to detect a ≥28% difference in the 106 
primary nerve function outcome (with 5% significance) between arms of the original 107 
trial. 108 
 109 
Participants attended King’s College Hospital at study baseline and provided a blood 110 
sample and undertook a series of neurophysiological function tests. At the baseline 111 
appointment data were also collected on educational history, current prescribed 112 
medication, including statins and proton-pump inhibitors, dietary habits and 113 
frequency of alcohol consumption. Height and weight were measured to allow 114 
calculation of Body Mass Index. Blood samples were analysed for serum 115 
concentrations of vitamin B-12 (microbiologic assay); holotranscobalamin (HoloTC; 116 
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Axis-Shield radioimmunoassay; Axis-Shield plc), total homocysteine (Hcy; Abbott IMx 117 
analyzer; Abbott Laboratories), and folate (chloramphenicol-resistant microbiologic 118 
assay) in a single laboratory in Trinity College Dublin. The Beckman Coulter method 119 
(12) was used to assess vitamin B-12 status to screen participants for study 120 
eligibility.  A microbiological assay was used at study baseline to assess the vitamin 121 
B-12 status of study participants.  A full blood count was analysed for haematological 122 
markers including haemoglobin, haematocrit and mean corpuscular volume.  123 
 124 
A single expert physician (KM) conducted a battery of peripheral nerve conduction 125 
tests (including motor and sensory nerve conduction in the right median, ulnar, 126 
superficial peroneal, sural, common peroneal, and tibial nerves), and central motor 127 
conduction tests. These standard techniques used surface electrodes. As nerve 128 
conduction in peripheral nerves is sensitive to temperature of the limbs (13), skin 129 
temperature of the dorsum of the foot and hand were measured to allow for 130 
appropriate adjustments in the analyses.  131 
 132 
The sensory action potential (SAP) amplitude (maximum deviation of the electrical 133 
response) and conduction velocity (distance divided by onset latency) were 134 
measured in the median, ulnar, superficial peroneal and sural nerves. Common 135 
peroneal, tibial, median and ulnar motor conduction were measured by recording 136 
from extensor digitorum brevis, abductor hallucis (AH), abductor pollicis brevis and 137 
abductor digiti minimi (ADM) respectively. Supramaximal stimuli were used at 138 
proximal and distal sites to ensure that all nerve fibres within the nerve were 139 
activated.  Conduction velocity was calculated and compound muscle action potential 140 
(CMAP) amplitude, distal motor latency, and F-wave latency (a measure of 141 
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conduction time from the distal stimulation site to the spinal cord) were also 142 
measured.  143 
 144 
Transcranial magnetic stimulation, which painlessly and noninvasively excites the 145 
motor cortex (14), was used to measure central motor conduction in the corticospinal 146 
tract. A 13-cm diameter circular coil connected to a magnetic stimulator that provided 147 
a monophasic pulse was centred over the vertex to excite the hand area of the left 148 
motor cortex. A standard technique (15) determined the threshold for excitation. With 149 
the right ADM muscle partially activated voluntarily, 8 stimuli at 1.2 times the 150 
threshold were delivered to evoke motor evoked potentials (MEPs), the mean 151 
amplitude and minimal latency of which were measured. Similarly, by using a double 152 
cone coil, the leg area of motor cortex was excited to measure MEPs evoked in AHs. 153 
Central motor conduction time was calculated by subtracting the time to response in 154 
a given muscle from an estimate of the peripheral nerve conduction time. A 155 
maximum of 70 brain stimuli was performed on any participant. Any participants 156 
shown to have significant neurologic deficit were referred to their general 157 
practitioners. 158 
 159 
Outcomes and exposures 160 
In total 19 nerve conduction outcomes were measured in the right side of the body. 161 
Peripheral nerve conduction outcomes were grouped in the analyses as follows: four 162 
SAP amplitudes in the sural, superficial peroneal, median and ulnar nerves as an 163 
index of nerve fibre number; four sensory conduction velocities in the sural, 164 
superficial peroneal, median and ulnar nerves to indicate degree of myelination; four 165 
distal CMAP amplitudes in the tibial, common peroneal, median and ulnar nerves 166 
which reflects the number of motor axons accessed by an electrical stimulus, which 167 
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in turn reflects muscle strength (16, 17); and four motor conduction velocities in the 168 
tibial, common peroneal, median and ulnar nerves to indicate degree of myelination. 169 
Reduced sensory or motor conduction velocity is a sign of demyelination (18).  The 170 
remaining three outcomes assessed central nerve conduction: mean right ADM MEP 171 
amplitude and central motor conduction time to the right AH and ADM (the latter two 172 
were grouped in the analyses). The single physician (KM) also assessed four clinical 173 
measures of neurologic function at baseline: presence or absence of right knee and 174 
ankle jerks and of joint position sense and vibration sense in the right great toe. 175 
 176 
Vitamin B-12 and holoTC were used as measures of vitamin B-12 status. In view of 177 
the limited sensitivity and specificity of individual biomarkers of vitamin B-12, experts 178 
have advocated combined use of at least one biomarker of circulating vitamin B-12 179 
(serum vitamin B-12 or holoTC) together with one functional biomarker [methyl 180 
malonic acid (MMA) or Hcy] (9) as a composite indicator of vitamin B-12 status, 181 
cB-12. The use of cB-12 is a novel approach that combines measures of vitamin B-182 
12, holoTC, Hcy and MMA into one indicator (19). cB-12 can be derived using 183 
equations that allow incomplete indicators, i.e. based on two or three of these 184 
markers (19). In the present study, three markers (vitamin B-12, holoTC and Hcy) 185 
were used to derive cB-12 values.  186 
 187 
Ethics 188 
The OPEN study was reviewed and approved by the National Research Ethics 189 
Committee (08/H0305/18) and the London School of Hygiene and Tropical Medicine 190 
Ethics Committee (no. 5298). The secondary analyses presented here were 191 
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approved by the London School of Hygiene & Tropical Medicine Ethics Committee 192 
(no. 7176). 193 
 194 
Statistical analysis 195 
All statistical analyses were conducted using STATA (version 14, StataCorp, Texas 196 
USA). Descriptive statistics for all exposures, outcomes and known or potential 197 
confounders have been generated. Scatter plots were used to visually explore the 198 
nature of any potential associations present. The functional form of any potential 199 
relationships was also explored by producing lowess smoother curves (20). Three 200 
measures of vitamin B-12 status and two nerve conduction outcomes had >10% 201 
missing data, but preliminary analysis suggested that there was no reason to assume 202 
that these were not missing at random, so all analyses were on all available cases. 203 
 204 
Nerve conduction outcomes were grouped in multivariate regression models.  205 
Multivariate regression differs from multiple regression in that several dependent 206 
variables are jointly regressed on the same independent variables (21). Nerve 207 
conduction outcomes were grouped (as defined above) according to the component 208 
of nerve function they reflect, in order to minimise multiple testing of several 209 
outcomes. All multivariate models were boot-strapped to allow for non-normal 210 
distributions and results were presented as appropriate effect sizes with bias 211 
corrected 95% confidence intervals. Clinical marker outcomes were analysed 212 
separately using logistic regression; results were presented as odds ratios with 95% 213 
confidence intervals. Because the analyses involved multiple comparisons, p-values 214 
have been interpreted with caution, with a p-value of <0.01 used to test for statistical 215 
significance. 216 
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 217 
Age and sex are known confounders of the relationship between vitamin B-12 status 218 
and neurological function and so have been adjusted for in analyses. In addition, the 219 
following variables: alcohol frequency (daily, >once a week, approximately once a 220 
fortnight, rarely/never); haemoglobin (g/l); haematocrit (%); mean corpuscular volume 221 
(fl); and use of statins (yes/no) or proton-pump inhibitors (yes/no) were assessed as 222 
potential confounders. If a potential confounder was found to be associated with both 223 
an exposure and outcome, and its inclusion altered the effect size by ≥10%, then it 224 
was included in the final model. 225 
 226 
Skin temperature is a known confounder for nerve conduction outcomes, specifically 227 
hand skin temperature for nerve conduction parameters in nerves of the upper limbs 228 
(median and ulnar) and foot skin temperature for equivalent parameters in nerves of 229 
the lower limbs (tibial, common peroneal, sural and superficial peroneal). The 230 
analyses presented here combine outcomes in upper and lower limbs and so 231 
inclusion of both hand and foot skin temperature in the models was considered. 232 
However, hand and foot skin temperature were strongly positively correlated, so only 233 
foot skin temperature was included in the final models due to concerns over 234 
collinearity.  235 
 236 
Sensitivity and subgroup analyses were conducted to test the robustness of the 237 
findings. Sensitivity analyses were performed excluding participants with clinical 238 
(previously decompressed nerves) or neurophysiological evidence [a median nerve 239 
sensory conduction velocity <40 m/s and (an ulnar sensory conduction velocity at 240 
least 10 m/s faster and/or a median distal motor latency of >4.5 m/s)] of carpal tunnel 241 
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syndrome as this syndrome is known to affect median sensory and motor nerve 242 
conduction parameters. Subgroup analyses were done to explore whether any 243 
association between vitamin B-12 and neurologic function differs by age, by testing 244 
for interaction between age and vitamin B-12 status on nerve conduction outcomes 245 
 246 
Results 247 
The mean age of the 201 study participants was 80 years and 47% of the population 248 
were male (Table 1). At study baseline, 88% of recruited participants had vitamin B-249 
12 status below the median value for the microbiologic assay reference standard 250 
(derived from a random sample of 470 nationally representative adults in the Irish 251 
National Adult Nutrition Survey) (personal communication Dr Anne Molloy, 2013), 252 
indicating that study participants had moderately low vitamin B-12 status. Table 2 253 
shows nerve conduction outcomes and clinical markers of the study participants. The 254 
clinical markers of neurologic function show that neurologic function was sub-optimal 255 
amongst participants. In particular, 66% of participants had absent right great toe 256 
vibration sense and 28% absent right ankle jerks. 257 
 258 
In multivariate models, there was no evidence of an association between any 259 
measure of vitamin B-12, holoTC or cB-12 and any of the nerve conduction 260 
outcomes in either unadjusted (Supplemental table 1) or adjusted analyses (Table 261 
3). Results were consistent across all measures of peripheral and central nerve 262 
conduction and all measures of vitamin B-12 status. Coefficients were very close to 263 
zero and direction of effects were inconsistent within each group of nerve function 264 
outcomes. Likewise, there was no evidence of an association of any measure of 265 
vitamin B-12 status with any clinical markers of neurologic function (Supplemental 266 
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table 2). Overall, there was no evidence to support an association between any 267 
measure of vitamin B-12 status, with any measure of central, or peripheral sensory or 268 
motor nerve function. 269 
 270 
Sensitivity analysis, excluding 31 participants with carpal tunnel syndrome, did not 271 
alter these conclusions (Supplemental table 3).  There was also no evidence of an 272 
interaction between age and vitamin B-12 status for any electrophysiological 273 
measure of nerve function (Supplemental table 4).  274 
 275 
Discussion 276 
Key findings 277 
This study identified no evidence of an association of vitamin B-12 status with a suite 278 
of measures of peripheral or central neurologic function or any measures of clinical 279 
markers of neurologic function in older people with moderately low vitamin B-12 280 
status. The null results were consistent in all categories of vitamin B-12 status and 281 
consistent across all neurological outcomes. 282 
 283 
Comparison with other studies 284 
Few other studies have assessed neurologic function using nerve conduction tests. 285 
In a longitudinal study (22), no association was reported between vitamin B-12 status 286 
and CMAP and nerve conduction velocity measured between the fibular head and 287 
ankle. Results from two cross-sectional studies were mixed. Vitamin B-12 deficient 288 
individuals in one study had lower CMAP and nerve conduction velocity (measured 289 
between popliteal fossa and ankle) (23), but it is notable that vitamin B-12 deficiency 290 
was defined as vitamin B-12<260 pmol/L and elevated MMA, the latter of which might 291 
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be important. A second cross-sectional study measured sensory and motor nerve 292 
conduction velocity in the median nerve and reported no association with vitamin B-293 
12 status (depletion defined as serum B-12 <148 pmol/L) (24). Heterogeneity in 294 
assays and cut-offs used to assess vitamin B-12 status (25) constrains fair 295 
comparison between similar studies. The present study was the first to assess 296 
vitamin B-12 status as measured by cB-12 and its relationship with neurologic 297 
function, and offers a high quality dataset in which to investigate the relationship 298 
between vitamin B-12 status and neurologic function. The results presented here are 299 
consistent with a conclusion of no association of moderately low vitamin B-12 status 300 
with nerve function. 301 
 302 
Strengths and weaknesses 303 
A strength of the study was the use of several measures of vitamin B-12 status. Of 304 
particular note, holoTC (which measures the active fraction of B-12) has been 305 
proposed as appropriate to use in the subclinical situation (26, 27). Further, the use 306 
of cB-12 has tested a novel approach to assess vitamin B-12 status. This approach 307 
has an advantage over single biomarker tests because it also includes a functional 308 
biomarker of B-12 status (Hcy in this case). However, cB-12 is more reliable when 309 
based on four markers, which was not possible in the current study because MMA 310 
was not measured. When using three markers, having MMA missing is less reliable 311 
than having any of the other three markers missing (19). Furthermore, renal function, 312 
which is known to affect Hcy (28) , was not measured in OPEN. In fact, cB-12 has 313 
recently been reported to be independently associated with renal function (29). There 314 
is uncertainty about the most appropriate measures or cut-offs to assess vitamin B-315 
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12 status. It has been suggested that age and sex-specific reference cut-offs may be 316 
needed (25). 317 
 318 
The OPEN study exclusion criteria means that the study participants had moderately 319 
low vitamin B-12 status. The exclusion criteria reflect the intention of the OPEN study 320 
to be relevant to population health in older people. However, it is possible that the 321 
participants were too replete in vitamin B-12 to be able to detect any associations 322 
between vitamin B-12 status and neurological function. Furthermore, the sample of 323 
older people recruited for the study was not selected at random, and may be in better 324 
health than a representative sample of older people in the UK. Participants also had 325 
relatively high levels of educational achievement, suggesting that the sample is not 326 
representative of older people in the UK. The results of this study are unlikely to be 327 
generalisable to a less healthy older population with more prevalent vitamin B-12 328 
deficiency. 329 
 330 
An important attribute of the current study was the use of nerve conduction tests to 331 
measure neurologic function. Nerve conduction tests provided objective measures of 332 
neurologic function by using state-of-the-art methods, and all testing was conducted 333 
by a single neurophysiologist which eliminated inter-observer variability. A wide 334 
range of neurologic outcomes were used to allow both sensory and motor 335 
components of nerve function in upper and lower limbs to be assessed.  336 
 337 
Risk of bias from confounding was minimised by conducting an extensive exercise to 338 
identify potential confounders. Sensitivity and subgroup analyses were also 339 
conducted to test the reliability of study findings.  340 
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 341 
Policy relevance and research needs 342 
In conclusion, this study did not identify an association between vitamin B-12 status 343 
and peripheral or central neurologic function or clinical markers of neurologic function 344 
in moderately vitamin B-12 deficient older people. The robustness of this finding is 345 
supported by the use of a composite measure of vitamin B-12 status and a wide 346 
range of nerve conduction tests to measure neurologic function. At a population level, 347 
these findings cast doubt over concerns about moderately low vitamin B-12 status in 348 
older people in relation to neurologic function.  349 
 350 
Nevertheless, vitamin B-12-dependent impairment of neurological function in less 351 
healthy and more vitamin B-12 deplete populations cannot be excluded. Impaired 352 
nerve function as a result of lower vitamin B-12 status could remain undetected at the 353 
population level and therefore still have implications for public health.  354 
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Tables 
Table 1: Demographic characteristics and blood biochemical measures of 
study participants 
 Total n  
Demographics   
Age (years)1 201 80.0 (3.6) 
Sex male, n (%) 201 94 (47) 
Age left education (years) 1 201 18.1 (6.0) 
Educational achievement 
     None, n (%) 
     Basic or clerical, n (%) 
     Advanced or university, n (%) 
     Other, n (%) 
198  
54 (27) 
34 (17) 
52 (26) 
58 (29) 
Body mass index2 
     <18.5, n (%) 
     18.5 – 24.9, n (%) 
     25.0 – 29.9, n (%) 
     ≥30, n (%) 
201 26.8 (24.0, 29.3) 
1 (0) 
69 (34) 
87 (43) 
44 (22) 
Statins use, n (%) 162 67 (41) 
Proton-pump inhibitor use, n (%) 162 53 (33) 
Frequency of alcohol consumption 
    Daily, n (%) 
    >once/week, n (%) 
    approx. once/fortnight, n (%) 
    rarely/never, n (%) 
195  
68 (35) 
63 (32) 
19 (10) 
45 (23) 
Frequency of meat consumption 
     >once/week, n (%) 
191  
139 (73) 
 
Blood biochemical measures 
  
Vitamin B-12 (pmol/L)2,3   165 225.5 (196.0, 269.6) 
Holotranscobalamin (pmol/L) 2 159 49.3 (38.8, 64.8) 
Homocysteine (µmol/L) 2 162 16.2 (13.8, 19.5) 
Folate (nmol/L) 2 164 17.6 (4.8, 25.4) 
cB-121      159 -0.2 (0.4) 
Haematocrit (%)1 177 40.8 (3.1) 
Haemoglobin (g/L) 1 177 139.3 (12.0) 
Mean corpuscular volume (fL) 1 177 88.6 (4.3) 
 
1Mean (SD) 
2Median (IQR) 
3Vitamin B-12 status assessed using a microbiological assay. 
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Table 2: Neurological function of study participants1 
 
 Total n  
 
Neurological function 
  
SAP amplitudes (µV)2,3 
     Median  
     Ulnar 
     Sural 
     Superficial peroneal 
 
200 
200 
199 
199 
 
8.2 (5.6, 11.9) 
6.6 (4.1, 9.1) 
3.8 (1.6, 6.3) 
2.9 (1.1, 5.4) 
Sensory nerve conduction velocities (m/s)4 
     Median  
     Ulnar 
     Sural 
     Superficial peroneal 
 
194 
192 
172 
159 
 
45.1 (5.5) 
44.7 (4.6) 
40.4 (5.3) 
41.1 (5.6) 
CMAP amplitudes (mV)2 
     Median  
     Ulnar 
     Tibial 
     Common peroneal 
 
200 
200 
199 
199 
 
3.8 (2.7, 5.0) 
9.7 (8.5, 11.2) 
4.6 (2.1, 7.3) 
2.4 (1.1, 3.6) 
Motor nerve conduction velocities (m/s)4 
     Median  
     Ulnar 
     Tibial 
     Common peroneal 
 
200 
200 
193 
189 
 
51.3 (5.2) 
54.5 (5.2) 
40.0 (5.1) 
42.8 (4.3) 
Central motor conduction 
     Left hemisphere ADM CMCT (ms)4 
     Left hemisphere AH CMCT (ms)4 
     Left hemisphere mean ADM MEP amplitude (mV)2 
 
198 
182 
200 
 
5.5 (1.3) 
13.6 (3.4) 
3.4 (2.1, 4.4) 
 
Clinical markers 
  
Absent right knee jerk, n (%) 201 21 (10) 
Absent right ankle jerk, n (%) 201 57 (28) 
Absent right great toe position sense, n (%) 201 14 (7) 
Absent right great toe vibration sense, n (%) 201 132 (66) 
 
 
  
1SAP, sensory action potential; CMAP, compound muscle action potential; ADM, 
abductor digiti minimi; CMCT, central motor conduction time; AH, abductor hallucis; 
MEP, motor evoked potential.  
2Median (IQR) 
3Percentage of absent (SAP amplitude=0) responses= 3 for median, 4 for ulnar, 14 
for sural and 20 for superficial peroneal nerves. 
4Mean (SD) 
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Table 3: Multivariate regression models to assess association between vitamin B-12 
status and nerve conduction outcomes1. 
 
  
 Adjusted2 
coefficients 
(95% CI) 
B-12 (pmol/l) HoloTC (pmol/l) cB-12 
Sensory SAP amplitudes (µV)3 n 164 158 158 
 
 Median  -0.01 (-0.02 – 0.00) -0.02 (-0.05 – 0.02)4 -1.05 (-3.19 – 1.06) 4 
     
 Ulnar -0.01 (-0.02 - -0.00) -0.01 (-0.04 – 0.02)4 -0.72 (-2.10 – 0.52) 4 
     
 Sural -0.00 (-0.01 – 0.01) -0.01 (-0.04 – 0.02) 4 -0.17 (-1.72 – 1.42) 4 
 
 Superficial 
peroneal 
0.00 (-0.01 – 0.01) -0.01 (-0.03 – 0.02) 4 0.26 (-1.11 – 1.45) 4 
 
  p=0.12 p=0.874 p=0.604 
Sensory nerve conduction 
velocities (m/s) 
n 115 110 110 
 Median  0.01 (-0.01 – 0.02) 
 
0.03 (-0.00 – 0.08) 2.80 (0.37 – 5.59) 
 Ulnar -0.01 (-0.02 – 0.01) 
 
-0.02 (-0.06 – 0.02) -0.77 (-2.60 – 1.04) 
 Sural -0.01 (-0.03 – 0.01) 
 
0.01 (-0.03 – 0.05) -0.56 (-2.83 – 1.47) 
 Superficial 
peroneal 
-0.01 (-0.02 – 0.01) 
 
0.01 (-0.03 – 0.05) 0.20 (-2.54 – 2.72) 
  p=0.28 p=0.12 p=0.05 
Motor CMAP amplitudes (mV) n 164 158 158 
 
 Median -0.01 (-0.01 - -0.00) 
 
-0.00 (-0.02 – 0.01) -0.17 (-0.72 – 0.48) 
 Ulnar 0.01 (-0.00 – 0.01) 
 
0.01 (-0.01 – 0.03) 0.73 (-0.19 – 1.66) 
 Tibial -0.01 (-0.02 – 0.01) 
 
-0.00 (-0.03 – 0.02) -0.14 (-1.79 – 1.24) 
 Common peroneal 0.00 (-0.00 – 0.01) 
 
0.01 (-0.01 – 0.02) 0.54 (-0.23 – 1.22) 
  p=0.02 p=0.49 p=0.11 
Motor nerve conduction 
velocities (m/s) 
n 153 148 148 
 Median -0.00 (-0.02 – 0.01) 0.00 (-0.05 – 0.04) -0.14 (-2.22 – 2.40) 
     
 Ulnar 0.00 (-0.02 – 0.02) 0.01 (-0.03 – 0.06) 0.84 (-1.82 – 3.01) 
     
 Tibial 0.00 (-0.01 – 0.02) 0.00 (-0.04 – 0.05) 0.54 (-1.53 – 2.84) 
 
 Common peroneal -0.01 (-0.02 – 0.01) -0.02 (-0.05 – 0.01) -0.33 (-2.03 – 1.65) 
 
  p=0.80 p=0.66 p=0.86 
Central motor conduction (ms) n 147 142 142 
 
 ADM CMCT 0.00 (-0.00 – 0.01) -0.00 (-0.01 – 0.01) 0.20 (-0.29 – 0.67)  
 
 AH CMCT 0.00 (-0.01 – 0.01) -0.00 (-0.03 – 0.03) -0.09 (-1.90 – 1.80) 
 
  p=0.41 p=0.72 p=0.66 
 n 164 158 158 
 
 Mean ADM MEP 
amplitude (mV) 
-0.00 (-0.00 – 0.00) 5 -0.00 (-0.01 – 0.01) 5 0.05 (-0.53 – 0.59) 5 
  p=0.995 p=0.925 p=0.865 
1HoloTC, holotranscobalamin; SAP, sensory action potential; CMAP, compound muscle action potential; ADM, abductor digiti minimi; CMCT, 
central motor conduction time; AH, abductor hallucis; MEP, motor evoked potential.  
2All analyses adjusted for age, sex and skin temperature (foot), unless otherwise stated. 
3 Percentage of absent (SAP amplitude=0) responses= 3 for median, 4 for ulnar, 14 for sural and 20 for superficial peroneal nerves. 
4Mean corpuscular volume confounded the relationship between holoTC and cB-12 with SAP amplitudes; these models have therefore been 
adjusted for age, sex, skin temperature (foot) and mean corpuscular volume. 
5Adjusted for age, sex, skin temperature (hand) 
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ONLINE SUPPORTING MATERIAL 
Supplemental table 1: Multivariate regression models to assess association  
between vitamin B-12 status and nerve conduction outcomes (unadjusted analyses)1. 
  
 Unadjusted 
coefficients 
(95% CI) 
B-12 (pmol/l) HoloTC (pmol/l) cB-12 
Sensory SAP amplitudes (µV)2 n 164 158 158 
 
 Median  -0.01 (-0.03 – 0.00) -0.01 (-0.04 – 0.03) -0.84 (-3.10 – 1.26) 
 Ulnar -0.01 (-0.02 - -0.00) -0.00 (-0.03 – 0.03) -0.61 (-2.09 – 0.80) 
 Sural -0.00 (-0.01 – 0.01) -0.01 (-0.04 – 0.03) 0.01 (-1.48 – 1.47) 
 Superficial 
peroneal 
-0.00 (-0.01 – 0.01) -0.00 (-0.02 – 0.02) 0.33 (-0.92 – 1.44) 
  p=0.17 p=0.99 p=0.75 
Sensory nerve conduction 
velocities (m/s) 
n 115 110 110 
 Median  0.00 (-0.02 – 0.02) 0.02 (-0.02 – 0.06) 1.31 (-1.51 – 4.34) 
 Ulnar -0.01 (-0.03 – 0.00) -0.03 (-0.07 – 0.00) -1.80 (-3.64 – 0.10) 
 Sural -0.01 (-0.03 – 0.00) -0.01 (-0.05 – 0.03) -2.54 (-4.90 - -0.01) 
 Superficial 
peroneal 
-0.01 (-0.03 – 0.01) 0.00 (-0.05 – 0.05) -1.05 (-3.67 – 1.79) 
  p=0.10 p=0.10 p=0.00 
Motor CMAP amplitudes (mV) n 164 158 158 
 
 Median -0.01 (-0.01 - -0.00) -0.00 (-0.02 – 0.01) -0.18 (-0.76 – 0.54) 
 Ulnar 0.01 (-0.00 – 0.01) 0.01 (-0.01 – 0.03) 0.85 (-0.11 – 1.75) 
 Tibial -0.01 (-0.01 – 0.00) -0.00 (-0.03 – 0.02) -0.11 (-1.79 – 1.38) 
 Common peroneal 0.00 (-0.00 – 0.01) 0.00 (-0.01 – 0.02) 0.58 (-0.15 – 1.24) 
  p=0.01 p=0.60 p=0.05 
Motor nerve conduction 
velocities(m/s) 
n 153 148 148 
 Median -0.00 (-0.02 – 0.01) 0.00 (-0.04 – 0.04) -0.22 (-2.22 – 2.39) 
 Ulnar 0.00 (-0.02 – 0.02) 0.01 (-0.04 – 0.05) 0.71 (-1.84 – 2.77) 
 Tibial 0.00 (-0.01 – 0.02) 0.00 (-0.03 – 0.05) 0.28 (-1.88 – 2.44) 
 Common peroneal -0.01 (-0.02 – 0.01) -0.02 (-0.05 – 0.02) -0.38 (-2.17 – 1.84) 
  p=0.79 p=0.76 p=0.93 
Central motor conduction (ms) n 147 142 142 
 
 ADM CMCT 0.00 (-0.00 – 0.01) -0.00 (-0.01 – 0.00) 0.17 (-0.34 – 0.62) 
 AH CMCT 0.00 (-0.01 – 0.01) -0.00 (-0.03 – 0.03) 0.02 (-1.78 – 1.84) 
  p=0.40 p=0.66 p=0.74 
 n 164 158 158 
 
 Mean ADM MEP 
amplitude (mV) 
-0.00 (-0.00 – 0.00) -0.00 (-0.01 – 0.01) -0.01 (-0.61 – 0.60) 
  p=0.99 p=0.61 p=0.98 
1HoloTC, holotranscobalamin; SAP, sensory action potential; CMAP, compound muscle action potential; ADM, abductor digiti minimi;  
 CMCT, central motor conduction time; AH, abductor hallucis; MEP, motor evoked potential.  
2 Percentage of absent (SAP amplitude=0) responses= 3 for median, 4 for ulnar, 14 for sural and 20 for superficial peroneal nerves.  
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Supplemental table 2: Logistic regression models to assess association between vitamin B-12 status and clinical markers of  
nerve function 
 
Vitamin B12 (pmol/L) 
 Unadjusted Adjusted for age 
and sex 
Clinical marker Absent Mean (sd)  Present Mean (sd)  OR (95% CI) OR (95% CI) 
Right knee jerk 15 246.71 (61.09) 150 231.83 (54.09) 1.01 (1.00 – 1.01) 1.01 (1.00 - 0.02) 
Right ankle jerk 45 235.60 (51.75) 120 232.28 (55.99) 1.00 (1.00 – 1.01) 1.00 (0.99 – 1.01) 
Joint position sense (right great toe) 12 257.27 (58.46) 153 231.30 (54.17) 1.01 (1.00 – 1.02) 1.01 (1.00 – 1.02) 
Vibration sense (right great toe) 105 229.20 (52.73) 60 240.16 (57.85) 0.97 (0.99 – 1.00) 1.00 (0.99 – 1.00) 
 
Holotranscobalamin (pmol/L) 
 Unadjusted Adjusted for age 
and sex 
Clinical marker Absent Mean (sd)  Present Mean (sd)  OR (95% CI) OR (95% CI) 
Right knee jerk 15 51.16 (18.81) 144 52.75 (19.93) 1.00 (0.97 – 1.02) 1.00 (0.97 – 1.03) 
Right ankle jerk 43 51.57 (19.87) 116 52.98 (19.81) 1.00 (0.98 – 1.01) 1.00 (0.98 – 1.02) 
Joint position sense (right great toe) 11 51.57 (19.82) 148 52.67 (19.84) 1.00 (0.97 – 1.03) 1.00 (0.97 – 1.03) 
Vibration sense (right great toe) 101 51.55 (18.54) 58 54.43 (21.81) 0.99 (0.98 – 1.01) 0.99 (0.98 – 1.01) 
 
cB-12 
 Unadjusted Adjusted for age 
and sex 
Clinical marker Absent Mean (sd)  Present Mean (sd)  OR (95% CI) OR (95% CI) 
Right knee jerk 15 -0.19 (0.35) 144 -0.23 (0.37) 1.32 (0.30 – 5.79) 1.32 (0.26 – 6.66) 
Right ankle jerk 43 -0.24 (0.41) 116 -0.22 (0.35) 0.85 (0.33 – 2.18) 0.90 (0.33 – 2.43) 
Joint position sense (right great toe) 11 -0.20 (0.52) 148 -0.22 (0.36) 1.17 (0.22 – 6.29) 1.34 (0.25 – 7.38) 
Vibration sense (right great toe) 101 -0.25 (0.37) 58 -0.17 (0.36) 0.52 (0.21 – 1.30) 0.52 (0.21 – 1.30) 
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Supplemental table 3: Multivariate regression models to assess association between 
vitamin B12 status and nerve conduction outcomes (subjects with carpal tunnel 
syndrome excluded)1,2. 
 Adjusted coefficients2 
(95% confidence 
interval) 
B-12 (pmol/l) HoloTC (pmol/l) cB-12 
Sensory SAP 
amplitudes (µV) 
 n=139 n=133 n=133 
 Median  -0.01 (-0.02 – 0.01) -0.02 (-0.06 – 0.01)3 -1.30 (-3.34 – 0.87) 3 
 Ulnar -0.01 (-0.02 - -0.00) -0.01 (-0.04 – 0.02) 3 -0.53 (-1.96 – 0.87) 3 
 Sural -0.00 (-0.01 – 0.01) -0.02 (-0.05 – 0.02) 3 -0.26 (-2.02 – 1.49) 3 
 Superficial peroneal 0.00 (-0.01 – 0.01) -0.00 (-0.02 – 0.02) 3 0.55 (-1.03 – 1.76) 3 
  p=0.23 p=0.733 p=0.483 
Sensory nerve 
conduction 
velocities (m/s) 
 n=99 n=94 n=94 
 Median  0.00 (-0.02 – 0.01) 0.01 (-0.05 – 0.02) 0.17 (-2.45 – 2.31) 
 Ulnar -0.01 (-0.03 – 0.00) -0.03 (-0.07 – 0.01) -1.33 (-3.44 – 0.70) 
 Sural -0.01 (-0.03 – 0.00) -0.01 (-0.05 – 0.03) -1.62 (-4.12 – 0.53) 
 Superficial peroneal -0.01 (-0.02 – 0.01) -0.00 (-0.05 – 0.04) -0.04 (-2.97 – 2.75) 
  p=0.24 p=0.63 p=0.34 
Motor CMAP 
amplitudes (mV) 
 n=139 n=133 n=133 
 Median -0.01 (-0.01 - -0.00) -0.01 (-0.02 – 0.01) -0.38 (-0.95 – 0.26) 
 Ulnar 0.01 (-0.00 – 0.01) 0.02 (-0.00 – 0.03) 0.97 (-0.01 – 1.85) 
 Tibial -0.00 (-0.02 – 0.01) -0.01 (-0.03 – 0.02) -0.16 (-1.82 – 1.33) 
 Common peroneal 0.00 (-0.00 – 0.01) 0.00 (-0.01 – 0.02) 0.58 (-0.24 – 1.33) 
  p=0.01 p=0.14 p=0.01 
Motor nerve 
conduction 
velocities (m/s) 
 n=131 n=126 n=126 
 Median -0.00 (-0.02 – 0.01) -0.00 (-0.04 – 0.04 -0.73 (-2.57 – 1.19) 
 Ulnar 0.00 (-0.02 – 0.02) 0.02 (-0.03 – 0.06) 0.97 (-1.971 – 3.34) 
 Tibial 0.00 (-0.01 – 0.02) 0.01 (-0.03 – 0.06) 0.70 (-1.37 – 2.83) 
 Common peroneal -0.00 (-0.02 – 0.01) -0.02 (-0.05 – 0.01) -0.28 (-2.09 – 1.96) 
  p=0.85 p=0.52 p=0.72 
 
1SAP, sensory action potential; CMAP, compound muscle action potential.  
2All analyses adjusted for age, sex and foot skin temperature, unless otherwise stated. 
3Adjusted for age, sex, skin temperature (foot) and mean corpuscular volume. 
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Supplemental table 4: Multivariate regression models to assess interaction between vitamin 
B12 status and age for nerve conduction outcomes1, 2. 
 Coefficients 
(95% CI) for interaction 
parameter2 
B-12 (pmol/l) 
 
 
 
 
HoloTC (pmol/l) 
 
 
 
cB-12 
 
 
Sensory SAP amplitudes 
(µV) 
 n=164 n=158 n=158 
 Median  -0.00 (-0.01 -0.00) -0.00 (-0.01 – 0.01)3 0.03 (-0.73 – 0.63) 3 
 Ulnar -0.00 (-0.01 -0.00) -0.00 (-0.01 – 0.00) 3 -0.28 (-0.60 – 0.05) 3 
 Sural -0.00 (-0.00 -0.00) 0.00 (-0.01 – 0.01) 3 0.07 (-0.39 – 0.52) 3 
 Superficial peroneal 0.01 (-0.00 – 0.00) -0.00 (-0.01 – 0.00) 3 0.05 (-0.42 – 0.46) 3 
  p=0.42 p=0.743 p=0.353 
Sensory conduction 
velocities (m/s) 
 n=115 n=110 n=110 
 Median  0.00 (-0.01 – 0.01) 0.00 (-0.01 – 0.02) 0.40 (-0.33 – 1.34) 
 Ulnar 0.00 (-0.00 – 0.01) -0.00 (-0.01 – 0.00) -0.11 (-0.62 – 0.31) 
 Sural -0.00 (-0.01 – 0.01) -0.00 (-0.01 – 0.01) -0.46 (-1.33 – 0.31) 
 Superficial peroneal 0.00 (-0.00 – 0.01) -0.01 (-0.02 – 0.00) -0.70 (-1.45 - -0.05) 
  p=0.54 p=0.57 p=0.38 
Motor CMAP amplitudes 
(mV) 
 n=164 n=158 n=158 
 Median -0.00 (-0.00 – 0.00) -0.00 (-0.01 – 0.00) -0.13 (-0.29 – 0.07) 
 Ulnar -0.00 (-0.00 – 0.00) 0.00 (-0.00 – 0.00) -0.02 (-0.30 – 0.25) 
 Tibial -0.00 (-0.00 – 0.00) 0.00 (-0.01 – 0.01) 0.03 (-0.36 – 0.44) 
 Common peroneal 0.00 (-0.00 – 0.00) -0.00 (-0.01 – 0.00) -0.18 (-0.40 – 0.01) 
  p=0.95 p=0.06 p=0.23 
Motor conduction 
velocities (m/s) 
 n=153 n=148 n=148 
 Median 0.00 (-0.00 – 0.01) 0.00 (-0.01 – 0.02) 0.45 (-0.17 – 1.26) 
 Ulnar -0.00 (-0.01 – 0.00) -0.00 (-0.01 – 0.01) -0.40 (-1.16 – 0.23) 
 Tibial 0.00 (-0.00 – 0.01) -0.00 (-0.01 – 0.01) 0.01 (-0.75 – 0.77) 
 Common peroneal 0.00 (-0.00 – 0.00) -0.01 (-0.02 - -0.00) -0.40 (-0.99 – 0.44) 
  p=0.76 p=0.09 p=0.21 
Central Motor Conduction 
Time (ms) 
 n=147 n=142 n=142 
 ADM 0.00 (-0.00 – 0.00) -0.00 (-0.00 – 0.00) -0.03 (-0.17 – 0.12) 
 AH -0.00 (-0.01 – 0.00) -0.01 (-0.01 - -0.00) -0.55 (-0.99 - -0.18) 
  p=0.70 p=0.06 p=0.03 
  n=164 n=158 n=158 
 Mean ADM MEP 
amplitude (mV) 
-0.00 (-0.00 – 0.00)4 0.00 (-0.00 – 0.00) 4 -0.14 (-0.31 – 0.02) 4 
  p=0.164 p=0.834 p=0.114 
 
1SAP, sensory action potential; CMAP, compound muscle action potential; ADM, abductor digiti minimi; CMCT, central motor conduction time; AH, abductor 
hallucis; MEP, motor evoked potential.  
2All analyses adjusted for age, sex and foot skin temperature, unless otherwise stated. 
3Adjusted for age, sex, skin temperature (foot) and mean corpuscular volume. 
4Adjusted for age, sex, skin temperature (hand) 
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Chapter 4: Systematic review of evidence from interventions 
 
4.1  Introduction 
To date, the scientific evidence on effectiveness of vitamin B12 supplementation on 
neurological function in older people has not been systematically reviewed. A 
systematic review was conducted to assess the impact of vitamin B12 supplementation 
on neurological outcomes, with a research question as follows: 
 
1b) Is there any evidence in the available literature that vitamin B12 supplementation 
improves neurological function in older people? 
 
A common search strategy was used for both systematic reviews presented in Chapters 
2 and 4. However, the systematic review presented in Chapter 2 sought epidemiological 
studies assessing the association between vitamin B12 and neurological function, 
whereas the systematic review presented here (Chapter 4) includes intervention studies 
that have measured the effectiveness of a vitamin B12 intervention on neurological 
outcomes. The common systematic search of nine bibliographic databases was 
conducted on 28 March 2013 as described in Chapter 2. This systematic search of the 
literature was updated with a further search of Medline covering the period from 1 
January 2013 to 18 March 2016, using the same search terms. This second search of the 
literature was conducted to ensure the systematic review of interventions was up-to-
date for thesis submission. Papers for the systematic review of interventions were 
assessed for inclusion based on the criteria in Box 1.  
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Box 1: Inclusion criteria for studies 
 
 
Methods for assessing eligibility of studies, assessing risk of bias, data extraction and 
synthesising results are as described in Chapter 2, and were the same for the original 
systematic review of interventions and its update. No study was excluded on the basis 
of quality. Forms for data extraction and assessment of risk of bias were developed 
based on controlled trial checklists developed by SIGN1. Data were extracted into forms, 
defined according to the SIGN guidance, and risk of bias was assessed for each study 
based on the research question, randomisation procedures, blinding to treatment 
allocation, similarity of treatment and control groups at baseline, outcome assessment 
and percentage drop out. 
 
4.2  Study selection 
The original search identified 982 records. Of these, 835 were excluded as not relevant 
following title and abstract review.  Full-text articles for the remaining 147 records were 
 
Study design  
All study types assessing the effects of a vitamin B12 intervention on neurological outcomes, except 
intervention studies without a placebo comparison group, case reports/series, narrative reviews, 
editorials, conference reports and observational studies comparing treatment status. 
 
Subjects 
Older people with a median or mean age ≥50 years resident in institutions or the community. 
Studies of subject groups with known existing medical conditions affecting neurological function 
(including alcoholism, HIV, diabetes-associated neuropathy or motor neurone disease), vitamin B12 
status (including bariatric surgery) or metabolites of vitamin B12 (including renal insufficiency) were 
excluded. 
 
Intervention 
All forms of vitamin B12 (cobalamin, cyanocobalamin or hydroxocobalamin) supplementation were 
included, administered orally or intramuscularly. This included foods fortified with vitamin B12 but 
not multiple vitamin and mineral supplements. 
 
Outcome 
Included outcomes were peripheral sensory or motor nerve function/conduction, central motor 
conduction; peripheral neuropathy; clinical signs and symptoms of neurological (but not cognitive) 
function (somatosensory disorders, knee and ankle jerk/reflexes, joint, position and vibration sense, 
ataxia, and proprioception); and self-reported neurological (but not cognitive) symptoms (pain, 
altered sensation, unsteadiness, prickly feelings, weakness, numbness, and difficulty walking). 
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sought, though one was not retrievable2. Two additional papers identified through 
handsearching did not meet the inclusion criteria. A total of 148 full-text articles were 
examined in detail. 144 of these articles did not meet the inclusion criteria leaving four 
articles3-6 included in the primary review. The systematic review update identified 69 
unique records. Of these, 63 were excluded as not relevant following title and abstract 
review. Full-text articles for the remaining six articles were examined in detail. Five of 
these did not meet the inclusion criteria leaving one article7 to add to those identified 
in the primary review, giving a total of five articles (Figure 1).
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Figure 1: Study selection process for the systematic review of the effects of vitamin B12 supplementation on neurological function in older 
people. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1648 records identified through database search 
982 records screened for inclusion based on title/abstract 
147 full-text articles identified to assess for eligibility 
2 articles identified 
through 
handsearching 1 article not 
retrievable 
148 full-text articles assessed for eligibility 
4 articles included in original systematic 
review 
982 unique records after duplicates removed 
835 records excluded 
144 full-text articles 
excluded 
71 records identified through database search 
69 records screened for inclusion based on title/abstract 
6 full-text articles assessed for eligibility 
1 articles included in systematic review 
update 
69 unique records after duplicates removed 
63 records excluded 
5 full-text articles 
excluded 
5 articles included in final systematic 
review 
PRIMARY SYSTEMATIC REVIEW TO 28/03/2013 SYSTEMATIC REVIEW UPDATE (01/01/2013-18/03/2016) 
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4.3  Study characteristics 
The five included articles reported three randomised controlled trials (RCTs)3-5, 7 and one 
non-randomised controlled trial (nRCT)6. Two articles describing RCTs are from the same 
study. One article reports the original RCT findings4 and the second article5 describes 
subsequent sub-group analyses from the same RCT based on baseline holoTC status.  
 
One RCT reported by Kwok et al. 3 was based on subjects in Hong Kong, with subjects 
for the remaining three studies based in Europe. RCTs by Kwok et al.3 and Hvas et al.4, 5 
were conducted in subjects with biological evidence of low vitamin B12 status; the RCT 
by Dangour et al.7 was conducted in asymptomatic adults with moderately low vitamin 
B12 status; and the nRCT by Bjorkegren and Svardsudd6 was conducted in a general 
population group. However, the nRCT intervention varied according to the presence of 
neurological symptoms. 
 
Interventions used in studies by Kwok et al.3 and Hvas et al.4, 5 were similar and based 
on cyanocobalamin administered intramuscularly and follow-up was at 3-6 months. The 
study by Dangour et al.7 used a 1 mg vitamin B12 oral supplement intervention with 12 
months follow-up. Kwok et al.3 and Hvas et al.4, 5 assessed neurological function through 
clinical examination; Hvas et al.4, 5 also measured self-reported neurological symptoms. 
Bjorkegren and Svardsudd6 assessed neurological function through clinical examination 
and self-reported neurological symptoms. The study by Dangour et al.7 was the only one 
to measure nerve function through electrophysiological measures; a wide range of 
nerve conduction outcomes were reported covering peripheral motor and sensory 
nerve function and central motor conduction. Clinical markers of nerve function were 
reported in addition.  All study characteristics and findings are summarised in Table 1. 
Table 2 displays study characteristics used to assess risk of bias (based on the adapted 
SIGN checklist). 
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Table 1: Study characteristics and findings of intervention studies 
Author 
(year) 
Subject characteristics Intervention(s) Blinding and 
follow-up 
Outcomes Effects (sizes) of intervention (s) 
Kwok et al. 
(1998)3 
Subjects with serum 
B12<120 pmol/l, 
based in Hong Kong 
(n=50),  
mean age=76.6y 
(intervention), 77.4y 
(control). 
1) 3X 1mg cyanocobalamin 
administered i/m for first 
week, one dose weekly for 
further 3 weeks, followed by 
one monthly dose thereafter 
until follow-up (n=23) 
2) No placebo given to 
control group (n=27) 
 
3-6 Mo 
follow-up. 
Not blinded 
to subjects or 
investigators. 
NP: Motor function scale 
of the adult Luria-
Nebraska 
neuropsychological 
battery: measure of 
kinesthesia, drawing, fine 
motor, spatial movement 
and oral motor skills 
NP: 
Baseline versus follow-up in intervention group: 
- Kinesthesia deteriorated at follow-up [4.2 (2.8) vs 2.6 (2.4), p<0.05] 
- Fine motor skills deteriorated at follow-up [9.8 (3.0) vs 8.6 (3.4), p<0.05] 
- Drawing deteriorated at follow-up [10.1 (2.5) vs 7.2 (2.8), p<0.005] 
- No stat sig change in spatial movement or oral motor scores. 
Baseline versus follow-up in control group: 
- Drawing deteriorated at follow-up [9.1 (3.9) vs 7.3 (3.5), p<0.005] 
- Oral motor deteriorated at follow-up [0.2 (0.6) vs 1.1 (1.5), p<0.005] 
- No stat sig change in spatial movement, kinesthesia or fine motor scores. 
Differences in changes in score between intervention and control groups: 
- Stat sig deterioration in kinesthesia, fine motor and oral motor scores in intervention group compared to 
controls (p<0.05) 
Hvas et al.  
(2001) 4 
Hvas and 
Nexo 
(2005)5 
Patients with elevated 
MMA (0.40-2.00 
µmol/l), based in 
Denmark (n=140), 
median age=75y 
(intervention group), 
74y (placebo group). 
1) Intervention: i/m 
injections of 1mg 
cyanocobalamin once weekly 
for 4 wks (n=70) 
2) Placebo: i/m injections of 
1ml isotonic NaCl once 
weekly for 4 wks(n=70) 
3 Mo follow-
up 
Double-
blinded to 
investigators 
and subjects 
NP: Vibration sensation, 
neurological disability 
score based on finger-nose 
test, heel-knee-shin test, 
dysdiadochokinesis, 
Romberg test and gait.  
 
NS: Neurological symptom 
score based on presence 
of muscle weakness, 
sensory disturbances or 
autonomic symptoms. 
 
NP: 
- Vibration sensation: small improvements in treatment (upper extremities p=0.04, lower extremities p=0.89) and 
placebo (upper extremities p=0.01, lower extremities p=0.08) groups; no stat sig improvement in treatment group 
compared to placebo group. 
- No stat sig difference between treatment/placebo in change in neurologic disability score. 
NS: 
- No stat sig difference between treatment/placebo in change in neurologic symptom score or neurologic 
disability score. 
Subgroup analyses based on baseline P-MMA, P-B12, P-Hcy or holoTC: 
NP: 
- Vibration sensation: no stat sig improvement in treatment group with P-MMA≥0.6 µmol/l compared to the 
placebo group.  
- No stat sig difference between treatment/placebo in change in neurologic disability score. 
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- No stat sig differences between treatment group and placebo group in neurological disability score, vibration 
sensation (upper or lower extremities) if stratified by baseline holoTC (< or ≥ 40pmol/l). 
NS: 
- Stat sig association between improvement in neurologic symptoms in treatment group compared to placebo if P-
MMA≥0.6 µmol/l (p=0.014) (n=24 treatment/21 placebo) or if P-tHcy ≥15µmol/l (p=0.034) (n=25 treatment/26 
placebo).  
- Borderline stat sig association if P-B12<250pmol/l (p=0.06) (n=29 treatment/34 placebo). 
- No stat significant differences between treatment group and placebo group in neurological symptoms if 
stratified by baseline holoTC (< or ≥ 40pmol/l). 
Bjorkegren 
and 
Svardsudd 
(2004)6 
General population in 
Sweden (n=118). 
Treated group had 
serum B12 <300 
pmol/l and (serum 
MMA≥0.37 µmol/l or 
serum Hcy 
≥15µmol/l). B12 status 
of untreated group 
unknown. Mean 
age=78.5y (treated 
group), 74.6y 
(untreated group). 
1) Treatment for 6 Mo: 
(a) If neurological or 
psychiatric symptoms were 
present 1mg of 
hydroxocobalamin  given i/m 
5d/wk for 2 wk, then once 
weekly for 2 Mo and then 
once monthly. 
(b) If such symptoms not 
present given 2mg 
cyancobalamin tablets twice 
a day for 1 Mo then 1 mg 
daily. Those subjects with 
elevated serum MMA or Hcy 
at 6 Mo, then received 5mg 
folic acid daily (n=61). 
2) Untreated group did not 
receive a placebo (n=57) 
Treatments continued until 
follow-up. 
36 Mo follow-
up 
Not blinded 
to subjects or 
investigators 
NP: Vibration perception 
threshold, mean reflex 
intensity  
 
NS: Neurological symptom 
score assessed by 
questionnaire 
NP: 
- No stat significant differences between treated/untreated groups in any of the outcomes at 36 Mo**. 
- No stat significant change across the study period within groups for any outcome (except a stat sig decline in 
mean reflex intensity in the treated group)**. 
 
NS: 
- No stat significant differences between treated/untreated groups in any of the outcomes at 36 Mo**. 
- No stat significant change across the study period within groups for any outcome**. 
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Dangour et 
al. (2015)7 
Asymptomatic people 
based in the UK, with 
moderately low 
vitamin B12 status 
(≥107 and 
<210pmol/l) who did 
not have anaemia. 
Mean age=79.9y 
(intervention group), 
80.1y (placebo group). 
1) Daily 1mg cyanocobalamin 
as oral supplement (n=99). 
2) Daily oral placebo 
supplement (n=102) 
12 Mo follow-
up 
Double-
blinded to 
investigators 
and subjects 
NF: Motor nerve 
conduction (tibial and 
common peroneal CMAP 
amplitude and conduction 
velocity); sensory nerve 
conduction (sural and 
superficial peroneal SAP 
amplitude and conduction 
velocity); central motor 
conduction (abductor digiti 
motor evoked potential 
amplitude, abductor digiti 
minimi CMCT and 
abductor hallucis CMCT) 
 
NP: Knee and ankle jerk 
reflexes, great toe position 
and vibration sense.  
NF:  
- No stat sig difference between intervention and placebo groups in motor nerve conduction outcomes* 
- No stat difference between intervention and placebo groups in sensory nerve conduction outcomes* 
- No stat difference between intervention and placebo groups in central motor conduction outcomes* 
 
NP: 
- No stat sig difference between intervention and placebo groups in knee or ankle jerk reflexes* 
- No stat sig difference between intervention and placebo groups in great toe position or vibration sense* 
 
*Adjustments made for age and sex. 
** Adjustments made for age, sex and serum creatinine. 
 
Abbreviations  
B12, Vitamin B12; CMAP, Compound muscle action potential; CMCT, Central motor conduction time; d, days; Hcy, homocysteine; HoloTC, holotranscobalamin; i/m, intramuscular; MMA, methyl malonic acid; Mo, 
months; NaCl, sodium chloride; NF, electrophysiological measure of nerve function; NP, clinically assessed signs of neuropathy; NS, self-reported neurological symptoms; P-B12, Plasma vitamin B12; P-Hcy, Plasma 
homocysteine; P-MMA, plasma methyl malonic acid; SAP, sensory action potential; stat sig, statistically significant; vs, versus; wk, weeks; y, years. 
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Table 2: Study characteristics used to assess risk of bias (based on adapted SIGN 
checklist) 
 
Study characteristic Kwok et al. 
(1998)3 
Hvas et al. (2001)4 
Hvas and Nexo 
(2005)5  
 
Bjorkegren and 
Svardsudd (2004)6 
Dangour et al. 
(2015)7 
Focussed research 
question 
Poorly 
addressed 
Well covered Poorly addressed Well covered 
The assignment of subjects 
to treatment groups is 
randomised 
Adequately 
addressed 
Well covered Not addressed Well covered 
Subjects and investigators 
are kept blind about 
treatment allocation 
Not addressed Adequately 
addressed 
Not addressed Well covered 
The treatment and control 
groups are similar at the 
start of the trial 
Poorly 
addressed 
Adequately 
addressed 
Not addressed Well covered 
All relevant outcomes are 
measured in a standard, 
valid and reliable way 
Poorly 
addressed 
Adequately 
addressed 
(neurological 
markers based on 
clinical examination 
Poorly addressed 
(self-reported 
neurological 
symptoms) 
Adequately 
addressed 
(neurological 
markers based on 
clinical examination 
Poorly addressed 
(self-reported 
neurological 
symptoms) 
Well covered 
Percentage of subjects 
recruited into each 
treatment arm that 
dropped out before the 
study completed 
0% both arms 7% treatment 
1% placebo 
 
36% treatment 
0% control referents 
 
5% both arms 
 
 
4.4  Findings 
Included studies varied in their risk of bias (see Table 2). The study by Bjorkegren and 
Svardsudd 6 has a risk of bias for a number of reasons: the research question was not 
clearly defined; the vitamin B12 intervention varied accordingly to the neurological 
symptom status of the subjects; over a third of the subjects receiving the intervention 
were lost to follow-up, there was no blinding and the controls did not receive a placebo. 
Therefore, limited conclusions can be drawn from this study. 
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The remaining RCTs varied in risk of bias. Dangour et al. 7 reported a well designed, 
double-blinded RCT with low-drop out and a wide range of nerve conduction outcomes. 
Accordingly, it was assessed to have a low risk of bias. The study did not detect any 
benefits of daily 1mg vitamin B12 supplementation over one year on a wide range of 
neurologic outcomes.  
 
The RCT by Hvas et al. 4, 5  showed relatively low risk of bias. All study characteristics 
used to assess bias were at least adequately addressed but follow-up was short and 
nerve function was assessed by clinical examination and self-reported symptoms only. 
This study reports on the effectiveness of 1mg cyanocobalamin administered 
intramuscularly weekly for four weeks on neurological outcomes at three months. 
Primary analyses show no statistically significant difference in vibration sensation, 
neurological disability score (based on clinical markers) or neurological symptom score 
between intervention and control groups. There is, however, some suggestion of 
effectiveness of the intervention in further subgroup analyses to isolate subjects with 
the lowest vitamin B12 status. A statistically significant association between 
improvement in neurologic symptom score (but not vibration sensation or neurological 
disability score) in the treatment group compared to placebo if P-MMA≥0.6 µmol/l 
(p=0.014) or if P-tHcy ≥15µmol/l (p=0.034) was reported4. The association between 
improvement in neurologic symptom score in treatment versus placebo reached 
borderline statistical significance (p=0.06) if P-B12<250pmol/l. These subgroup analyses 
were based on subject numbers ranging from 21-34 in each placebo/treatment group. 
However, in analyses stratified according to patients’ holoTC status at baseline (< or ≥ 
40pmol/l), there was no statistically significant difference between placebo and 
treatment group5. 
 
The RCT by Kwok et al.3 suffered from lack of blinding (to investigators or subjects), a 
poorly defined outcome based on an aggregate measure of clinical measures of 
neurological function and a poorly defined research question. This study reported a 
statistically significant deterioration in kinesthesia, fine motor and oral motor scores in 
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the intervention compared to the control group, but the poor quality of the study means 
that this finding needs to be interpreted with caution. 
 
4.5  Discussion 
Very few studies are available to help understand whether vitamin B12 supplementation 
improves neurological function or clinically relevant neurological outcomes in older 
people.  
 
Only four studies were available to answer the research question, and two of these were 
subject to risk of bias. The remaining two studies assessed the effectiveness of different 
types of intervention (oral supplementation versus intramuscular injection) and only 
one used electrophysiological measures of nerve conduction, which are the most 
sensitive and objective measures of neurologic function.  It difficult to reach firm 
conclusions from heterogeneous evidence so limited in size and quality.  
 
One RCT by Dangour et al.7 assessed the effects of daily 1mg vitamin B12 
supplementation, and reported no difference between intervention and placebo in a 
wide range of outcomes covering all aspects of neurologic function. Theoretically, if the 
benefits of vitamin B12 supplementation are limited to a particular aspect of nerve 
function, this study would have been able to detect such differences; for example if 
benefits were limited to the PNS or CNS, sensory or motor peripheral nerve function, or 
measures reflective of axonal degeneration (CMAP and SAP amplitudes) or impaired 
myelination (motor or sensory conduction velocities). As there was no evidence of an 
effect of vitamin B12 supplementation, this suggests no such aspects of neurologic 
function were affected. However, there remains the possibility that the follow-up period 
was not long enough to detect an effect of vitamin B12 supplementation or that dose of 
vitamin B12 was too low. Furthermore, as subjects were asymptomatic and had only a 
moderately low vitamin B12 status, it is possible that subjects were too replete in 
vitamin B12 for supplementation to have a benefit.  
 
A further RCT by Hvas et al.4, 5 provided information about the effectiveness of a 1mg 
weekly cyanocobalamin intervention administered intramuscularly. Subjects already 
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had elevated MMA and the study4 provided no evidence of effectiveness. However, a 
statistically significant association between improvement in neurologic symptom score 
(but not vibration sensation or neurological disability score) was reported in the 
treatment group compared to placebo, in subjects with the lowest baseline vitamin B12 
status. Such subgroup analyses were not reported in any other study included in the 
review but further investigation in future studies may be warranted. 
 
Systematic reviews specifically aim to minimise bias resulting from partial identification, 
evaluation and reporting of the available evidence base. The search strategy used in the 
present systematic review was comprehensive. However, the literature search was 
limited to English language and published literature, and may have missed relevant 
studies published in other languages or in the grey literature such as conference 
proceedings. The search strategy for the systematic review update was limited to 
Medline and so relevant studies indexed in other bibliographic databases could have 
been missed. However, 75% of the studies identified in the original search were indexed 
in Medline. Both assessment of papers for inclusion and data extraction have been 
conducted by one reviewer. Ideally these processes would have been conducted in 
duplicate independently by two reviewers. Therefore, it is possible that some studies 
could have been included or excluded from the review inappropriately. The 
heterogeneity of the available evidence precluded the conduct of meta-analysis. 
 
4.5.1  Comparison with other studies 
To the best of my knowledge, this is the first systematic review investigating the impact 
of vitamin B12 supplementation on neurological function in older people. Existing 
evidence has been shown to be limited. A clustered RCT designed to compare two 
modes of vitamin B12 supplementation (daily 1mg vitamin B12 oral supplementation 
alongside consumption of standard fortified foods; consumption of fortified foods to 
supply 1mg vitamin B12 daily) on nerve conduction among healthy older people living 
in Chile has also been conducted8 but the results are not yet published.  
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4.6  Conclusion 
This systematic review shows that the currently available evidence indicates that 
vitamin B12 supplementation does not improve neurological function or clinically 
relevant neurological outcomes in older people. However, the available evidence was 
limited in size and quality so definitive conclusions cannot be drawn and some questions 
remain unanswered. One RCT provides evidence to suggest those with the lowest 
vitamin B12 status benefit from an intramuscular vitamin B12 intervention in terms of 
improvement in neurological symptoms. It is not known whether this extends to clinical 
markers of neurologic function or nerve conduction or whether the same effect would 
be seen with an oral vitamin B12 intervention. 
  
Impaired neurological function is a recognised consequence of vitamin B12 deficiency 
but it is not known what needs to be done to identify and treat those at risk. It has been 
suggested that routine vitamin B12 supplementation is needed in older people in light 
of the high prevalence of mild, preclinical deficiency9 but it is important to be clear 
whether there is sufficient evidence to infer those at risk will benefit. Further high 
quality research is warranted to investigate whether those older people with low 
vitamin B12 status, but not clinically identified as vitamin B12 deficient, would benefit 
from vitamin B12 supplementation in terms of neurologic function. 
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Chapter 5: Impact of baseline or change in vitamin B12 status on the 
effects of vitamin B12 supplementation on neurologic function in older 
people in the OPEN study 
 
Preface 
 
As described in Chapter 4, the systematic review of intervention studies identified four 
studies that overall show that the currently available evidence indicates that 
supplementation with vitamin B12 does not improve neurologic function in older people 
(research question 1b). However, subgroup analyses from a single study suggested that 
it is possible that improvement in neurologic function from vitamin B12 
supplementation is only apparent in people with the lowest vitamin B12 status. This 
hypothesis could be tested further in order to advance knowledge about the effects of 
vitamin B12 supplementation on neurologic function in older people. 
 
Data from the OPEN study afforded an opportunity to test whether the effectiveness of 
oral vitamin B12 supplementation on electrophysiological indices of neurologic function 
alters according to baseline B12 status or change in B12 status.  Conducting such 
secondary analyses in OPEN had the advantage of using a high quality dataset derived 
from asymptomatic older people with moderately low vitamin B12 status.  
 
Chapter 5 presents a secondary analysis of data from the OPEN study to address the 
following research question: 
 
2b) Does baseline vitamin B12 status or change in vitamin B12 status alter the 
effectiveness of dietary supplementation with vitamin B12 on 
electrophysiological indices of neurologic function in asymptomatic older people 
with moderately low vitamin B12 status? 
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My role in this research was to design the study, conduct the statistical analyses, 
interpret findings and write the manuscript. This report has been submitted for 
publication in a peer-reviewed journal. The manuscript is presented here.  
 


121 
 
Impact of baseline or change in vitamin B12 status on the effects of vitamin B12 1 
supplementation on neurologic function in older people in the OPEN study. 2 
 3 
Authors 4 
Lisa M Miles, Elizabeth Allen, Robert Clarke, Kerry Mills, Ricardo Uauy and Alan D Dangour 5 
Affiliations 6 
Faculty of Epidemiology and Population Health, London School of Hygiene & Tropical 7 
Medicine, London, UK (LMM, EA, RU and ADD) 8 
Clinical Trial Service Unit & Epidemiological Studies Unit, University of Oxford, Oxford, UK 9 
(RC) 10 
Department of Clinical Neurosciences, King’s College, London, UK (KM) 11 
Corresponding author 12 
Lisa Miles, Faculty of Epidemiology and Population Health, London School of Hygiene & 13 
Tropical Medicine, Keppel Street, London, WC1E 7HT, UK. Tel: 07962865272; email: 14 
lisa.miles@lshtm.ac.uk 15 
Sources of support 16 
Funding for the OPEN study was provided by the Food Standards Agency (N05072) and the 17 
Department of Health.  National Health Service Research and Development and King’s 18 
College Hospital Trust Research and Development provided service support costs.  No 19 
further funding was received for the secondary analyses presented here. 20 
 21 
Trial registration www.isrctn.com ISRCTN54195799 22 
  23 
122 
 
Abstract 24 
Background 25 
Studies to date suggest that vitamin B12 supplementation does not improve neurologic 26 
function in older people but it is possible that improvement is only apparent in people with 27 
the lowest vitamin B12 status. This study assessed whether baseline or change in vitamin 28 
B12 status (from baseline over 12 months) altered the effectiveness of dietary vitamin B12 29 
supplementation on electrophysiological indices of neurologic function in asymptomatic 30 
older people with moderately low vitamin B12 status. 31 
Methods 32 
Vitamin B12 status was assessed using vitamin B12, holotranscobalamin, homocysteine and 33 
combination of all three such measures (cB12). Eleven electrophysiological measures of 34 
sensory and motor components of peripheral and central nerve function were also 35 
assessed.  Analyses were restricted to the intervention arm (n=91) of the trial. 36 
Results 37 
Linear regression analyses revealed some moderate associations between several measures 38 
of baseline vitamin B12 status and neurologic responses to supplementation for some 39 
outcomes.  However, the directions of effect varied and heterogeneity in findings across 40 
outcomes cannot be explained according to type of neurologic outcome. There were no 41 
differences in the neurologic response to vitamin B12 supplementation according to any 42 
indicator of change in B12 status. 43 
Conclusions 44 
This study provides no evidence of a difference in the effect of vitamin B12 supplementation 45 
on peripheral or central nerve conduction dependent on baseline or change in vitamin B12 46 
status. There is insufficient evidence of efficacy on neurological function to support 47 
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population-wide recommendations for vitamin B12 supplementation in healthy 48 
asymptomatic older people, even among those with the lowest vitamin B12 status.   49 
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Introduction 50 
Ageing is associated with a decline in vitamin B12 status, and prevalence of deficiency 51 
increases with age1 . As dietary intakes are usually adequate in healthy populations2 , the 52 
age-related decline in vitamin B12 status is usually attributed to atrophic gastritis which 53 
reduces absorption of vitamin B123. Adequate vitamin B12 is necessary for optimal 54 
neurologic function. Symptoms of peripheral neuropathy associated with vitamin B12 55 
deficiency commonly include symmetric paresthesias, numbness or gait problems,  impaired 56 
position and cutaneous sensation, impaired vibration sense and weakness4, 5.  57 
 58 
It has been suggested that routine vitamin B12 supplementation is needed in older people 59 
in light of the high prevalence of mild, preclinical deficiency6 7. Indeed, US adults aged >50 60 
years are advised to meet their vitamin B12 recommended daily allowance of 2.4 µg/day 61 
mainly by consuming food fortified with vitamin B12 or a vitamin B12-containing 62 
supplement7. Yet, few studies8-11 are available to help understand whether vitamin B12 63 
supplementation improves neurological function in older people. Overall, these studies 64 
suggest that vitamin B12 supplementation does not improve neurologic function in older 65 
people but the available evidence is limited in size and quality. 66 
 67 
It is possible that improvement in neurologic function from vitamin B12 supplementation is 68 
only apparent in people with the lowest vitamin B12 status. This may explain the lack of 69 
treatment effect reported in studies available to date. Although primary analyses from the 70 
study by Hvas et al.,9 showed no statistically significant differences in neurologic outcomes 71 
between intervention (1mg cyanocobalamin administered intramuscularly weekly for four 72 
weeks) and control groups, there was evidence of effectiveness of treatment in individuals 73 
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with the lowest vitamin B12 status. A statistically significant association between 74 
improvement in neurologic symptom score was reported in the treatment group compared 75 
to placebo if plasma methyl malonic acid ≥0.6 µmol/l or plasma total homocysteine (Hcy) 76 
≥15µmol/l at baseline. There is further evidence to support greater benefits of vitamin B12 77 
supplementation in people with the lowest vitamin B12 status from studies considering the 78 
effects of B vitamin supplementation on cognitive outcomes. The VITACOG trial reported 79 
that administering high doses of folic acid, vitamin B6 and vitamin B12 over two years on 80 
measures of brain atrophy and several other cognitive outcomes was more beneficial in 81 
individuals with the highest baseline plasma Hcy levels 12, 13.  82 
 83 
The Older People and Enhanced Neurological function (OPEN) study afforded an 84 
opportunity to further explore in a high quality dataset whether improvement in neurologic 85 
function from vitamin B12 supplementation is limited to people with the lowest vitamin B12 86 
status. The OPEN study was a double-blind placebo-controlled randomised controlled trial 87 
(RCT) investigating the effects of 1 mg vitamin B12 oral supplementation on 88 
electrophysiological indices of neurologic function in older people with moderately low 89 
vitamin B12 status. The results demonstrated no effect of supplementation with vitamin 90 
B12 on any measure of nerve conduction compared with placebo11, but it is possible that 91 
overall the participants were too replete in vitamin B12 to be able to detect any benefit of 92 
vitamin B12 supplementation. The present study involves a secondary analysis of data from 93 
the OPEN study designed to explore whether differences in baseline vitamin B12 status or 94 
change in vitamin B12 status alters the effectiveness of vitamin B12 supplementation on 95 
electrophysiological indices of neurologic function in asymptomatic older people with 96 
moderately low vitamin B12 status.  97 
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 98 
Methods 99 
This study is a secondary analysis of data from the OPEN study, the protocol of which has 100 
been published14 (www.isrctn.com; ISRCTN54195799). Screening for participation in the 101 
OPEN study took place between November 2008 and February 2010. Participants were aged 102 
≥75 years and recruited from 7 general practices in South East England. Individuals with 103 
dementia, epilepsy, alcohol addiction, diabetes, pacemakers or other implanted metallic 104 
devices, residents of nursing homes, or a previous diagnosis of pernicious anaemia were 105 
excluded. Potential participants with significant cognitive impairment or who reported 106 
current consumption of vitamin B12 supplements or who had received a vitamin B12 107 
injection in the previous 6 months were excluded. Individuals with moderate vitamin B12 108 
deficiency [serum vitamin B12 concentrations ≥107 and <210 pmol/L (Beckman Coulter 109 
assay)] who did not have anaemia (haemoglobin concentrations ≥110 g/L for women and 110 
≥120 g/L for men) were eligible to join the study.  111 
 112 
Participants were enrolled in the trial and randomised to treatment (n=99) or placebo arms 113 
(n=102). Allocation to treatment was balanced by age and sex and all participants and 114 
investigators were blinded to treatment allocation.  Allocated treatment consisted of a 115 
single tablet containing 1 mg vitamin B12 (cyanocobalamin) administered daily.  91 116 
participants in each arm of the trial provided follow-up data on the primary trial outcome, 117 
posterior tibial compound muscle action potential (CMAP) amplitude.  The size of the study 118 
was determined by a sample size calculation designed to achieve 90% power to detect a 119 
≥28% difference in the primary outcome (with 5% significance) between arms of the trial. 120 
 121 
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At baseline and after 12 months follow-up, participants provided a blood sample and 122 
undertook a series of neurophysiological function tests. Blood samples were analysed for 123 
serum concentrations of vitamin B12 (microbiologic assay); holotranscobalamin (HoloTC; 124 
Axis-Shield radioimmunoassay; Axis-Shield plc), total Hcy (Abbott IMx analyzer; Abbott 125 
Laboratories), and folate (chloramphenicol-resistant microbiologic assay) in a single 126 
laboratory in Trinity College Dublin. 88% of participants had vitamin B12 status below the 127 
median value for the microbiologic assay reference standard (derived from a random 128 
sample of 470 from nationally representative adults in the Irish National Adult Nutrition 129 
Survey) (personal communication Dr Anne Molloy, 2013), indicating that participants had 130 
moderately low vitamin B12 status. 131 
 132 
A single neurophysiologist conducted a battery of peripheral nerve conduction tests and 133 
central motor conduction tests at baseline and follow-up. Standard techniques were used 134 
involving surface electrodes. Skin temperature of the dorsum of the foot and hand was 135 
measured to allow for appropriate adjustments in the analyses because nerve conduction in 136 
peripheral nerves is sensitive to temperature of the limbs15. Posterior tibial CMAP amplitude 137 
evoked by distal stimulation was the primary trial outcome. The seven secondary peripheral 138 
nerve outcomes were common peroneal CMAP amplitude (also evoked by distal 139 
stimulation); posterior tibial and common peroneal conduction velocities measured by 140 
recording from the adductor hallucis (AH) and extensor digitorum brevis muscles 141 
respectively; and sensory action potential (SAP) amplitude (maximum deviation of the 142 
electrical response) and conduction velocity measured in the sural and superficial peroneal 143 
nerves. Together these outcomes represent each component of peripheral nerve function: 144 
posterior tibial and common peroneal CMAP reflects the number of motor axons that can 145 
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be accessed by an electrical stimulus which in turn reflects muscle strength16, 17; sural and 146 
superficial peroneal SAP amplitudes are indices of nerve fibre number; and sensory (sural 147 
and superficial peroneal nerve) or motor (posterior tibial and common peroneal) conduction 148 
velocity is an indicator of myelination18.  All nerve conduction outcomes were measured in 149 
the right side of the body. 150 
 151 
Central motor conduction tests were measured using transcranial magnetic stimulation, 152 
which painlessly and noninvasively excites the motor cortex19. Detailed methods are 153 
reported by Dangour et al.11. Further secondary outcomes were mean abductor digiti motor 154 
(ADM) motor evoked potential (MEP) amplitude, and ADM and AH central motor 155 
conduction time (CMCT).  With the right ADM muscle partially activated voluntarily, stimuli 156 
were delivered to evoke MEPs, the mean amplitude of which were measured. Similarly, the 157 
leg area of motor cortex was excited to measure MEPs evoked in the AH muscle. ADM and 158 
AH CMCT was calculated by subtracting the time to response in each muscle from an 159 
estimate of the peripheral nerve conduction time.  160 
 161 
Vitamin B12 and HoloTC were used as measures of vitamin B12 status. In addition, cB12 was 162 
used as a composite indicator of vitamin B12 status combining vitamin B12, HoloTC and 163 
Hcy20.  Although Hcy alone does not have good specificity as an indicator of vitamin B12 164 
status, it is also included as an indicator of vitamin B12 in this study for exploratory 165 
purposes. 166 
 167 
 168 
 169 
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Statistical analysis 170 
Analyses were performed to explore whether baseline or change in vitamin B12 status alters 171 
the impact of dietary vitamin B12 supplementation on neurologic function in the OPEN 172 
study. Analyses have been restricted to the intervention arm (n=91), because the placebo 173 
arm did not receive any vitamin B12 supplementation and accordingly, change in vitamin 174 
B12 status was negligible11; minor changes in vitamin B12 status or nerve conduction in the 175 
placebo arm are assumed to be due to variability in repeated measures. All analyses were 176 
exploratory in nature with the aim to look for consistent patterns in findings rather than 177 
applying stringent p values to test for statistical significance. 178 
 179 
Firstly, the effects of vitamin B12 supplementation on vitamin B12 status according to 180 
baseline status were explored graphically, using vitamin B12, HoloTC, Hcy and cB12 as 181 
indicators of vitamin B12 status. Secondly, the effects of vitamin B12 supplementation on 182 
neurologic outcomes according to baseline or change in vitamin B12 status were assessed 183 
visually using scatter plots and lowess smoother curves to explore the nature and functional 184 
form of any potential associations.  185 
 186 
Linear regression models were used to test for associations between baseline and change in 187 
vitamin B12 status (measured by vitamin B12, HoloTC, Hcy and cB12) and neurologic 188 
response to vitamin B12 supplementation. Eleven nerve conduction outcomes were used, 189 
consistent with the outcomes used in the primary analyses from the OPEN study11. For each 190 
nerve conduction outcome, linear regression models tested for associations between 191 
baseline vitamin B12 status and change in the outcome (in response to supplementation), 192 
adjusted for the corresponding baseline measure of nerve conduction, age, sex and change 193 
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in skin temperature. Similarly, linear regression models tested for associations between 194 
change in vitamin B12 status and change in the outcome (in response to supplementation) 195 
for the same nerve conduction outcomes; adjustments included baseline measures of 196 
vitamin B12 in addition to those listed above. All linear regression models were boot 197 
strapped to allow for non-normal distributions of exposures and outcomes. Results were 198 
presented as mean change in outcome with bias-corrected 95% confidence intervals. 199 
Because the analyses involved multiple comparisons, p-values have been interpreted with 200 
caution. Statistical analyses were conducted using STATA (version 14 StataCorp, Texas USA). 201 
 202 
Ethics 203 
The OPEN study was reviewed and approved by the National Research Ethics Committee 204 
(08/H0305/18) and the London School of Hygiene & Tropical Medicine Ethics Committee 205 
(LSHTM) (no. 5298). The secondary analyses presented here were approved by the LSHTM 206 
Ethics Committee (no. 7176). 207 
 208 
Results 209 
Participants included in the current analysis had a mean age of 79.9 years and 46.5% were 210 
male. Comparing baseline with 12 months, oral supplementation was effective in increasing 211 
vitamin B12 status: vitamin B12, HoloTC and cB12 increased (mean change 409.6 pmol/l, 212 
184.3 pmol/l and 1.5 respectively) and Hcy (mean change -2.8 µmol/l) decreased at 12 213 
months follow-up. Levels of vitamin B12 and cB12 at follow-up are relatively constant across 214 
quartiles of baseline status, suggesting a plateau effect (Figure 1). There is no significant 215 
differences in follow-up vitamin B12 (F test p=0.44) or cB12 (F test p=0.21) across quartiles 216 
of baseline vitamin B12. The effects of vitamin B12 supplementation on Hcy and HoloTC 217 
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differs across baseline quartiles (Figure 1). There is a statistically significant difference in 218 
follow-up Hcy across baseline quartiles (F test p<0.001) and a borderline statistically 219 
significant difference in follow-up HoloTC across baseline quartiles (F test p=0.07). Figure 1 220 
shows that follow-up HoloTC increases across quartiles of baseline HoloTC (p=0.01 for linear 221 
trend), and follow-up Hcy increases across quartiles of baseline Hcy (p<0.001 for linear 222 
trend).  223 
 224 
Linear regression models found no evidence of a difference in impact of vitamin B12 225 
supplementation on the primary trial outcome (posterior tibial CMAP amplitude) across 226 
quartiles of baseline vitamin B12, HoloTC, Hcy or cB12 status (Table 1). However, there is 227 
evidence of a very small improvement in common peroneal CMAP amplitude in response to 228 
supplementation, in participants with lower baseline vitamin B12 status [β=-0.01 (-0.01 - -229 
0.00), p=0.02] for vitamin B12; p>0.05 for all other measures of vitamin B12 status. 230 
 231 
There is evidence of a small inverse association between baseline vitamin B12 and cB12 and 232 
change in posterior tibial motor conduction velocity; participants with the lowest baseline 233 
status tended to have a greater positive change in outcome in response to supplementation 234 
over 12 months. However, small associations in the opposite direction are detected in 235 
analyses between HoloTC and cB12 and change in common peroneal conduction velocity in 236 
response to supplementation. Further, there is evidence of a very small improvement in 237 
sensory sural conduction velocity in response to supplementation, in participants with 238 
higher baseline vitamin B12 status [β=0.02 (0.00 – 0.03), p=0.05] for vitamin B12; p>0.05 for 239 
all other measures of vitamin B12 status. 240 
 241 
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In terms of central nerve conduction, Table 1 shows that AH CMCT following vitamin B12 242 
supplementation improves (decreases) in participants with lower baseline cB12 status 243 
[β=2.19 (0.10 – 4.04), p=0.03]. Results for change in ADM CMCT are consistent in direction 244 
of effect but smaller in magnitude and not statistically significant [β=0.53 (-0.75 – 1.43), 245 
p=0.31]. However, results for mean ADM MEP amplitude suggest that neurologic function 246 
improves in response to supplementation in participants with higher baseline vitamin B12 247 
status (as measured by Hcy and cB12). 248 
 249 
Linear regression analyses show that neurologic response to vitamin B12 supplementation 250 
does not differ by change in vitamin B12 status (Table 2). Null results are consistent across 251 
each measure of vitamin B12 status and all nerve conduction outcomes.  252 
 253 
Discussion 254 
Key findings 255 
This study demonstrated no differences in the effect of vitamin B12 supplementation on the 256 
primary trial outcome across quartiles of baseline vitamin B12 status. However, when 257 
considering secondary outcomes, analyses using some indicators of vitamin B12 status (but 258 
not others) revealed suggestive evidence of associations between baseline vitamin B12 259 
status and some peripheral and central neurologic responses to supplementation.  260 
However, directions of effect were inconsistent: as many analyses showed suggestive 261 
evidence of greater neurologic improvement in response to supplementation in participants 262 
with higher baseline vitamin B12 status as analyses showing suggestive evidence of greater 263 
neurologic improvement in response to supplementation in participants with lower baseline 264 
vitamin B12 status. Heterogeneity in findings across neurologic outcomes cannot be 265 
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explained by the aspect of neurologic function each outcomes measures: there were no 266 
differences in findings in peripheral versus central nerve conduction; motor versus sensory 267 
peripheral nerve conduction; or conduction velocities versus CMAP or SAP amplitudes. 268 
Taken together, there is no evidence of differences in the effect of vitamin B12 269 
supplementation on measures of nerve conduction based on baseline vitamin B12 status. 270 
This study also finds no evidence of difference in neurologic response to vitamin B12 271 
supplementation according to any indicator of change in B12 status (vitamin B12, holoTC, 272 
Hcy or cB12) and any measure of peripheral or central nerve conduction. In addition, this 273 
study shows that different indicators of vitamin B12 status reveal different patterns in 274 
vitamin B12 status achieved after 12 months oral vitamin B12 supplementation: follow-up 275 
Hcy and HoloTC increase across baseline quartiles, whereas a relatively constant follow-up 276 
vitamin B12 and cB12 is achieved across baseline quartiles. 277 
 278 
Comparison with other studies 279 
Whilst previous reports9 suggested that individuals with the lowest vitamin B12 status might 280 
benefit most from an intramuscular vitamin B12 intervention in terms of neurological 281 
symptoms, results from this study indicate that this does not extend to benefits of an oral 282 
vitamin B12 intervention or improvements in nerve conduction. The findings of the present 283 
study differ from the results from the VITACOG trial which reported greater benefits of 284 
supplementation on cognitive outcomes in people with the lowest baseline status12, 13. This 285 
study also extends the primary findings of the OPEN RCT11 by exploring whether the null 286 
findings of the intervention might be attributed to the relatively replete vitamin B12 status 287 
of participants. As the secondary analyses found no consistent evidence of a greater benefit 288 
of vitamin B12 supplementation in terms of neurologic function in those with the lowest 289 
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vitamin B12 status, it remains unlikely that the intervention would have been effective if 290 
participants had had slightly poorer vitamin B12 status alongside absence of neurologic or 291 
haematological symptoms of deficiency. 292 
 293 
Strengths and weaknesses 294 
The use of several measures of vitamin B12 status and measurement of neurologic function 295 
by nerve conduction are strengths of the study. In particular, HoloTC measures the active 296 
fraction of vitamin B12 and has been proposed as appropriate to use in the subclinical 297 
situation21, 22. The use of cB12 has the advantage of combining biomarkers of circulating 298 
vitamin B12 and a functional biomarker of vitamin B12 status20, but it has been reported to 299 
be associated with renal function23 which was not measured in the OPEN study. Nerve 300 
conduction tests use state-of-the-art methods and are objective measures. All baseline and 301 
follow-up testing was conducted by a single neurophysiologist which eliminated inter-302 
observer variability.  303 
 304 
It is recognised that this study is limited in statistical power and so analyses have been 305 
exploratory. It is possible that trends would have been more easily detected in a larger 306 
study. It is also possible that the associations detected in this study were identified by 307 
chance as a result of multiple comparisons across several outcomes. Furthermore, it 308 
remains possible that the duration of the vitamin B12 supplementation was too short and 309 
that benefits of supplementation only become evident after several years of treatment.  310 
 311 
 312 
 313 
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Policy relevance and research needs 314 
This study provides no evidence to suggest that oral supplementation with vitamin B12 has 315 
any beneficial effect on neurological function in individuals with the lowest vitamin B12 316 
status. These results suggest that concerns over the neurologic impact of moderately low 317 
vitamin B12 status in older people are not justified by the available evidence. In terms of 318 
peripheral and central neurologic function, the authors suggest there is insufficient evidence 319 
to support population screening for moderate vitamin B12 deficiency in the absence of 320 
anaemia or neurological symptoms, nor support population-wide recommendations for 321 
vitamin B12 supplementation in healthy asymptomatic older people, even among those 322 
with the lowest vitamin B12 status. Treatment for neurological impairment attributed to 323 
vitamin B12 deficiency should be managed as appropriate by clinicians, rather than handled 324 
at the population level. 325 
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Table 1: Linear regression analyses to assess relationship between baseline vitamin B12 status and change in nerve conduction in response to supplementation1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1Adjusted for baseline measure of the neurologic outcome, baseline age, baseline sex and change in skin temperature (foot), unless otherwise stated. 
Change in outcome  Baseline B12 (pmol/L) Baseline HoloTC (pmol/L) Baseline Hcy (µmol/L) Baseline cB12 
Motor tibial CMAP 
amplitude (mV) 
n 
 
732 702 722 702 
β -0.00 (-0.01 - 0.00) 0.01 (-0.01 – 0.03) 0.04 (-0.03 – 0.15) -0.12 (-1.21 – 1.01) 
p 0.45 0.42 0.32 0.84 
Motor common peroneal 
CMAP amplitude (mV) 
n 
 
713 694 703 694 
β -0.01 (-0.01 - -0.00) 0.00 (-0.01 – 0.01) -0.00 (-0.06 – 0.08) -0.02 (-0.81 – 0.83) 
p 0.02 0.94 0.97 0.97 
Motor tibial conduction 
velocity (m/s) 
n 72 69 71 69 
β -0.02  (-0.04- -0.01) -0.02 (-0.06 – 0.03) 0.11 (-0.09 – 0.27) -2.12 (-4.40 – 0.34) 
p 0.01 0.40 0.21 0.08 
Motor common peroneal 
conduction velocity (m/s) 
n 
 
71 69 70 69 
β 0.00 (-0.01 – 0.02) 0.04 (0.00 – 0.09) -0.11 (-0.25 – 0.14) 2.05 (-0.28 – 4.21) 
p 0.75 0.04 0.25 0.07  
Sensory sural SAP 
amplitude (µV) 
n 595 586 597 586 
β -0.01 (-0.04 – 0.00) -0.01 (-0.04 – 0.03) 0.09 (-0.04 – 0.21) -1.03 (-3.09- 0.59) 
p 0.23 0.64 0.15 0.27 
Sensory superficial 
peroneal SAP amplitude 
(µV) 
n 
 
498 489 4910 489 
β -0.00 (-0.01 – 0.02) -0.00 (-0.07 – 0.03) 0.07 (-0.26 – 0.37) -0.81 (-4.50 – 1.84) 
p 0.85 0.85 0.66 0.61 
Sensory sural conduction 
velocity (m/s) 
n 59 58 59 58 
β 
 
0.02 (0.00 – 0.03) 0.03 (-0.02 – 0.07) 0.03 (-0.16 – 0.30) 1.81 (-0.96 – 4.35) 
p 0.05 0.18 0.82 0.17 
Sensory superficial 
peroneal conduction 
velocity (m/s) 
n 49 48 49 48 
β 
 
-0.00 (-0.03 – 0.03) -0.02 (-0.11 – 0.07) 0.17 (-0.15 – 0.62) -1.58 (-7.07 – 3.25) 
p 0.83 0.62 0.38 0.54 
ADM CMCT (ms) n 72 69 71 69 
β 
 
0.00 (-0.00 – 0.01)11 0.01 (-0.01 – 0.03)11 -0.00 (-0.08 – 0.09)11 0.53 (-0.75 – 1.43)11 
p 0.7711 0.2111 0.9811 0.3111 
AH CMCT (ms) n 66 63 65 63 
β 
 
0.00 (-0.01 – 0.02) 0.03 (-0.01 – 0.06) -0.07 (-0.20 – 0.08) 2.19 (0.10 – 4.04) 
p 0.77 0.12 0.35 0.03 
Mean abductor digiti 
motor (ADM) MEP 
amplitude (mV) 
n 74 71 73 71 
β 
 
0.00 (-0.00 – 0.01)11 0.00 (-0.01 – 0.01)11 -0.07 (-0.13 - -0.03)11 0.72 (0.04 – 1.29)11 
p 0.1711 0.3311 0.0011 0.0311 
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2 Three subjects with 0 values for tibial CMAP amplitude at baseline or follow-up excluded. 
3Five subjects with 0 values for common peroneal CMAP amplitude at baseline or follow-up excluded. 
4 Four subjects with 0 values for common peroneal CMAP amplitude at baseline or follow-up excluded. 
5 Seventeen subjects with 0 values for sural SAP amplitude at baseline or follow-up excluded; 8 of these had detectable sural SAP amplitude at baseline and no detectable (0) sural SAP 
amplitude at follow-up; and 3 of these had undetectable (0) sural SAP amplitude at baseline and detectable sural SAP amplitude at follow-up. 
6 Fifteen subjects with 0 values for sural SAP amplitude at baseline or follow-up excluded; 7 of these had detectable sural SAP amplitude at baseline and no detectable (0) sural SAP amplitude 
at follow-up; and 3 of these had undetectable (0) sural SAP amplitude at baseline and detectable sural SAP amplitude at follow-up. 
7 Sixteen subjects with 0 values for sural SAP amplitude at baseline or follow-up excluded; 7 of these had detectable sural SAP amplitude at baseline and no detectable (0) sural SAP amplitude 
at follow-up; and 3 of these had undetectable (0) sural SAP amplitude at baseline and detectable sural SAP amplitude at follow-up. 
8Twenty-seven subjects with 0 values for superficial peroneal SAP amplitude at baseline or follow-up excluded;  11 of these had detectable superficial peroneal SAP amplitude at baseline and 
no detectable (0) superficial peroneal SAP amplitude at follow-up; and 10 of these had undetectable (0) superficial peroneal SAP amplitude at baseline and detectable superficial peroneal SAP 
amplitude at follow-up. 
9Twenty-five subjects with 0 values for superficial peroneal SAP amplitude at baseline or follow-up excluded; 10 of these had detectable superficial peroneal SAP amplitude at baseline and no 
detectable (0) superficial peroneal SAP amplitude at follow-up; and 9 of these had undetectable (0) superficial peroneal SAP amplitude at baseline and detectable superficial peroneal SAP 
amplitude at follow-up. 
10Twenty-six subjects with 0 values for superficial peroneal SAP amplitude at baseline or follow-up excluded; 10 of these had detectable superficial peroneal SAP amplitude at baseline and no 
detectable (0) superficial peroneal SAP amplitude at follow-up; and 10 of these had undetectable (0) superficial peroneal SAP amplitude at baseline and detectable superficial peroneal SAP 
amplitude at follow-up. 
11 Adjusted for baseline measure of the neurologic outcome, baseline age, baseline sex and change in skin temperature (hand). 
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Table 2: Linear regression analyses to assess relationship between change in vitamin B12 status and change in nerve conduction in response to supplementation1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Change in outcome  Change in B12 Change in HoloTC Change in Hcy Change in cB12 
Motor tibial CMAP 
amplitude (mV) 
n 712 682 702 682 
β 0.00 (-0.00 – 0.00) 0.00 (-0.00 – 0.01) -0.07 (-0.22 – 0.08) 0.71 (-0.36 – 1.91) 
p 0.41 0.38 0.34 0.22 
Motor common peroneal 
CMAP amplitude (mV) 
n 693 674 683 674 
β 0.00 (-0.00 – 0.00) 0.00 (-0.00 – 0.00) 0.10 (-0.12 – 0.34) 0.52 (-0.14 – 1.39) 
p 0.98 0.31 0.41 0.18 
Motor tibial conduction 
velocity (m/s) 
n 70 67 69 67 
β 0.00 (-0.00 – 0.00) 0.00 (-0.00 – 0.01) -0.07 (-0.59 – 0.43) 0.72 (-1.50 – 3.35) 
p 0.98 0.52 0.77 0.57 
Motor common peroneal 
conduction velocity (m/s) 
n 69 67 68 67 
β -0.00 (-0.00 – 0.00) -0.00 (-0.01 – 0.00) 0.10 (-0.39 – 0.78) 0.24 (-1.70 – 2.46) 
p 0.81 0.35 0.75 0.82 
Sensory sural SAP 
amplitude (µV) 
n 585 576 587 576 
β -0.00 (-0.00 – 0.00) 0.00 (-0.01 – 0.01) -0.13 (-0.56 – 0.22) 0.23 (-1.62 – 2.59) 
p 0.93 0.98 0.51 0.82 
Sensory superficial 
peroneal SAP amplitude 
(µV) 
n 498 489 4910 489 
β 0.00 (-0.00 – 0.01) 0.00 (-0.01 – 0.02) -0.37 (-1.08 - -0.00) 2.45 (-0.52 – 7.40) 
p 0.66 0.69 0.15 0.19 
Sensory sural conduction 
velocity (m/s) 
n 58 57 58 57 
β 0.00 (-0.00 – 0.01) 0.00 (-0.01 – 0.01) 0.29 (-0.21 – 0.82) 0.94 (-2.43 – 3.23) 
p 0.05 0.64 0.25 0.51 
Sensory superficial 
peroneal conduction 
velocity (m/s) 
n 49 48 49 48 
β -0.01 (-0.02 – 0.01) -0.01 (-0.03 – 0.01) -0.18 (-0.82 – 0.74) -1.64 (-7.42 – 3.01) 
p 0.37 0.32 0.65 0.54 
ADM CMCT (ms) n 70 67 69 67 
β -0.00 (-0.00 - 0.00)11 -0.00 (-0.00 - 0.00)11 0.02 (-0.19 – 0.17)11 -0.19 (-1.01 – 0.90)11 
p 0.1511 0.3511 0.8111 0.6811 
AH CMCT (ms) n 64 61 63 61 
β 0.00 (-0.00 - 0.00) 0.00 (-0.01 – 0.01) 0.18 (-0.22 – 0.66) 0.42 (-1.53 – 2.02) 
p 0.41 0.84 0.42 0.64 
Mean abductor digiti 
motor (ADM) MEP 
amplitude (mV) 
n 72 69 71 69 
β 0.00 (-0.00 - 0.00)11 0.00 (-0.00 - 0.00)11 -0.03 (-0.13 – 0.07)11 0.50 (-0.27 – 1.23)11 
p 0.3611 0.7211 0.5211 0.1911 
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1 Adjusted for baseline measure of neurologic outcome, baseline B12/HoloTC/Hcy/cB12 status, baseline age, baseline sex and change in skin temperature (foot) unless otherwise stated. 
2 Three subjects with 0 values for tibial CMAP at baseline or follow-up excluded. 
3Five subjects with 0 values for common peroneal CMAP at baseline or follow-up excluded. 
4Four subjects with 0 values for common peroneal CMAP at baseline or follow-up excluded. 
5Sixteen subjects with 0 values for sural SAP at baseline or follow-up excluded; 7 of these had detectable sural SAP amplitude at baseline and no detectable (0) sural SAP amplitude at follow-
up; and 3 of these had undetectable (0) sural SAP amplitude at baseline and detectable sural SAP amplitude at follow-up. 
6 Fourteen subjects with 0 values for sural SAP at baseline or follow-up excluded; 6 of these had detectable sural SAP amplitude at baseline and no detectable (0) sural SAP amplitude at 
follow-up; and 3 of these had undetectable (0) sural SAP amplitude at baseline and detectable sural SAP amplitude at follow-up. 
7Fifteen subjects with 0 values for sural SAP at baseline or follow-up excluded; 6 of these had detectable sural SAP amplitude at baseline and no detectable (0) sural SAP amplitude at follow-
up; and 3 of these had undetectable (0) sural SAP amplitude at baseline and detectable sural SAP amplitude at follow-up. 
8Twenty-five subjects with 0 values for superficial peroneal SAP at baseline or follow-up excluded; 10 of these had detectable superficial peroneal SAP amplitude at baseline and no detectable 
(0) superficial peroneal SAP amplitude at follow-up; and 9 of these had undetectable (0) superficial peroneal SAP amplitude at baseline and detectable superficial peroneal SAP amplitude at 
follow-up. 
9Twenty-three subjects with 0 values for superficial peroneal SAP at baseline or follow-up excluded; 9 of these had detectable superficial peroneal SAP amplitude at baseline and no 
detectable (0) superficial peroneal SAP amplitude at follow-up; and 8 of these had undetectable (0) superficial peroneal SAP amplitude at baseline and detectable superficial peroneal SAP 
amplitude at follow-up. 
10Twenty-four subjects with 0 values for superficial peroneal SAP at baseline or follow-up excluded; 9 of these had detectable superficial peroneal SAP amplitude at baseline and no detectable 
(0) superficial peroneal SAP amplitude at follow-up; and 9 of these had undetectable (0) superficial peroneal SAP amplitude at baseline and detectable superficial peroneal SAP amplitude at 
follow-up. 
11Adjusted for baseline measure of neurologic outcome, baseline B12/HoloTC/Hcy/cB12 status, baseline age, baseline sex and change in skin temperature (hand). 
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Figure 1: Baseline and follow-up vitamin B12 status according to quartiles of serum vitamin B12, HoloTC, Hcy and cB12 at baseline. 
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Chapter 6: Discussion and conclusions 
 
6.1  Introduction 
Older people contribute to society in many ways, for example through informal care of 
family members and as an experienced workforce that can benefit local communities 
and the economy. Yet, making the most of older people in society is enhanced if their 
extra years are spent in good health, and this presents a public health challenge. 
Maintaining functional ability in older age reduces the need for dependence on carers 
and health services, and the costs associated with them, and can improve quality of life1-
3. Healthy ageing is affected by many factors, including physiological changes that affect 
nutrition.  Vitamin B12 is a nutrient whose status is affected by physiologic changes seen 
with ageing. A decline in vitamin B12 status is associated with ageing and this is largely 
due to impaired absorption rather than reduced intakes4-6. As neurologic impairment is 
a known consequence of frank vitamin B12 deficiency7-9, it is plausible that inadequate 
vitamin B12 has implications for functional ability in older age through its relationship 
with neurologic function. 
 
Neurological impairments associated with low vitamin B12 status are often assumed to 
be part of the natural ageing process, and so can be easily missed. This causes potential 
opportunities for prevention or treatment to be overlooked. In such cases, the 
neurologic signs and symptoms of low vitamin B12 status can have an important impact 
on physical function, social independence, mobility and ability to conduct activities of 
daily life. Accordingly, the neurologic impact of low vitamin B12 status in older people 
could contribute significantly to the burden of loss of functional ability in older age. 
However, very little is known about the public health consequences of neurologic 
implications of low vitamin B12 status at a population level. This study has aimed to 
improve our understanding of the contribution of vitamin B12-neurological impairment 
to the public health challenge of ageing.  
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This study aims to assess the relationship between low vitamin B12 status and 
neurologic function in older people by firstly systematically reviewing existing evidence, 
and secondly, by conducting secondary analyses using data from the OPEN Study. 
 
Here, I briefly synthesise the findings of work presented in Chapters 2-5 and relate them 
to the research questions that are the basis of this thesis; highlight some overall 
strengths and weaknesses of the study; provide some further reflections on vitamin B12 
status and neurological function in older people; and discuss the study implications, 
including for policy, and suggest directions for future research. 
 
The present study aimed to address the following two research questions in systematic 
reviews of the literature: 
 
1a) Is there any evidence in the available literature that vitamin B12 status is 
associated with neurological function in older people? 
1b) Is there any evidence in the available literature that vitamin B12 
supplementation improves neurological function in older people? 
 
The findings of the systematic reviews were then used to identify gaps in the evidence-
base. Secondary analyses (using data from the OPEN study) were then conducted to 
address these evidence gaps. Based on the findings of the systematic reviews, the 
following research questions for the secondary analyses were developed: 
 
2a) Is vitamin B12 status associated with electrophysiological indices of peripheral 
or central neurologic function in asymptomatic older people with moderately 
low vitamin B12 status? 
2b) Does baseline vitamin B12 status or change in vitamin B12 status alter the 
effectiveness of dietary supplementation with vitamin B12 on 
electrophysiological indices of neurologic function in asymptomatic older people 
with moderately low vitamin B12 status? 
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6.2  Synthesis of study findings by research questions 
 
6.2.1  Research questions 1a and 2a 
Chapter 2 presents findings from a systematic review designed to assess whether 
vitamin B12 status is associated with neurological function in older people (research 
question 1a). Twelve relevant reports from ten studies were identified. Among eight 
studies of general population groups of older people, one longitudinal study reported 
no association10, and four11-14 of seven cross-sectional studies reported limited evidence 
of an association of vitamin B12 status with some, but not all, neurological outcomes. 
Among four articles reporting on groups of older people with clinical and/or biochemical 
evidence of low vitamin B12 status, one longitudinal study15 reported an association of 
vitamin B12 status with some, but not all, neurological outcomes and three cross-
sectional analyses reported no association16-18. Overall, there is limited evidence from 
observational studies of older people to suggest an association of vitamin B12 status 
with neurological function. However, few studies are available, and the majority are 
cross-sectional in design so this limits the ability to infer causation or lack of it. 
 
Importantly, the systematic review identified several sources of heterogeneity and risks 
of bias in the available evidence, which have been useful to inform further research. 
There was considerable heterogeneity between studies in the definition of vitamin B12 
status and in the neurological outcomes reported. As discussed in Chapter 1, the use of 
composite measures of vitamin B12 status involving plasma/serum vitamin B12 plus 
MMA or hcy levels are now recommended19. This approach was used in three of the 
included studies, and interestingly all of these studies reported some positive 
associations between vitamin B12 status and neurologic function. It is possible that 
composite measures of vitamin B12 status are able to detect associations with 
neurologic function more effectively. Further, the systematic review found that only five 
of the included studies used electrophysiological measures of nerve conduction to 
assess neurologic function; these are the most sensitive and objective measures of 
neurological function. Measuring of self-reported neurologic symptoms and/or clinical 
markers of neurologic function, both of which are subjective, is much more widespread 
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in the available literature. Many existing studies also failed to identify and adjust 
appropriately for confounders. 
 
By identifying these limitations in the currently available evidence, the subsequent 
component of this study (presented in Chapter 3) could be designed to address these 
evidence gaps.  The OPEN study afforded an opportunity to test whether there was a 
cross-sectional association between vitamin B12 status and neurologic function in a high 
quality dataset with data on electrophysiological indices of peripheral and central 
neurologic function. A composite indicator of vitamin B12 status (cB12) was included in 
the analyses and an extensive exercise was conducted to identify potential confounders. 
A secondary analysis of baseline data from the OPEN study was conducted to determine 
whether vitamin B12 status is associated with electrophysiological indices of peripheral 
or central neurologic function in asymptomatic older people with moderately low 
vitamin B12 status (research question 2a). These analyses showed no evidence of an 
association of measures of vitamin B12 status with nerve conduction outcomes. There 
was also no evidence of an association of vitamin B12 status with clinical markers of 
neurologic function. Null results were consistent in all measures of vitamin B12 status 
and across a wide range of neurologic outcomes measuring sensory and motor 
components of peripheral nerve function in upper and lower limbs, as well as central 
motor conduction. 
 
Taken together, the currently available evidence-base (presented in Chapters 2 and 3) 
suggests that concerns about the neurologic implications of moderately low vitamin B12 
status in older people at the population level may be unwarranted. Nevertheless, the 
majority of the studies reviewed systematically, as well as the results from the OPEN 
study, are based on general population groups of healthy older people without clinical 
or biochemical evidence of vitamin B12 deficiency. As high quality studies have not been 
conducted to assess associations in less healthy and more vitamin B12 deplete 
populations, vitamin B12-dependent impairment of neurological function in such groups 
cannot be excluded. It is likely that older people identified as clearly vitamin B12 deplete 
would be selected for treatment and so simple observational studies on these people 
may be difficult to justify ethically. 
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 6.2.1.1  Comparison with other studies 
Since the systematic review of observational studies (Chapter 2) was published, a further 
relevant small (n=53) cross-sectional study in older people (median age 74 years) has 
been identified20. Matamala et al.20 reported a statistically significant lower peripheral 
motor conduction time in subjects with low vitamin B12 status (pre-defined as plasma 
vitamin B12 <221 pmol/l; mean 155 pmol/l and measured using a radioassay) versus 
normal vitamin B12 status (pre-defined as plasma vitamin B12 ≥221 pmol/l; mean 316 
pmol/l) but no difference in CNS outcomes. However, analyses did not adjust for 
potential confounders and a composite measure of vitamin B12 status was not used, 
which are limitations. Although healthy participants were recruited, comparability of 
their vitamin B12 status to OPEN participants is difficult due to use of different vitamin 
B12 assays. When considered alongside all existing evidence, this study does not alter a 
conclusion of limited evidence from observational studies of older people to suggest an 
association of vitamin B12 status with neurological function. 
 
6.2.2  Research questions 1b and 2b 
Chapter 4 presents findings from a systematic review designed to assess whether 
vitamin B12 supplementation improves neurologic function in older people (research 
question 1b). The review identified three relevant placebo-controlled RCTs16, 17, 21, 22 and 
one nRCT23; two of these were subject to risk of bias 22, 23 which limits the conclusions 
that can be drawn from these studies; and the remaining two studies used different 
types of vitamin B12 intervention (oral21 versus intramuscular injection16, 17) . The RCT 
by Dangour et al.21 was the only study to use electrophysiological indices of nerve 
function as outcomes and recruited older people without biochemical or clinical 
evidence of vitamin B12 deficiency. Primary analyses from all these studies indicate that 
supplementation with vitamin B12 does not improve neurologic function in older 
people. However, it is difficult to reach firm conclusions from heterogeneous evidence 
so limited in size and quality. 
 
Nevertheless, by performing a detailed assessment of the currently available evidence, 
the subsequent component of this study (presented in Chapter 5) could be designed to 
further advance knowledge about the effects of vitamin B12 supplementation on 
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neurologic function in older people. In subgroup analyses, Hvas et al.17 showed a 
statistically significant association between improvement in neurologic symptom score 
(but not vibration sensation or neurological disability score) in the treatment group 
compared to placebo, in subjects with the lowest baseline vitamin B12 status. 
Consequently, it is possible that improvement in neurologic function from vitamin B12 
supplementation is only apparent in people with the lowest vitamin B12 status. It is 
already known from case series that people with frank vitamin B12 deficiency show 
neurologic improvement after vitamin B12 treatment9, 24. Accordingly, this may explain 
the lack of treatment effect reported in the studies available to date. Interestingly, there 
is evidence to support greater benefits of vitamin B12 supplementation in people with 
the lowest vitamin B12 status from studies considering the effects of B vitamin 
supplementation on cognitive outcomes25, 26, lending further support to this hypothesis. 
 
Questions therefore remained about whether greater benefits of vitamin B12 
supplementation in people with the lowest vitamin B12 status extend to improvement 
in nerve conduction or whether the same effect would be seen with an oral vitamin B12 
intervention. Data from the OPEN study afforded an opportunity to test whether the 
effectiveness of oral vitamin B12 supplementation on electrophysiological indices of 
neurologic function alters according to baseline vitamin B12 status or change in vitamin 
B12 status (research question 2b).  Conducting such secondary analyses in OPEN had the 
advantage of using a high quality dataset derived from asymptomatic older people with 
moderately low vitamin B12 status.  
 
The secondary analyses presented in Chapter 5 showed that some indicators of vitamin 
B12 status (but not others) revealed evidence of associations between baseline vitamin 
B12 status and some peripheral and central neurologic responses to supplementation.  
However, directions of effect were inconsistent and such differences could not be 
explained by the aspect of neurologic function each outcome measured. Overall, no 
evidence of a difference in the impact of oral vitamin B12 supplementation on nerve 
conduction based on baseline vitamin B12 status or change in vitamin B12 status was 
observed. These findings do not support the hypothesis that improvement in neurologic 
function from oral vitamin B12 supplementation is only apparent in people with the 
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lowest vitamin B12 status. It is unlikely that the OPEN intervention would have been 
effective if participants had had slightly poorer vitamin B12 status alongside absence of 
neurologic or haematological symptoms of deficiency. 
 
Taken together, the currently available evidence-base (presented in Chapters 4 and 5) 
indicates that vitamin B12 supplementation does not improve neurologic function in 
asymptomatic older people. Although a single study suggests that those with the lowest 
vitamin B12 status (elevated vitamin B12 metabolites) benefit from an intramuscular 
injection of vitamin B12 in terms of neurologic symptoms, this finding has not been 
replicated in a high quality study assessing neurologic function by nerve conduction and 
using an oral vitamin B12 intervention. For healthy older people with no clinical or 
biochemical evidence of vitamin B12 deficiency, this thesis suggests that 
supplementation with vitamin B12 will not improve neurologic function, even if vitamin 
B12 status is at the lower end of the sub-clinical spectrum.  
 
6.2.2.1 Comparison with other studies 
Although it did not meet the inclusion criteria for the systematic review of intervention 
studies (Chapter 4) (because there was no control group), it is useful to reflect on a 
recent study by Brito et al.27  A small (n=51) pre- and post-treatment study of 
asymptomatic older subjects excluded from taking part in a larger cluster RCT28 was 
conducted in Chile; vitamin B12 levels were below <120 pmol/l in accordance with the 
exclusion criteria of the RCT 27. The response to a single dose of intramuscular treatment 
of 10 mg cyanocobalamin (B12), 100mg pyridoxine and 100 mg thiamin was assessed 
after 4 months, in terms of sensory and motor nerve conduction. Vitamin B12 status was 
defined by combining vitamin B12, holoTC, hcy and MMA into cB12. Sensory latency for 
left and right sural nerves and of the right median nerve statistically significantly 
decreased (improved) after treatment but no statistically significant differences in SAP 
amplitudes for these nerves were seen. The response to treatment in motor nerves was 
mixed but did include a faster nerve conduction velocity in the right peroneal nerve. 
There was no significant differences in central nerve conduction at 4 months. This study 
is limited by its small size and lack of a placebo group. Its comparability to results from 
the OPEN study is constrained by its different mode of intervention, short follow-up 
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period and the vitamin B12 status of its participants. Although asymptomatic, this group 
of subjects had clear biochemical evidence of vitamin B12 deficiency.  
 
A further pre- and post-treatment study in patients diagnosed with vitamin B12 
neurological syndrome was conducted by Kalita et al.24 Sixty-six patients were treated 
with 1000 μg intramuscular cyanocobalamin daily for 10 days followed by weekly for a 
month and monthly thereafter. Clinical examination, sensory testing and nerve 
conduction studies were done at 3 and 6 months follow-up. The majority of patients 
improved both in clinical and nerve conduction parameters following treatment; 
improvement in nerve conduction was more marked at 6 months. Again this study was 
in patients with clinical or biochemical evidence of vitamin B12 deficiency (vitamin B12 
<141 pmol/l) and so is not directly comparable to findings from the OPEN study. 
 
In line with the findings from Brito et al.27 and Kalita et al.24, the conclusions drawn from 
this thesis do not exclude the possibility that people with clinical or biochemical 
evidence of vitamin B12 deficiency will benefit from vitamin B12 supplementation. This 
thesis, including the systematic review of interventions (Chapter 4), was not specifically 
focussed on this question and therefore inappropriate in scope to be able to answer this 
question adequately (see Section 6.5.1 for reflections on clinical implications).  
 
6.3  Study strengths and limitations 
 
6.3.1 Study strengths 
Overall, this thesis adds to a relatively small body of existing literature, identifies gaps in 
knowledge in the current literature, and provides a cohesive synthesis of existing 
literature with new findings; and thereby offers new insights into the relationship 
between vitamin B12 and neurological function. 
 
A strength of the research presented in this thesis is the use of systematic methods to 
review existing scientific literature. Search strategies were comprehensive and standard 
systematic procedures were followed for study selection, data extraction and 
assessment of risk of bias. The systematic reviews presented in Chapters 2 and 4 are, to 
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the best of my knowledge, the first to address the relationship between vitamin B12 and 
neurologic function in older people. 
 
The secondary analyses presented in Chapters 3 and 5 are conducted on an existing high 
quality dataset. The OPEN study was a well-designed double-blinded placebo controlled 
trial with robust procedures followed for the selection of participants and data 
collection. Drop-out was very low and compliance to interventions was very high21. A 
particular strength of the OPEN study is the use of electrophysiological indices of nerve 
function, which were all collected by a single expert observer using state-of-the–art 
methods and are objective measures of nerve function. 
 
Many previous studies have been limited by the use of a single biomarker of circulating 
vitamin B12 as the sole marker of vitamin B12 status. The use of composite measures of 
vitamin B12 status involving plasma/serum vitamin B12 plus MMA or hcy levels are now 
recommended19, and therefore the novel use of the composite marker cB12 in Chapters 
3 and 5 is a strength of the study. Indeed, findings presented in Chapter 3 are, to my 
knowledge, the first to report on associations between cB12 and neurologic function. 
 
6.3.2 Study limitations 
Addressing research questions 1a) and 1b) has been limited by a heavy reliance on cross-
sectional studies. The systematic review of observational studies identified only two 
longitudinal analyses (of 12 analyses in total) and the secondary analysis of baseline data 
from the OPEN study is cross-sectional in design. As cross-sectional studies measure 
associations at one point in time they cannot be used to determine whether the 
exposure proceeded or followed the outcome. 
 
Of consideration for all aspects of the study, is the lack of a ‘gold standard’ test for 
assessing vitamin B12 status. Debate still remains around the use of various vitamin B12 
assays and cut-offs to define vitamin B12 deficiency and/or marginal status. In 
particular, there is a lack of age or sex-specific local reference ranges against which to 
evaluate individual study results and this hinders comparability across studies.  
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This study has taken an inclusive approach by reporting vitamin B12 status by several 
measures: vitamin B12, holoTC and cB12. Yet, each measure has its limitations (see 
Chapter 1). Vitamin B12 measures both active and inactive forms of the vitamin. 
Although  it measures the active form only, factors that influence holoTC have not been 
widely studied29. Whilst advantageous as a composite marker of vitamin B12 status, the 
use cB12 has not been fully explored yet or specifically validated against neurologic 
outcomes. cB12 has been used in only four27, 30-32 studies to date, one of which reported 
that cB12 was independently associated with renal function but not age30. Findings 
reported in Chapter 3 showed that use of cB12 did not alter study results. Similarly, Kobe 
et al.31 found that associations between serum vitamin B12 and memory performance 
were largely unchanged when cB12 was used as a measure of vitamin B12 status (see 
further reflections on composite measures and cB12 in Section 6.4).  
 
Investigators of the OPEN study did not measure renal function or MMA, which is a 
limitation. Ideally analyses using hcy and cB12 would have adjusted for a measure of 
renal function if this had been available. Further, the NHANES roundtable work on 
measurement procedures for assessing vitamin B12 status suggested that MMA has 
advantages over hcy as the functional marker of vitamin B12 status because MMA 
increases with vitamin B12 inadequacy but hcy increases with both folate and vitamin 
B12 inadequacies19. The availability of MMA  in the OPEN study would have allowed 
cB12 to be based on four markers rather than three; when using three markers, having 
MMA missing is less reliable than having any of the other three markers missing 33. 
Recent studies have investigated the use of urinary MMA as a biomarker of vitamin B12 
status which may be an option for consideration in future studies. It has been shown 
that urinary MMA ratio responds to vitamin B12 supplementation in a comparable 
manner to plasma MMA34 and may have advantages in studies where blood sampling 
proves difficult. 
 
Analyses using data from the OPEN study may also be limited by the relatively healthy 
characteristics of the study population. The sample of older people recruited for the 
study was not selected at random and may be in better health than a representative 
sample of older people in the UK, thereby limiting the generalisability of findings from 
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the study. Further, it is also possible that the duration of the vitamin B12 intervention 
was too short to have an effect on neurologic function. It is also recognised that there is 
some missing data in the OPEN study which may present a limitation. In particular, the 
number of observations for follow-up sensory nerve SAP responses (used in analyses 
presented in Chapter 5) was lower than for other neurologic outcomes. It is therefore 
possible that associations between vitamin B12 status and sensory nerve SAP responses 
were more difficult to detect. 
 
Whilst the OPEN study measured a wide range of peripheral and central neurologic 
outcomes, it remains possible that vitamin B12 status and/or supplementation is more 
closely related to a neurologic outcome not measured in OPEN. It has been suggested 
that somatosensory- and visual- evoked potentials (electrical activity from the 
somatosensory or visual systems) are likely to be more revealing in assessing neurologic 
improvement in asymptomatic vitamin B12-deficient people35, based on clinical and 
electrophysiological observations in case series7-9. Nevertheless, findings from a recent 
study in patients with vitamin B12 deficiency neurological syndrome suggest that it has 
been prudent to measure neurologic function by a wide range of nerve conduction 
outcomes that assess axonal function and myelination as used in OPEN. Kalita et al.24 
reported that 54.5% of 66 patients with vitamin B12 neurological syndrome had 
abnormal nerve conduction; 22.2% of these had axonal, 11.1% had demyelinating, and 
66.7% had mixed features (see further reflections on neurologic outcomes in Section 
6.4). 
 
6.4 Further reflections related to vitamin B12 status and neurological function in older 
people 
Preparing for, conducting and synthesising results presented in this thesis has enabled 
me to reflect further on research on vitamin B12 and neurological function, beyond the 
conclusions drawn to address the research questions (Section 6.2). 
 
As mentioned in Section 6.3.2, the lack of consensus on how to measure vitamin B12 
status in terms of cut-offs and assays used is a major consideration for research on 
vitamin B12 status and neurological function. Completely objective comparison across 
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studies using different measures and assays of vitamin B12 is simply not possible. 
Although the debate continues to some extent, it is preferable for studies on vitamin 
B12 status to use a functional measure of vitamin B12 status (hcy or MMA) in addition 
to serum/plasma vitamin B12 or holoTC. It is possible that composite measures of 
vitamin B12 status are able to detect associations with neurologic function more 
effectively if they exist (suggestive evidence in Chapter 2). Similarly, a systematic review 
on vitamin B12 status and cognitive decline and dementia concluded that studies that 
used composite measures of vitamin B12 status including a measure of hcy or MMA 
showed associations between poor vitamin B12 status and increased risk of cognitive 
decline or a dementia diagnosis36. Yet, uncertainty remains around the optimal 
composite marker for vitamin B12 status in terms of measuring its relationship with 
neurological function. The use of cB12 has some advantages (previously discussed) but 
its cut-off values are validated using haemoglobin and cognitive score rather than a 
measure of neurologic function. Neurologic symptoms of vitamin B12 deficiency can 
occur without concurrent anaemia37, so these cut-offs require further scrutiny if they 
are to be used to assess risk of vitamin B12-dependent neurological impairment. For this 
reason, analyses using cB12 presented in Chapters 3 and 5 are based on cB12 as a 
continuous variable rather than categorised according to the published cut-offs. 
Furthermore, generation of cB12 values could be regarded as a ‘black box’ process 
where the inputs are well-defined but the mechanisms by which cB12 values are 
generated remain unclear. MMA and hcy can become elevated in cases of poor renal 
function. There is a need to consider further the relationship between cB12 and renal 
function to allow investigators to be well-informed about whether possible confounding 
should be considered in future studies of older people. 
 
Screening for eligibility to join the OPEN study was based on serum vitamin B12 
concentrations of ≥107 and <210 pmol/L using the Beckman Coulter chemiluminescent 
immunoassay, with the aim to select individuals with moderate vitamin B12 deficiency 
who did not have anaemia. At baseline, vitamin B12 was then assessed using a 
microbiologic assay that estimated serum concentrations approximately 25% higher 
than did the Beckman Coulter method. The different values estimated by the two assays 
highlights the issue of comparability discussed earlier. Although at baseline, 88% of 
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recruited participants had vitamin B12 status below the median value for the 
microbiologic assay reference standard, it could be argued that vitamin B12 status 
should have been assessed at screening by measuring MMA or hcy in combination with 
vitamin B12, or by cB12, to be sure that participants had marginal vitamin B12 status. It 
can be said that selecting study participants with marginal nutrient status at baseline for 
trials of effectiveness of nutrient supplementation is critical. It has been proposed that 
many randomised trials of nutritional supplements have not targeted individuals with 
low or marginal status and so a likely explanation of null findings is that nutrient status 
of participants is already at a protective level and so further supplementation offers no 
further benefit38. 
 
Selecting the nutrient status of participants entering nutrient supplement randomised 
trials requires careful consideration depending on the how the study results are to be 
used. For example, participants in the OPEN study were selected on the basis of 
moderately low vitamin B12 status so that findings were relevant to population health 
in older people and could be used to inform public health recommendations. However, 
as assessment of vitamin B12 status at screening was based on vitamin B12 alone, it is 
possible that the participants were too replete in vitamin B12 to be able to detect any 
effect of vitamin B12 supplementation on neurological function. If participants had been 
selected with biochemical or clinical evidence of frank vitamin B12 deficiency, then it 
might be expected that neurologic markers of deficiency would improve after 
supplementation (because a deficiency is being corrected), but this type of study could 
not be reliably generalised for application to populations or be the basis for public health 
recommendations. It is also difficult to design a controlled-trial using vitamin B12 
deficient subjects because it is unethical to prevent clearly deficient subjects from 
receiving treatment. In such cases a study design without a control group would be most 
appropriate. Still, it is important to identify whether findings of studies intend to be 
applied to older people at risk of vitamin B12 deficiency in the population (and so used 
inform public health recommendations) or older people already living with signs and 
symptoms of frank deficiency (and so used to inform clinical practice). Balancing the 
likelihood of effectiveness of nutrient supplementation versus desired application of 
findings is a difficult challenge. 
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Suggestive findings that composite measures of vitamin B12 status are able to detect 
associations with neurologic function more effectively imply that hcy and/or MMA may 
have an important role (or be markers for biochemical changes) affecting nerve 
function. Yet, mechanistic evidence on the role of hcy and/or MMA in vitamin B12-
dependent neurological impairment remains inconclusive. As discussed in Section 1.6.1 
plausible mechanisms exist whereby impaired function of vitamin B12-dependent 
enzymes MCM (causing elevated MMA) and/or MeS (causing elevated hcy) elucidate 
biochemical changes affecting neurological function but direct mechanistic evidence in 
humans appears lacking. A thorough review of the scientific literature on potential 
mechanisms by which vitamin B12 status can affect neurological function (outside the 
scope of this thesis) would certainly be valuable to shed light on the importance of 
classical biochemical enzyme mechanisms versus other proposed mechanisms. The 
World Cancer Research Fund is currently testing a new methodology for conducting 
systematic reviews of mechanistic studies which may provide a helpful steer for such a 
review.  
 
A thorough review of mechanistic evidence could also help direct further observational 
or intervention research on vitamin B12 and neurological function by identifying which 
components of nerve function are most susceptible to low vitamin B12 status (for 
example sensory or motor outcomes, PNS or CNS). To date, there appears to be debate 
in the literature around whether axonal or demyelinating neurological impairment is 
likely to predominate with vitamin B12 deficiency24, 39-41 or whether the PNS or CNS is 
predominantly affected42, 43. If well-informed by mechanistic evidence, it may be 
possible to focus further research on vitamin B12 on the most relevant neurologic 
outcomes. 
 
6.5  Policy implications and directions for future research 
 
6.5.1  From a clinical perspective  
It is possible to reflect on the clinical implications of the findings of this study with 
reference to recent evidence-based guidance on how to diagnose and manage vitamin 
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B12 deficiency provided by Hunt44. This guidance recognises the limitations of vitamin 
B12, holoTC and hcy as measures of vitamin B12 status but still suggests vitamin B12 as 
the preferred choice for biochemical assessment of vitamin B12 status. I would suggest 
that the preferred first choice is both vitamin B12 and MMA if available. This guidance 
also importantly recognises that neurological symptoms can occur in vitamin B12 
deficiency in isolation so it is important to consider a diagnosis of vitamin B12 deficiency 
in the presence of neurological symptoms of unknown cause, as neurological features 
may progress and become irreversible. This is helpful to address the risk of missing 
vitamin B12-dependent neurological impairments because they are often assumed to 
be part of the natural ageing process or a result of ‘wear and tear’. 
 
The expert consensus for standard treatment of vitamin B12 deficiency in the UK is to 
begin parenteral treatment with intramuscular hydroxocobalamin, to avoid the 
possibility of treatment being absorbed and metabolised ineffectively. Standard initial 
treatment for patients without neurological involvement is 1000 μg intramuscularly 
three times a week for two weeks (or alternate days for up to three weeks in patients 
with neurological involvement). It is suggested that oral treatment be considered in mild 
or subclinical deficiency when problems with absorption and compliance can be ruled 
out 44.  
 
Clinical guidance indicates that expectations about neurological recovery after 
treatment are less clear than haematological responses; this is consistent with the 
findings of this study. Although not a primary focus, findings presented in this study 
highlight that research on the impact of vitamin B12 supplementation on neurologic 
function in people with clinically or biochemically defined vitamin B12 deficiency is 
limited in size and quality (Chapter 4). Clinical guidance highlighted a separate 
systematic review investigating the effectiveness of oral versus intramuscular 
administration of vitamin B12 to correct deficiency that included two RCTs45, 46; these 
trials were not blinded or placebo-controlled and detail on assessment of neurologic 
response was scant but appears to be restricted to self-reported symptoms and clinical 
markers47. 
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The systematic review of interventions performed as part of this thesis (Chapter 4) was 
not specifically focussed on neurologic effects in people with frank vitamin B12 
deficiency and was therefore inappropriate in scope to be able to fully assess the impact 
of vitamin B12 supplementation on neurologic function in people with clinically or 
biochemically defined vitamin B12 deficiency. Further research may be warranted in this 
group of subjects to assess the most effective mode and duration of vitamin B12 
treatment and which aspects of neurologic function are most responsive. The WHO has 
also identified a research need to establish objective criteria to assess early neurological 
impairment caused by vitamin B12 deficiency, ideally using neurophysiologic 
measurements48. A systematic review of evidence on effectiveness of all modes and 
duration of vitamin B12 treatment on neurologic function in older people with frank 
vitamin B12 deficiency would be valuable to inform clinical practice. Such a review 
would benefit from broader inclusion criteria than used in the systematic review of 
interventions that has formed part of this study (Chapter 4); for example inclusion of 
case series, pre- and post-treatment and other study designs not utilising a control 
group. 
 
6.5.2  From a public health perspective 
The results of this thesis suggest that concerns over the neurologic impact of moderately 
low vitamin B12 status in otherwise healthy older people may not be warranted. In 
accordance with limited and inconsistent evidence of association of vitamin B12 status 
and neurologic function, it is proposed that there is insufficient evidence of a benefit of 
population screening for moderate vitamin B12 deficiency in the absence of anaemia 
or neurological symptoms. 
 
However, the majority of the studies reviewed systematically, as well as the results from 
the OPEN study, are based on general population groups of healthy older people without 
clinical or biochemical evidence of vitamin B12 deficiency. As high quality datasets have 
not been used to assess associations in less healthy and more vitamin B12 deplete 
populations, vitamin B12-dependent impairment of neurological function in such groups 
cannot be excluded. 
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This study concludes that evidence does not support supplementation with vitamin B12 
to improve neurologic function in healthy older people, even if vitamin B12 status is at 
the lower end of the sub-clinical spectrum. Accordingly, there is insufficient evidence to 
support population-wide recommendations for vitamin B12 supplementation in 
healthy asymptomatic older people. The conclusions drawn in this thesis do not exclude 
the possibility that people with clinical or biochemical evidence of vitamin B12 
deficiency will benefit from vitamin B12 supplementation, but treatment for 
neurological impairment attributed to vitamin B12 deficiency should be managed as 
appropriate by clinicians, rather than handled at the population level. 
 
The nutritional status of the UK population is monitored in the NDNS. At the moment 
vitamin B12 status is assessed by serum vitamin B12 using a threshold of 150 pmol/l 
(chemiluminescence immunoassay), which is based on a recommendation by WHO. This 
threshold was developed using data from the NHANES and based on concentrations 
below which plasma MMA becomes elevated48. This threshold is appropriate for use 
with serum vitamin B12 alone, but measurement of population-wide vitamin B12 status 
would benefit from the additional measurement of a functional biomarker, preferably 
MMA as it has a greater specificity for vitamin B12 than hcy. Nevertheless, continued 
use of the same chemiluminescence assay and threshold across subsequent years of the 
NDNS rolling programme will allow trends in vitamin B12 status in older people to be 
monitored. Further, there may be an opportunity to develop an age- and sex-specific UK 
reference standard for assessing vitamin B12 status by the chemiluminescence assay for 
serum vitamin B12, by using a representative sample of the NDNS, in a similar fashion 
to what has been done in Ireland (Dr. A. Molloy personal communication). 
 
Treatment with folic acid can mask the diagnosis of vitamin B12 deficiency and therefore 
exacerbate neurologic impairment49; therefore the findings of this study may be of 
interest to countries that fortify grains with folic acid.  Mandatory folic acid fortification 
has been introduced in over 70 countries since 1991 and on the whole has been cited a 
success in terms of reducing incidence of neural tube defects in pregnancy50. This thesis’ 
finding of limited and inconsistent evidence of association of vitamin B12 status and 
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neurologic function in healthy older people supports no need for concern around 
unrecognised vitamin B12-associated neurological impairment amongst populations. 
However, the OPEN study was conducted in the UK where flour is not currently fortified 
with folic acid, and so its results may not be directly generalisable to countries that 
fortify grains or other foods with folic acid.   The UK’s Scientific Advisory Committee on 
Nutrition has issued recommendations for folic acid fortification to UK governments in 
2006, and again further refined in 200949, 51, so this is possible if taken forward by current 
or successive governments.  In such an event, it may be important for future studies to 
revisit the research questions addressed in this thesis with further consideration of 
interaction with folate status. For example in Chile, where flour is fortified with folic 
acid, Brito et al.27 reported that subjects with higher baseline serum folate had 
statistically significantly less improvement in vitamin B12 status in response to vitamin 
B12 supplementation than those with lower baseline folate. The influence of the 
interaction between folate and neurologic response to vitamin B12 supplementation is 
being further explored in this study52. 
 
The present study has focussed on a single nutrient, vitamin B12, and a single 
component of physical function, neurologic function, as a potentially important 
contributor to loss of functional ability in older age.  Considered alone, this study 
concludes that neurological impairment attributed to low vitamin B12 does not make a 
recognisable contribution to the public health challenge of ageing. But in terms of 
improving functional ability in older age and the opportunities afforded by improved 
nutrition, there is a need to take a broader view than simply supplementing with 
individual nutrients that might be linked to specific diseases seen in old age. Amongst 
the research literature, trials that have evaluated the effectiveness of single nutrient 
interventions on age-related health outcomes are prevalent, and many do not show 
evidence of effectiveness. For example, on vitamin B12 specifically, several reviews have 
concluded that there is no or limited evidence of effectiveness of vitamin B12 
supplementation on cognitive function53-55.  Even when a wide range of lifestyle, 
behavioural and therapeutic interventions were reviewed for effectiveness to reduce 
cognitive decline and risk of Alzheimer’s disease, overall single-domain interventions 
were found to yield mainly negative results56. It may be that a holistic approach to 
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dietary interventions involving wholescale changes to dietary patterns (and 
improvements in physical activity) would be expected to change the levels and balance 
of a range nutrients and therefore be more effective in improving outcomes related to 
functional ability in older age. Such multi-domain interventions can target several risk 
factors and disease mechanisms simultaneously, and are important for chronic disease 
prevention as well as optimising functional ability in later years57-60. It can be claimed 
that multi-domain interventions in combination are likely to be more effective on age-
related health outcomes than those that use single-component interventions. A 
successful example is the FINGER trial58, a large RCT that combined diet, exercise, 
cognitive training and vascular risk monitoring in a multi-domain intervention to 
improve or maintain cognitive function in at-risk older people. After 2 years, significant 
improvements in cognition were detected; further findings from a 7 year extended 
follow-up will be even more informative about incidence of dementia and AD. 
 
6.6  Concluding remarks 
This thesis concludes that there is limited evidence from observational studies of older 
people to suggest an association of vitamin B12 status with neurological function. 
Overall, the available evidence suggests that concerns about the neurologic implications 
of moderately low vitamin B12 status in older people at the population level may be 
unwarranted. Further, the currently available evidence-base indicates that vitamin B12 
supplementation does not improve neurologic function in asymptomatic older people, 
even if vitamin B12 status is at the lower end of the sub-clinical spectrum.  
 
Research on vitamin B12 and neurological function is constrained by a lack of consensus 
on how to measure vitamin B12 status in terms of cut-offs and assays. The use of 
composite measures of vitamin B12 status show promise but need to be specifically 
validated using neurologic outcomes. Future research on vitamin B12 and neurologic 
function would benefit from careful selection of study participants with marginal 
vitamin B12 status and a greater understanding of the mechanisms by which vitamin 
B12 status can affect neurological function. 
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 1 Executive summary 
Coeliac disease is an autoimmune condition elicited by gluten and related prolamines 
from barley and rye, in genetically susceptible individuals. It is characterised by the 
presence of a variable combination of gluten‐dependent clinical manifestations, 
coeliac disease specific antibodies, HLA DQ2 and DQ8 haplotypes and enteropathy. 
Currently, the only treatment is strict adherence to a lifelong gluten‐free diet. 
During the last 10 years, we have spent over £1.3M on research into coeliac disease 
and dermatitis herpetiformis (DH), the skin manifestation of coeliac disease that 
appears as a rash of raised red patches, often with blisters.  
Coeliac UK supported an Organisational Policy Analysis (OPA) to overview the Charity’s 
research activities including funding research. The findings of the OPA have been used 
to develop this Research Strategy in collaboration with our Members, Health Advisory 
Council, Food Standards Committee and in conjunction with our Board of Governors. 
This strategy provides a framework for the Charity’s research activities for 2013‐2016. 
Working together with our Members, healthcare professionals, our Health Advisory 
Council and Health Associates Network, Food Standards Committee, researchers, 
research organisations and policy makers, we will improve the lives of people living 
with coeliac disease and DH. 
We will fund research that underpins and integrates with our business plan activities 
whilst also considering and where possible, funding, the wider long term research 
agenda in understanding coeliac disease and DH. 
We will ensure our funds are committed to research which provides the maximum 
benefit to people with coeliac disease and/or DH. We will diversify our income 
streams, proactively seeking new and alternative sources of funding and develop 
partnerships both nationally and internationally in order to achieve our objectives.  
However funding research is only one way the Charity supports research. The Charity’s 
Membership is a valuable resource for the research community providing the largest 
register of patients with the condition in the UK. In addition, the employees within the 
Charity are an important source of expertise and as such they are increasingly 
becoming involved as active members of research teams and can facilitate an outreach 
to the wider research community. 
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 2 Introduction 
Coeliac UK was founded in 1968. It is the largest charity for people with coeliac disease 
in the world representing more than 65,000 Members with coeliac disease and/or 
dermatitis herpetiformis (DH). 
Coeliac disease is an autoimmune condition elicited by gluten and related prolamines 
from barley and rye in genetically susceptible individuals. It is characterised by the 
presence of a variable combination of gluten‐dependent clinical manifestations, 
coeliac disease specific antibodies, HLA DQ2 and DQ8 haplotypes and enteropathy. 
Currently, the only treatment is strict adherence to a lifelong gluten‐free diet. 
Screening studies in the UK show that the prevalence of coeliac disease is 1 in 100 
(West J et al. 2003) people but only 24% of them are diagnosed (West J et al. 2014).  
Our vision is to see a world full of choice for people with coeliac disease and DH and 
eventually, a world free of the condition. Our mission is to improve the lives of people 
with coeliac disease and DH. 
The Charity has committed significant funds into medical research in the last 10 years. 
Research of this kind is increasingly expensive, requiring innovative approaches to 
provide solutions to funding, such that a move to develop partnerships and 
collaborative working, both nationally and internationally is required.  
Funding research is only one way that the Charity supports research. The Charity’s 
Membership is a valuable resource for the research community providing the largest 
register of patients with the condition in the UK. In addition, the employees within the 
Charity are an important source of expertise and as such they are increasingly 
becoming involved as active members of research teams and can facilitate an outreach 
to the wider research community. 
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 3 Research Strategy 
3.1 The Charity’s strategic aims 
Our Research Strategy for 2013‐2016 is in alignment with the Charity’s 10 year 
Strategy approved by the Board of Governors.  
For people with coeliac disease and DH: 
x We will maintain our position as the authoritative source of support and 
advice. 
x We want to see an accelerated rate of diagnosis and uniformly high quality care 
and management. 
x We will improve cost, availability and access to a wider range of good quality 
products. 
x We want more gluten‐free choices on menus so people with coeliac disease 
and DH can eat out with confidence and pleasure. 
x We want an effective use of funds for research to build a strong evidence base 
supporting the work of the Charity. 
x We shall ensure the Charity’s resources are used in line with the strategic aims 
of the Charity and provide value for money. 
3.2 How the research strategy was developed 
The Research Strategy has been developed in the context of the Charity’s 10 year 
Strategy and from the findings of an Organisational Policy Analysis (OPA) conducted in 
2012. The OPA provided an overview of the Charity’s research activities, including 
funding research, between 2007‐2011. The process involved a review of 
documentation, interviews with key stakeholders and shadowing of day to day 
operations within the Charity.  
The Research Strategy was also developed taking into account existing guidance and 
bench marking against comparable organisations also involved in funding research. 
3.3 Key principles 
x We will fund research that underpins and integrates with our business plan 
activities whilst also considering and where possible, funding, the wider long 
term research agenda in understanding coeliac disease and DH. 
x Research proposals will be reviewed for both relevance to the Charity’s 
research priorities and scientific excellence; only the best will be considered for 
funding. 
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x All research funded by Coeliac UK must benefit people with coeliac disease and 
DH and if this is not realised in the short or medium term, the potential to 
make a difference with time must be demonstrated. 
x Only appropriately qualified individuals, as determined during the peer review 
process, may apply for research funding. 
x Applicants must be contracted to work in an appropriate institution which has 
the necessary networks to support education, training and professional 
development. 
x Applications from within the UK and overseas will be considered. 
x All research proposals must have a statement of originality; replication of work 
carried out elsewhere will not be accepted. However there may be exceptions 
eg where the same research question may have a different outcome depending 
on the cultural environment. 
x The Charity will consider exceptional proposals of novel research, not included 
within the scope of this strategy. Such proposals must demonstrate how the 
research will further the understanding of coeliac disease and DH and the 
potential to improve the lives of people living with the condition. 
3.4 Research areas 
The Charity supports research covering a wide range of topics (with past examples):   
3.4.1 Underpinning Research 
Research that underpins investigations into the cause, development, detection, 
treatment and management of coeliac disease and DH. (Comprehensive gluten T‐cell 
epitope mapping in coeliac disease – Professor Bob Anderson) 
3.4.2 Aetiology 
Identification of determinants that are involved in the cause, risk or development of 
coeliac disease and DH. (Identifying rare large effect size genetic variants predisposing 
to coeliac disease – Professor David van Heel) 
3.4.3 Prevention of disease and promotion of wellbeing 
Research aimed at the primary prevention of disease, conditions or ill health or 
promotion of well‐being. (Psychological and social factors associated with coeliac 
disease: a UK based study – Dr Ruth Howard) 
3.4.4 Detection, screening and diagnosis 
Discovery and development of diagnostic, prognostic and predictive markers and 
technologies. (Pre‐endoscopy serological testing for coeliac disease – a novel approach 
using rapid antibody testing ‐ Prof Dave Sanders and Prospective coeliac disease 
diagnosis evaluation ‐ Dr Adrian Thomas) 
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3.4.5 Development of treatments 
Discovery and development of treatments, in addition to the gluten‐free diet, in 
preclinical settings. (We have supported researchers working in this area by providing 
advice and facilitating a survey of Members for their views on the acceptability of 
enzyme technology) 
3.4.6 Evaluation of treatments 
Testing and evaluation of treatments in clinical, community or applied settings. 
(Investigations of the morbidity, mortality and effect of treatment in coeliac disease 
and DH – Dr Nina Lewis) 
3.4.7 Management of coeliac disease and DH 
Research into the individual care needs and management of the disease and 
associated conditions. (Osteoporosis in coeliac disease associated with novel auto‐
antibodies – Dr Philip Riches) 
3.4.8 Health and social care services research 
Research into the provision and delivery of health and social care services and health 
policy. (We have provided local healthcare teams with available evidence to support 
the role of the dietitian in delivery of post diagnosis care and education in coeliac 
disease.   
3.4.9 The gluten‐free diet 
Including but not limited to the investigation of; ingredients, preparation, nutritional 
composition, access, cost and availability of foods to support a gluten‐free diet. 
(Preparation of gluten‐free food in a kitchen where wheat flour is being used 
simultaneously ‐ Coeliac UK) 
3.5 Research Strategy objectives 
x We will review allocation of research funding by the Charity to ensure that 
research supports the key evidence gaps in promoting improved healthcare 
and food options whilst achieving value for money. 
x We will extend our research portfolio and develop international research 
networks using links with European and global research partners eg the 
Association of European Coeliac Societies and Coeliac UK grant holders, to 
secure partnerships. 
x We will take a leading role in the creation of an international research fund 
which will fund research into greater understanding of the diverse nature of 
the disease and effective management solutions. 
x We will continue to commit at least 5% of the Charity’s income to supporting 
research. 
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3.6 How we will achieve our research objectives 
3.6.1 Research call 
A call for research, the focus and priority, is ultimately approved by the Board of 
Governors, usually in the summer. The research call and application process will be 
clearly advertised on the Coeliac UK website and networks, with relevant professional 
bodies and in a peer reviewed journal.  
Types of research call: 
x Specific, where only research proposals supporting a given research question 
will be accepted. ie research commissioned to directly underpin the Charity’s 
business activities.  
x Open, where research proposals on any topic related to improving long term 
understanding of the fundamentals of coeliac disease and DH will be accepted 
ie researcher led, response mode 
Grant applications are screened for completeness by the Research Manager and 
qualifying applications are internally reviewed by Members of the Charity’s Health 
Advisory Council (HAC) and/or the Food Standards Committee (FSC) before external 
independent peer review. The advice of the HAC and/or FSC and the independent peer 
review is considered by the Board of Governors before making an ultimate decision on 
applications to be approved for funding. 
All grant holders are required to: 
x provide progress updates every 6 months as a condition of funding; annual 
reports will be reviewed by the HAC or the FSC before the release of ongoing 
funds (refer to associated documentation) 
x provide lay summaries of progress for our Members, to be uploaded on our 
website. 
x attend Charity events to present findings and also contribute to publications 
and other conferences. 
x complete an end of grant report (refer to associated documentation) 
This is to ensure the achievements and the implications of the research Coeliac UK has 
funded are recorded and communicated. This information allows us to determine if 
the research has been carried out in accordance with the grant conditions and 
objectives of the Charity. It also helps with the reporting to our Members and for our 
future planning and strategy development.        
3.6.2 Commissioning research outside of a research call 
There may be occasions throughout a year when the Charity needs to commission 
research, outside a traditional research call, to underpin the Charity’s business 
activities and inform a food or health policy on a shorter term basis. In this situation, 
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depending on the research question to be answered, the research need will either be 
advertised for open tender or via a more targeted approach. 
Where the required funding is less than £30K, the research proposals will not require 
peer review by the HAC or the FSC. The proposals will be reviewed within the Coeliac 
UK Policy, Research and Campaigns (PRC) team and where considered necessary, the 
expertise and advice of one or more Members of the HAC and/or the FSC or other 
external experts may be sought. In this case the final decision for funding is made by 
the Charity’s Chief Executive Officer. 
Where the required funding is more than £30K, external expertise and advice (from 
the HAC and/or the FSC with possible additional advice from other experts) will be 
consulted and funding approval will be sought from the Board of Governors. 
The reporting structure will be specified in the terms and conditions of contract. 
3.6.3 Researcher‐led proposals submitted to the Charity on speculation 
There are times when researcher‐led proposals are submitted on speculation to the 
Charity outside a research call. All submissions will be recorded on a Research Register. 
They will, in the first instance, be screened by the Coeliac UK Research Manager.  
The Charity is receptive to such research ideas so as not to overlook opportunities 
which it may otherwise not have considered but which are innovative and may be 
important to underpinning the work of the Charity or for the greater understanding of 
coeliac disease and DH. 
Where the requested funding is more than £30K, the research proposal will either be 
filed for consideration during the next research call or if considered appropriate by the 
PRC team and the Charity’s Chief Executive officer, the proposal will be forwarded to 
the HAC and/or the FSC or other external experts for formal peer review and where 
applicable, funding approval sought from the Board of Governors.   
Where the requested funding is less than £30K the proposal will be reviewed within 
the Coeliac UK PRC team and, where necessary, the expertise and advice of one or 
more Members of the HAC and/or the FSC or other external experts may be sought. In 
this case the final decision for funding is made by the Charity’s Chief Executive Officer. 
3.6.4 Research Fellowship 
The objective of the fellowship (clinical or non‐clinical) is to build capacity in research 
into coeliac disease and DH, where there is currently a deficit, by encouraging the best 
postgraduates to embark on an early career in coeliac disease and DH.  
Research fellowships will be advertised and applications processed in the same way as 
for a research call.    
3.6.5 Sponsored dissertation 
The Charity will provide a small grant (max. £1000 per student) to encourage 
undergraduates or postgraduates (including but not limited to dietitians, 
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immunologists, food technologists, clinicians, epidemiologists, social scientists, 
psychologists, medical students) studying at UK institutions, to focus on coeliac disease 
or DH in their project work. 
The primary objective is to place coeliac disease, a culturally specific condition, on the 
research agenda of UK academic institutions, whilst commissioning research that 
underpins the Charity’s business plan activities. 
Applications will be reviewed within the PRC team and the decision for funding will be 
made by the Charity’s Chief Executive Officer based on the advice of the PRC team. 
The grants will be advertised on the Coeliac UK website and networks.  
3.6.6 Our Members 
In a survey of our Members, 79% indicated research to be a priority (Coeliac UK 2012).  
Our Members and their carers/families play a vital role in research, their participation 
in the past has advanced the understanding of coeliac disease and DH. 
We will use our available communication channels to connect researchers with our 
Members; via our website, electronic newsletter, Crossed Grain magazine and social 
media networks. 
3.6.7 Our Staff 
Our staff have a wealth of experience, expertise and knowledge in coeliac disease and 
DH. Where appropriate we will support researchers in the preparation of their 
research proposals and/or applications for funding. Where resource allows and the 
expertise is available we contribute to steering committees and facilitate an outreach 
to the wider research network.    
3.6.8 Professional and public engagement 
We will aim to hold an annual research conference for healthcare professional 
Members of the Charity: dietitians, clinicians and researchers. This will provide the 
opportunity for researchers, including those funded by Coeliac UK, to share their 
research findings with others and also contribute to their continuing professional 
development.  
We will develop and promote training and education opportunities into coeliac disease 
and DH.   
The results of our research can inform the Charity’s work on policy and campaigning, 
as well as influence the research agenda of others. 
3.6.9 Collaborations 
Where research into coeliac disease and DH is a common interest to other national 
charities in Europe and beyond, we will lead the way for cofunding. 
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We will develop successful relationships with other charities and research networks 
where there are synergies in research, to strengthen our voice and raise the profile of 
coeliac disease and DH.  
We will also work to influence the multi‐national research agenda into coeliac disease 
and DH.     
3.6.10 Research priorities 
Our research priorities are those identified to fill the evidence gaps of relevance to our 
strategic aims. They will be determined through an interpretative ‘listening model’ 
approach, based on the engagement and exchange between research funders, 
researchers and the potential users and beneficiaries of research. They are established 
as part of our annual business planning and in conjunction with: 
x Healthcare professionals including the HAC, the FSC and the Health Associates 
Network 
x Research experts in the field of coeliac disease and DH 
x Relevant professional bodies and funders of research 
x Our Members and patient representatives 
x The Senior Management team 
The Board of Governors has the ultimate decision on the research priorities of the 
Charity. 
We will also endeavour to achieve a wider identification and agreement on the 
uncertainties in coeliac disease and DH.   
3.7 Funding 
Investment in research is a priority for Coeliac UK and the Charity will commit to invest 
a minimum 5% of annual income. Currently our income streams originate from a 
combination of Membership fees, donations and legacies. 
The Charity is also committed to diversifying its current income streams to extend its 
research portfolio; we will proactively survey external grant opportunities such as 
those from the NHS, research councils, other charities and industry and submit 
applications to obtain additional funding to close the gap. 
3.8 Research Register 
The Charity has access to a network of researchers working in the field of coeliac 
disease and maintains a register of known research projects. If you are researching in 
the field of coeliac disease and DH and would like to be added to the Research Register 
or placed in contact with other researchers, please contact our Research Manager at 
heidi.urwin@coeliac.org.uk 
Issue 1: October 2013 
Revision 1: July 2014 
13
3.9 Associated documentation 
Application for a Coeliac UK research grant award 
Application for a Coeliac UK research fellowship 
Application for a sponsored dissertation 
Information for grant applicants 
Grant conditions 
Grant progress report form 
Grant final report from 
Research priorities 
Terms and conditions of the HAC and the FSC 
3.10 Acknowledgements 
The Charity wishes to acknowledge the work of Lisa Miles, former Research Manager 
at Coeliac UK, for the findings of the Organisational Policy Analysis.  
3.11 Your views 
If you have any comments or questions about our Research Strategy 2013‐2016 please 
contact our Research Manager at heidi.urwin@coeliac.org.uk  
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Ethical approval for secondary analyses on OPEN study 
                                 Observational / Interventions Research Ethics Committee
Ms. Lisa Miles 
DPH / EPH
LSHTM
16 April 2014 
Dear Ms. Miles,
Submission Title:    Secondary analyses on the OPEN (Older People and Enhanced Neurological Function) study 
LSHTM Ethics Ref:   7176 
Thank you for your application of 3 April 2014 for the above research, which has now been considered by the Observational Committee via Chair’s Action.
Confirmation of ethical opinion
On behalf of the Committee, I am pleased to confirm a favourable ethical opinion for the above research on the basis described in the application form, protocol and supporting
documentation, subject to the conditions specified below.
Conditions of the favourable opinion
Approval is dependent on local ethical approval having been received, where relevant. 
Approved documents
The final list of documents reviewed and approved is as follows:
Document Type File Name Date Version
Investigator CV CV ea 2 pages_v3.docx 19/12/2013 1
Investigator CV CV Dangour June 2013.docx 19/12/2013 1
Local Approval OPEN study LSHTM ethics application.doc 19/12/2013 1
Local Approval FORMB ‐ Dangour 23.04.08.pdf 19/12/2013 1
Investigator CV cv201213LMiles.docx 20/12/2013 1
Protocol / Proposal Secondary Analyses of OPEN Protocol v2.docx 07/02/2014 2
After ethical review
Any subsequent changes to the application must be submitted to the Committee via an Amendment form on the ethics online applications website. All studies are also required to
notify the ethics committee of any serious adverse events which occur during the project via an Adverse Event form on the ethics online applications website. At the end of the study,
please notify the committee via an End of Study form on the ethics online applications website. Ethics online applications website link: http://leo.lshtm.ac.uk   
Yours sincerely,
Professor John DH Porter
Chair
ethics@lshtm.ac.uk
http://www.lshtm.ac.uk/ethics/ 
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